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Abstract 
Tight junctions are an intercellular adhesion complex of epithelial and endothelial 
cells. They form a paracellular diffusion barrier and interact with a network of 
intracellular signalling mechanisms that control junction function, gene expression 
and cell behaviour. Tight junctions are formed by multiprotein complexes containing 
cytosolic and transmembrane proteins.  In this thesis I have identified a novel four-
pass transmembrane protein of the tight junction called MarvelD3 and begun to 
analyse its function in the regulation of intracellular signalling pathways from the 
junction.  There are two isoforms of MarvelD3, both of which show a broad tissue 
distribution and are expressed in different types of epithelial and endothelial cells.  
MarvelD3 co-localises with occludin at the tight junction in epithelial cells. I have 
found that MarvelD3 is not necessary for junction formation, but may have a role in 
the regulation of ion conductance properties of the tight junction.  Functional analyses 
combining loss- and gain-of-function approaches in epithelial cell lines have further 
identified a role for MarvelD3 in the regulation of cell proliferation, migration and the 
cellular response to hyperosmotic shock.  MarvelD3 expression regulates levels of 
active c-Jun N-terminal kinase (JNK) and AP1 signalling, possibly via an interaction 
between its N-terminus and the MAP kinase kinase kinase MEKK1.  I have also 
shown MarvelD3 to be implicated in regulation of the actin cytoskeleton, affecting 
leading edge formation in migrating cells and cytoskeletal rearrangements in response 
to hyperosmotic shock.  I will also describe some initial studies conducted in Xenopus 
laevis embryos in which depletion of Xenopus MarvelD3 by morpholino injection 
results in curvature of the anterioposterior axis and reduced pigmentation, possibly 
resulting from a defect in neural crest cell migration. 
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Chapter 1 - Introduction 
Parts of this introduction were published as a review entitled “Dynamics and 
functions of tight junctions” (Steed et al., 2010). 
 
Epithelial cells line the internal cavities and external surfaces of multicellular 
organisms, and are imperative for the maintenance of organ homeostasis.  The 
polarised nature of epithelial cells, which have an apical membrane domain exposed 
to the internal cavity or external environment and a basolateral membrane domain 
interacting with neighbouring cells and the underlying extracellular matrix, enables 
them to regulate the necessary behaviours at the interface between external and 
internal milieu.  Further specializations equip epithelia for specific functions, like 
microvilli enhancing absorption by cells of the intestine, and cilia on the apical 
surface of cells lining the respiratory tract facilitating the directional movement of 
mucous out of the body.   
Many diseases are associated with aberrant behaviour of epithelial cells marking them 
as an important focus for scientific research.  The majority of cancers, for example, 
are epithelial in origin and are associated with disintegrated junctional structures, 
which facilitates disease progression.  Understanding epithelial cells and their 
properties, therefore, is important to our ability to get a handle such pathological 
conditions.  It is the aim of this thesis to analyse the function of a novel component of 
the tight junction in epithelial cells, in the hope that advancing our understanding of 
epithelial tight junction architecture, will contribute to our future understanding of the 
mechanisms they control and the roles they may play in pathological processes.   
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First I will introduce the tight junction and its presence within the epithelial junctional 
complex, and describe some of the proteins from which it is made up.  Then I will 
describe how this composition enables a variety of functions to be performed by the 
tight junction before introducing the novel transmembrane component, and focus of 
this thesis, MarvelD3.  Cellular behaviours and signalling pathways required for the 
understanding of this thesis are also introduced as appropriate. 
The apical junctional complex 
In order to perform their functions and maintain the integrity of the epithelium, 
epithelial cells need to adhere tightly to their neighbours.  Indeed, epithelial 
monolayers comprise densely packed cells connected by complex junctional 
structures; adherens junctions, tight junctions and desmosomes, which together form 
the epithelial junctional complex (Figure 1.1).  Adherens junctions and desmosomes 
are adhesive junctions within the junctional complex enabling the epithelium to form 
a physical barrier between tissues, while tight junctions regulate the movement of ions 
and solutes through the paracellular pathway in an ion- and size-selective manner. In 
addition, gap junctions provide another type of intercellular junction.  These small 
connexin-based channels allow small molecules and ions to move between 
neighbouring cells, affording epithelial cells the ability to propagate signals between 
their neighbours (Koval, 2002). 
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Figure 1.1 – Schematic representation of the epithelial junctional complex.  
The apical localisation of the tight junctions (red) to the adhesive epithelial junctions 
adherens junctions (green) and desmosomes (blue), is shown.  The yellow arrows 
indicate the paracellular route for the diffusion of ions and hydrophilic solutes, and 
suggest how diffusion is restricted at the level of the tight junction.  This figure was 
taken from (Steed et al., 2010). 
Adherens junctions 
Composition of adherens junctions 
The adherens junctions and desmosomes (described below) provide important 
adhesive contacts between neighbouring epithelial cells. The adherens junction is 
composed of integral membrane proteins, E-cadherin and nectin, and underlying 
cytoplasmic proteins affording association with the actin cytoskeleton and an input to 
intracellular signalling pathways.  E-cadherin is a type I classical cadherin primarily 
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expressed in epithelial cells.  It has an extracellular N-terminus, a single 
transmembrane region, and a C-terminus extending in to the cytoplasm.  Adherens 
junction assembly is thought to proceed via initial nectin-based contacts, followed by 
lamellipodia formation and subsequent binding between cadherins on the membranes 
of adjacent cells.   In the extracellular space, cis-dimers are formed between two E-
cadherin molecules from the same cell, which then interact with cis-dimers on the 
adjacent cell to form trans-dimers and provide adhesive activity (Takai and 
Nakanishi, 2003).  In the cytoplasm, the C-terminus of E-cadherin interacts with !-
catenin and p120-catenin via their armadillo repeats (Ozawa et al., 1989).  The site 
where p120-catenin interacts with E-cadherin is also the target of ubiquitination and 
implicated in clathrin-mediated endocytosis, thus implicating p120-catenin binding in 
the stabilization of cadherin-catenin contacts between adjacent cells (Ishiyama et al., 
2010).  !-catenin binding mediates the interaction between E-cadherin and #-catenin, 
which also binds actin in a mutually exclusive manner (Yamada et al., 2005).  
Interactions between E-cadherin, !-catenin and #-catenin thus provide a dynamic link 
between the junction and the underlying actin cytoskeleton. Adherens junctions are 
also linked to the cytoskeleton via l-afadin-mediated binding of nectin and F-actin 
(Mandai et al., 1997).  Perturbations in actin cytoskeleton organization following loss 
of adherens junction contacts suggest the importance of these cell-cell adhesion 
structures in maintaining epithelial integrity. 
Adherens junctions and intracellular signalling 
In addition to a role in cadherin-catenin adhesions, !-catenin also functions in the 
regulation of intracellular signalling pathways.  Under basal conditions, any non-
junctional, cytosolic !-catenin forms a complex with the tumour suppressor 
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adenomatous polyposis coli (APC), axin and glycogen synthase kinase 3! (GSK3!), 
in which !-catenin becomes phosphorylated by the latter and is degraded by the 
proteosome (Kikuchi, 2000).  In the presence of Wnt signalling, however, !-catenin 
phosphorylation is inhibited, allowing cytosolic !-catenin to accumulate and interact 
with TCF/LEF family of DNA-binding proteins that go on to activate Wnt responsive 
genes (Behrens et al., 1996; Huber et al., 1996).  By regulating the ratio of junctional 
or cytosolic !-catenin, therefore, the adherens junction can impact upon intracellular 
signalling and gene expression via the Wnt signalling pathway.  Deregulation of !-
catenin signalling is seen in many cancers (Morin, 1999). 
Desmosomes 
Composition of Desmosomes 
Desmosomes are localised sites of cell-cell contact at which cells are held together 
very tightly.  Desmosomal adhesion proteins desmocollin and desmoglein belong to 
the cadherin superfamily of adhesion molecules and, like E-cadherin, bind 
cytoplasmic proteins at their intracellular C-termini, while the N-terminus interacts 
with desmosomes on adjacent cells providing adhesion (Garrod et al., 2002).  
Armadillo protein family members plakoglobin and plakophilin are found in the 
desmosomal cytoplasmic domain and demonstrate a dual junctional and nuclear 
localisation.  Linked to the desmosomal cadherins by plakoglobin, desmoplakin 
associates with intermediate filaments, thus completing the desmosome structure and 
linking intermediate filaments to the plasma membrane (Kouklis et al., 1994; 
Stappenbeck and Green, 1992).  Plakophilin also mediates association with the 
intermediate filaments and has been shown to interact with plakoglobin, the 
 25 
desmosomal cadherins as well as keratin (Hofmann et al., 2000).  This interaction 
between desmosomal proteins in the plasma membrane and the intermediate filaments 
equips the cell with the ability to resist mechanical stress (Garrod and Chidgey, 2008; 
Getsios et al., 2004).  Cells of the skin and heart, which are particularly exposed to 
mechanical stress, express high levels of desmosomal proteins.   In the absence of 
correct desmosomal function, tissue integrity becomes severely compromised (Kottke 
et al., 2006).   
Desmosomes and regulation of intracellular signalling pathways 
In addition to providing significant adhesive strength between adjacent cells, 
desmosomes are also implicated in the regulation of intracellular signalling pathways 
(Thomason et al., 2010).  As mentioned, desmosomal proteins plakoglobin and 
plakophilin demonstrate nuclear and junction localisation, indicating their potential as 
signalling molecules.  Like !-catenin, plakoglobin complexes with APC/GSK3! 
which targets it for degradation by the proteasome.  Plakoglobin has also been shown 
to be able to interact with TCF/LEF transcription factors indicating its potential to 
regulate Wnt signalling (Maeda et al., 2004; Miravet et al., 2002; Zhurinsky et al., 
2000).  Furthermore, plakoglobin has been shown to both promote and suppress the 
expression of c-myc (Kolligs et al., 2000; Williamson et al., 2006).  The contribution 
of desmosomal regulation of these pathways, however, to physiological and 
pathological events has yet to be fully understood.  
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Tight junctions 
The tight junctions, or zonula occludens, are the most apical of the epithelial 
junctional complexes and continuously circumvent the cell bringing the plasma 
membranes of neighbouring cells into close apposition (Farquhar and Palade, 1963).  
This is evident on electron micrographs in which the so-called “kissing points” of the 
outer leaflets of the plasma membrane and the consequent loss of intercellular space 
can be seen (Figure 1.2A).  Underlying the membrane domain is the cytoplasmic 
plaque, which consists of a meshwork of densely packed cytoplasmic proteins. These 
morphological features enable tight junctions to perform three fundamental functions.  
First, to form a semi-permeable barrier capable of finely regulating the movement of 
ions, solutes and cells across the paracellular space (Tsukita et al., 2001).  Second, to 
participate in establishing and maintaining apico-basal polarity (Shin et al., 2006).  
Third, to serve as a site for both the integration and divergence of various signalling 
pathways controlling gene expression, cell differentiation and proliferation (Guillemot 
et al., 2008; Matter et al., 2005). 
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Figure 1.2 – Morphological features of the tight junction. (A) Electron micrograph 
sections of retinal pigment epithelial cells (POS; photoreceptor outer segments) 
clearly demonstrates the bringing together of plasma membranes at the level of the 
tight junction (TJ), but not at the level of the adherens junction (AJ).  (B) Preparation 
of cells for freeze-fracture microscopy demonstrates the tight junctions as a series of 
strands. (C) Epifluorescence analysis of occludin localisation in an epithelial cell 
monolayer shows the tight junction to completely encircle the cell.  Combined these 
observations of tight junction morphology enable one to imagine how the tight 
junction encircles the cell generating a barrier and effectively sealing the epithelium 
to free-moving molecular traffic.  EM image in (A) was kindly provided by Professor 
Claire Futter, UCL Institute of Ophthalmology.  Image in (B) was taken from (Steed et 
al., 2010). 
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Composition of the tight junction 
The characteristic morphology of tight junctions is attributable to the protein 
complement from which they are composed. Integral membrane proteins of the tight 
junction are generally classified into two main classes depending upon the number of 
transmembrane domains they contain: the four-pass transmembrane proteins, like 
occludin, tricellulin and the claudin family; and single-span transmembrane proteins, 
like junctional adhesion molecule (JAM) and coxsackie and adenovirus-associated 
receptor (CAR).  Underlying the plasma membrane domain of the tight junction are a 
variety of cytoplasmic proteins which together with the transmembrane proteins form 
a highly dynamic multiprotein complex enabling the tight junction to perform both a 
structural and a signalling role within the cell (Figure 1.3).  While both single and 
four-pass transmembrane domain proteins participate in mediating cell-cell adhesion 
and facilitating various signalling processes, only the polytopic proteins form the 
diffusion barrier and regulate paracellular permeability (Matter and Balda, 2007). 
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Figure 1.3 – Schematic representation of the tight junction and its protein 
constituents.  Tight junctions are composed of a variety of different types of 
proteins.  The transmembrane proteins are shown in blue.  These include four-pass 
transmembrane proteins like claudins, occludin and tricellulin, and single-pass 
transmembrane proteins like JAM and CAR.  Underlying the membrane proteins, 
adaptor/complex-forming proteins (green) regulate interaction between the 
membrane proteins and signalling molecules or the actin cytoskeleton.  They also 
include cell polarity proteins like the Par polarity complex that localise at the tight 
junction.  Signalling proteins (yellow) and transcriptional regulators (red) are also 
found at the tight junction.  Some of these proteins, like ZONAB, show dual 
localisation at the junction and in the nucleus.  For details of individual proteins, see 
the text below. 
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Four-pass integral membrane proteins of the tight junction 
Claudins and the barrier function  
Freeze-fracture electron microscopy shows tight junctions as a series of anastomosing 
membrane strands found at close contact sites between the outer leaflets of the plasma 
membrane of neighbouring cells, demonstrating the effective occlusion of the 
intercellular space between adjacent cells.  Claudins have been identified as the major 
component of these tight junction strands (Furuse et al., 1998a; Furuse et al., 1998b).  
Lateral association between claudin molecules within the plasma membrane 
combined with homotypic adhesive interactions between claudin molecules on 
adjacent cells is thought to underlie the characteristic structure of the tight junction 
strands (Furuse et al., 1999).  The number and distribution of charged residues in the 
first extracellular loop domain varies between claudin family members and enables 
the selective permeability of ions through the paracellular pathway based on charge. 
Claudin-2, for example, allows cations, but excludes the passage of anions through 
the paracellular space (Amasheh et al., 2002).  Furthermore, alterations to specific 
charged residues in the first extracellular loop of claudin-15 has been shown to be 
sufficient to alter the preference from cations to anions through the paracellular space 
(Colegio et al., 2002).  The ability of specific claudins to bestow distinct permeability 
properties is further demonstrated by the differential expression of claudin-1 and 
claudin-2 to tighter and more leaky segments of kidney tubules, indicating that 
variations to the complement of claudins expressed is one mechanism by which cells 
and tissues may organize their ionic permeability properties (Reyes et al., 2002).  
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The mechanism by which tight junctions regulate size-selective diffusion is not yet 
clear.  When GFP-tagged claudin-1 was expressed in L cells, the network of 
intramembrane paired strands formed at plains of adhesion between adjacent cells 
were seen to be highly dynamic, constantly remodeling through rounds of breaking 
and annealing (Sasaki et al., 2003).  Since the high density of endogenous strands and 
their orientation parallel to the observation axis makes visualization of strand 
behaviour in live cells difficult, it remains to be confirmed whether tight junctions in 
situ display the same dynamic properties.  Visualizing tight junctions as a flexible 
network of strands, however, provides an attractive model of how tight junctions 
achieve size-selective diffusion, without compromising overall integrity (Figure 1.3) 
(Sasaki et al., 2003; Steed et al., 2010).  It is likely, however, that interactions with the 
underlying cytoskeleton or cytoplasmic proteins would influence strand organization 
and their dynamic behaviour, and this is not yet fully understood. 
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Figure 1.4 – Proposed model for regulation of paracellular permeability by a 
series of dynamic tight junction strands. Tight junctions are shown as grey lines 
that represent the intramembrane strands. The strands contain ion-selective 
channels that are thought to be formed by claudins and can be in an open or a 
closed state. Because claudins have characteristic ion-conductive properties, the 
types of claudin expressed determine the ion-selectivity of the paracellular pathway. 
The intramembrane strands are dynamic; hence, the network of strands is reshaping 
itself continuously, resulting in occasionally open network compartments that allow 
small solutes to enter and slowly diffuse across the junction (broken grey lines 
represent strand opening, while the integrity of the overall network is maintained). 
The size selectivity is determined by the functional distance of the two neighbouring 
plasma membranes at the level of tight junctions. Size-selective paracellular diffusion 
is also regulated by various signalling pathways and could involve interactions with 
the actin cytoskeleton and additional protein components of the strands.  It is not yet 
known how ions are restricted from passing through the open strands, but perhaps 
the strand state could influence the state of opening of the channel. Taken from 
(Steed et al., 2010). 
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Occludin 
Integration of additional transmembrane proteins in to the claudin-based strands 
provides additional complexity to the tight junction structure.  Occludin was the first 
transmembrane component of the tight junction to be identified and localizes to the 
strands by electron microscopy (Furuse et al., 1993).  The specific primary role for 
occludin at the tight junction is still unclear.  Initial in vitro assays suggested that 
occludin might function in the regulation of permeability properties of the tight 
junction since expression of occludin constructs in MDCK cells resulted in increased 
transepithelial resistance (TER) and increased paracellular flux (Balda et al., 1996). 
Later observations made in the occludin knockout mouse, however, demonstrated 
that, despite the lack of occludin expression, physiologically and structurally normal 
tight junctions were present in these animals (Saitou et al., 2000; Schulzke et al., 
2005).  In addition, cells arising from occludin-deficient embryonic stem cells 
demonstrated a comprehensive network of tight junction strands, further suggesting 
that occludin is dispensible for strand formation (Saitou et al., 1998).  The reported 
discrepancies between over-expression studies in vitro and observations following 
loss of occludin in vivo could be due to interruption of endogenous complexes 
following the expression of occludin or occludin domain constructs in vitro.  Studies 
utilizing RNA interference to deplete cells of occludin support the hypothesis that 
occludin influences barrier properties by demonstrating that occludin depletion 
resulted in reduced barrier disruption in response to cytokines (Van Itallie et al., 
2010).  Addition of Interferon gamma (IFN") and tumour necrosis factor alpha 
(TNF#) increased TER and paracellular flux across control cell monolayers, but these 
increases were attenuated in occludin knockdown monolayers, suggesting occludin is 
important for regulating the barrier properties of the tight junction in response to 
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cytokines (Van Itallie et al., 2010).  Taken together, these studies suggest loss of 
occludin may not affect basal barrier properties, but may instead be important for the 
regulation of tight junction function in response to specific stimuli, like inflammatory 
cytokine signalling.  Indeed, cytokine-induced cytoskeletal reorganization in 
endothelial cells required activation of the small GTPase RhoA (Campos et al., 2009), 
the activity levels of which are significantly reduced in epithelial cells depleted of 
occludin by RNA interference (Yu et al., 2005).  Since the organization of the actin 
cytoskeleton appears to influence permeability properties of the tight junction (Nusrat 
et al., 1995), the ability to regulate F-actin organization at the tight junction via RhoA 
may be one mechanism in which occludin regulates barrier properties of the tight 
junction.  More recently, it has been demonstrated that phosphorylation of occludin at 
serine residue 408 affected paracellular permeability by regulating the dynamic 
behaviour of other tight junction proteins (Raleigh et al., 2011).  Therefore, perhaps 
the regulation of tight junction properties by individual constituents is more subtle 
than over-expression or siRNA-mediated depletion studies enable to be seen.  Post-
translational modifications in response to specific stimuli may be the significant factor 
in enabling occludin, and other tight junction components, to regulate the properties 
of the tight junction.   
Tricellulin 
Tricellulin is also a four-pass transmembrane protein of the tight junction, aptly 
named for its concentration at tricellular contact sites between three adjacent cells 
(Ikenouchi et al., 2005), as opposed to localization along the bicellular junction 
between two adjacent cells illustrated by the claudins and occludin.  Tricellulin 
expression is thought to be instrumental in maintaining the integrity of the monolayer 
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since in its absence, both the tricellular and bicellular contact sites appeared to be 
compromised (Ikenouchi et al., 2005).  Given the vulnerable nature of tricellular 
contacts as points of potential leakage it seems intuitive that these specialized points 
of cell contact may require some kind of reinforced structure that may not be 
necessary along the bicellular junctions.  Indeed, exogenous expression of tricellulin 
caused increased cross-linking of claudin-1-based tight junction strands in L cells, 
suggesting tricellulin expression may mediate tricellular-specific organization of the 
tight junction (Ikenouchi et al., 2008).  
Mutations of tight junction transmembrane proteins and disease 
In addition to their altered expression in cancer, identification of specific mutations 
has implicated the transmembrane proteins of the tight junction in additional 
pathological conditions, further highlighting the importance of their physiological 
functions.  Mutations in claudin-14 have been shown to cause hearing loss in humans 
(Wilcox et al., 2001) and loss of claudin-14 in knockout mouse studies causes 
alterations in ionic permeability within the inner ear resulting in significant loss of 
outer hair cells (Ben-Yosef et al., 2003).  Mutations in tricellulin have also been 
associated with hearing loss (Riazuddin et al., 2006).  These results suggest the 
importance of tight junction proteins in maintaining the correct compartmentalization 
of the inner ear, without which hearing becomes significantly impaired.  Studies in 
knockout mice have also demonstrated the importance of claudin-11 expression in 
central nervous system (CNS) function and reproduction.  Loss of tight junctions in 
CNS myelin and Sertoli cells in the absence of claudin-11 rendered mice with 
neurological deficits and left males sterile  (Gow et al., 1999).  Mutations in claudin-
16 cause familial hypomagnesemia as renal Mg2+ resorption is perturbed (Simon et 
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al., 1999).  Mutations in cytoplasmic components of the tight junction can also have 
pathological consequences.  Mutations in the first PDZ domain of ZO-2, for example, 
have been linked to familial hypercholanemia (Carlton et al., 2003).  Identification of 
such pathologies caused by loss of tight junction protein function demonstrates that 
tight junction function is important in a range of tissues.  The tissue-specific 
phenotypes also allude to the ability of tight junctions to perform specific roles in 
different tissue types. 
 
Tight junction-associated cytoplasmic proteins 
The presence of protein-protein interaction domains in the cytoplasmic regions of the 
tight junction transmembrane proteins enables interaction with a number of 
scaffolding proteins in the underlying cytoplasm.  The PDZ domain (an acronym of 
post-synaptic density protein 95, PSD-95; discs large, Dlg; and ZO-1, in which the 
common domain was first recognised) is a frequently occurring region of sequence 
homology eliciting protein-protein interactions between a variety of signalling 
proteins.  Implicated in the organisation of functional plasma membrane domains, 
PDZ domain-containing scaffolding proteins serve to cluster together transmembrane 
proteins and recruit signalling molecules in larger protein complexes from which 
intracellular signalling pathways may be regulated.  The Src homology 3 (SH3) 
domain facilitates protein-protein interaction by binding proline-rich sequences and is 
also found in many proteins of the tight junction.  
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Zonula Occludens proteins 
Zonula occludens (ZO)-1, ZO-2 and ZO-3 are tight junction-associated members of 
the membrane-associated guanylate kinase-like homologue (MAGUKs) family.  
MAGUKs possess multiple PDZ domains, one SH3 domain and one guanylate 
kinase-like (GUK) domain.  The PDZ domains of the ZO proteins facilitate 
interaction with PDZ domains found in the C-termini of tight junction transmembrane 
proteins.  ZO-1, -2 and -3 have been shown to interact with claudins (Itoh et al., 
1999a) and occludin (Furuse et al., 1994; Haskins et al., 1998; Itoh et al., 1999b).  The 
interaction between ZO-1 and tricellulin however is not yet clear (Ikenouchi et al., 
2008; Riazuddin et al., 2006).  The PDZ domain also mediates interactions between 
the ZO proteins themselves, with ZO-2 and ZO-3 both being able to associate with 
ZO-1, but not with each other (Haskins et al., 1998).  Since ZO proteins are 
increasingly implicated in the regulation of intracellular signalling pathways 
(discussed below), the identity of their membrane-binding partners is important in 
understanding how transmembrane proteins function in their regulation and 
subsequent effect on downstream signalling pathways.  
Polarity proteins 
The epithelial tight junction is also important in the establishment and maintenance of 
apicobasal polarity.  Two important complexes in the regulation of cell polarity are 
found to concentrate at the tight junctions; the Par polarity complex, composed of 
Par3, Par6 and atypical protein kinase C (aPKC), and the Crumbs (Crb) polarity 
complex, made up of Crb, PatJ and Pals1.  The recruitment of these complexes in the 
establishment of apicobasal polarity occurs after the formation of initial cell-cell 
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contacts and is necessary for the establishment of a distinct tight junction complex, 
apical to the adherens junction.  Recruitment of JAMs to the plasma membrane 
following the initial formation of nectin and E-cadherin-based contacts is followed by 
recruitment of Par3 (Ebnet et al., 2001; Itoh et al., 2001).   This is followed by the 
recruitment of Par6 and aPKC and establishment of the apical membrane domain 
(Horikoshi et al., 2009).  Depletion of Par3 prevented Par6-aPKC recruitment and the 
formation of the apical domain is perturbed, indicating the importance of Par complex 
assembly in establishment of epithelial polarity (Horikoshi et al., 2009).  Cdc42 
activation after initial adherens junction contacts also promotes polarisation around 
the young contact sites by interacting with Par6 and subsequently activating its 
binding partner aPKC.  Active aPKC is necessary for tight junction formation and 
establishment of cell polarity in epithelial cells.  Par3 also promotes tight junction 
assembly via TIAM1-mediated activation of Rac1 (Chen and Macara, 2005). 
Depletion of Par3 by RNA interference results in constitutive activation of Rac1 and 
disruption of tight junction assembly in MDCK cells (Chen and Macara, 2005). 
In the Crb complex, Pals1 links Crb and PATJ, which localises to the tight junction30.  
Inhibition of PATJ and Pals1 by RNA interference has been shown to impede tight 
junction formation and disrupt cell polarity (Roh et al., 2003; Straight et al., 2004).  
Interestingly, Par6 and Pals1 also directly interact providing a link between the two 
polarity complexes (Hurd et al., 2003).  It is becoming increasingly apparent that in 
addition to regulating apicobasal polarity, interactions between tight junction proteins 
and polarity proteins may also play a significant role in migration.  This will be 
discussed below. 
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Cytoskeletal proteins 
Preparation of cells for freeze-fracture electron microscopy demonstrated the presence 
of an actin filament network underlying the tight junction membrane domain, alluding 
to a potential association between the actin cytoskeleton and the tight junction 
(Hirokawa and Tilney, 1982).  Subsequent studies utilising cytochalasin D treatment 
to disrupt the polymerization state of actin in intestinal cells caused reductions in the 
extent of cross-linking and number of tight junction strands and perturbations in both 
paracellular permeability and TER, generating the hypothesis that interactions 
between the tight junction and the underlying actin cytoskeleton may be of functional 
relevance (Madara et al., 1986).  Now, many proteins associated with the cytoskeleton 
and capable of interacting with actin have been identified, and the actin cytoskeleton 
is integral to the formation of tight junctions and the regulation of their behaviour 
therein.  
Actin cytoskeleton and junction assembly 
During junction assembly, actin filaments associate with E-cadherin contact sites and 
remodel as E-cadherin complexes associate to form a continuous band of cell-cell 
contact.  This is facilitated by actin regulatory proteins recruited to the initial E-
cadherin contact sites.  Arp2/3, for example, is recruited to early contact sites by 
binding to E-cadherin (Kovacs et al., 2002) and subsequently promotes actin filament 
branching and lamellipodial extension necessary for the extension and assembly of 
cadherin-based cell-cell contacts (Verma et al., 2004).  Arp2/3 activity in the apical 
junctional complex is, at least in part, regulated by #-catenin which, in its dimeric 
form, is thought to compete with Arp2/3 for actin binding and, in so doing, suppresses 
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Arp2/3-mediated actin polymerization and stabilizes actin at the junction (Drees et al., 
2005).   Recruitment of tight junction proteins to the E-cadherin-based cell contact 
sites and stabilization of the initial contacts is followed by the apical segregation of 
the tight junction away from the adherens junction to form two distinct junctional 
complexes.  This segregation is prompted by integrin-mediated adhesion to the 
underlying extracellular matrix, which enables cells to recognize their apical-basal 
polarity (Drubin and Nelson, 1996) and involves reorganization of actin filaments to 
elongate the cell into a cuboidal morphology and generate the circumferential actin 
ring typical of polarized epithelial cells.  This process appears to rely on the ability of 
Myosin II to activate contraction of the thin actin bundles peripherally located to 
initial junctional actin, to generate mature junctional actin and a polarized cell shape 
(Zhang et al., 2005a).  Contraction of the perijunctional actin ring is believed to 
regulate paracellular permeability properties by opening the tight junction, thus the 
actin cytoskeleton plays a role in moderating the properties of the mature tight 
junction, in addition to mediating its assembly. 
Regulation of the cytoskeleton by the tight junction 
In addition to the requirement for actin cytoskeleton dynamics in the initiation and 
maturation of tight junctions, the tight junctions themselves appear to regulate the 
actin cytoskeleton in various cellular processes.  Occludin, for example, has been 
implicated in the regulation of actin cytoskeleton reorganization via a signalling 
pathway involving RhoA (Yu et al., 2005).  Occludin knockdown cells failed to 
activate RhoA in response to cholesterol addition and thus did not elicit the 
cytoskeletal rearrangements observed in control cells (Yu et al., 2005).  In addition, 
apoptotic cells were not extruded from occludin-knockdown monolayers (Yu et al., 
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2005).  While loss of occludin could simply mean the healthy cells can no longer 
detect their dying neighbour, since occludin depletion does not affect other modes of 
cell-cell contact, it is also possible that in the absence of occludin cells are unable to 
initiate the Rho-mediated cytoskeletal rearrangements shown to be necessary for 
apical extrusion (Rosenblatt et al., 2001).  In consideration, it seems logical that a 
junction protein be able to coordinate such a process, thus enabling dead cells to be 
extruded from the epithelium without compromising the integrity of the monolayer.  
Indeed, epithelial barrier function was maintained despite the extrusion of large 
numbers of apoptotic cells (Rosenblatt et al., 2001). 
In addition to stabilizing the tight junction complex, interactions between the actin 
cytoskeleton and transmembrane proteins of the tight junction provide a scaffold for 
the recruitment of intracellular signalling proteins, from which signalling pathways 
can be regulated in response to external cues.  In the next section I will discuss what 
is known about the regulation of migration and intracellular signalling pathways by 
proteins of the tight junction.  I will also introduce signalling pathways not yet 
associated with the tight junction, but that are of significance to this thesis. 
Cell migration 
Cell migration describes the movement of a single cell or group of cells (collective 
migration) relative to the underlying substrate.  Both single cell and collective cell 
migration are relevant to a number of physiological and pathological processes.  
During development, for example, cells migrate both singularly and collectively to 
generate tissues and organs within the embryo.  Carefully regulated epithelial-to-
mesenchymal transitions (EMT) generate mesenchymal cells, which migrate 
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individually or as loosely associated groups of cells, with increased cell migration 
often correlating with weaker cell-cell interactions.  Neural crest cells are a highly 
migratory cell population, which demonstrate dynamic cell-cell contacts enabling 
them to migrate as a cohort through the embryo to their site of differentiation.  Cell-
cell contacts between neural crest cells are important for directional migration 
(Carmona-Fontaine et al., 2008).  Single cell migration also occurs during the immune 
response and during cancer progression, where the induction of single cell migration 
can play an important role in the promotion of metastasis (Giampieri et al., 2009).   
Collective cell migration is also significant in tumour cell metastasis, as well as in the 
physiological wound healing response.  Given its importance in development and 
physiology, understanding the mechanisms behind epithelial cell migration is likely to 
be of great biological and therapeutic significance.  
Mechanisms of cell migration 
Single cell migration can be further subdivided into amoeboid migration and 
mesenchymal migration.  Both describe the movement of individual cells, but the 
mechanisms by which this movement is achieved differ considerably.  During 
amoeboid migration, cells move with a rounded morphology and in a protease-
independent manner.  Amoeboid migration may proceed via membrane blebbing or 
through the extension of filopodia at the leading edge.  In both cases however, and in 
contrast to mesenchymal migration, amoeboid cells show little or weak engagement 
with the substrate, lacking mature focal adhesions and stress fibres (Fackler and 
Grosse, 2008; Friedl and Wolf, 2010; Lammermann and Sixt, 2009).  In mesenchymal 
migration, cells extend lamellipodia and filopodia at the leading edge, driven by 
polymerisation of the actin cytoskeleton.  Attachment of these protrusions to the 
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underlying substrate followed by contraction of the actinomyosin cytoskeleton 
generates tension across the length of the cell and provides a driving force to propel 
the cell forwards. Detachment of the cell rear followed by continuing rounds of 
leading edge extension and substrate adhesion serves to coordinate the forward 
migration of the cell.   Mesenchymal cell migration also utilises proteolysis to 
degrade the extracellular matrix.  Production of matrix metalloproteinases (MMPs) by 
migrating cells results in degradation of the surrounding extracellular matrix and can 
promote cell migration and tumour cell invasion (Basbaum and Werb, 1996; 
Bjorklund and Koivunen, 2005; Giannelli et al., 1997; Koshikawa et al., 2000).   In 
some cell types, inhibition of proteases has been shown to induce cells to change from 
a mesenchymal to an amoeboid, protease-independent mode of migration (Wolf et al., 
2003). 
During collective cell migration, cell-cell contacts between neighbouring cells are 
maintained and cells progress along the substrate as a group (Ilina and Friedl, 2009).  
Cells become polarised in a coordinated manner with cells at the front of the 
migrating sheet extending protrusions from which the sheet moves forwards.  
Interactions and coordinated cytoskeletal changes in cells behind those at the leading 
edge then enable forward migration of the sheet.  Epithelial cells display collective 
migration as a sheet, which is important during the wound healing response. 
Regulation of cell migration 
Effective cell migration requires coordinated regulation of the actin cytoskeleton, 
which is achieved by the balance of activity of the RhoGTPases; RhoA at the rear of 
the cell and Rac and Cdc42 at the cell front.  The activity of RhoGTPases plays an 
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important role in establishing polarity in the migrating cells.  Extension of 
lamellipodia and filopodia from the leading edge cells relies on activity of the small 
GTPases Rac and Cdc42, respectively (Nobes and Hall, 1995).  RhoA activity at the 
rear of single cells or in adjacent rear cells during collective migration allows forward 
movement by controlling actinomyosin contractility.  Thus GTPases help to define 
the front-rear polarity axis required for directional migration. 
Polarity proteins are also important regulators of epithelial cell migration.  As 
discussed, localisation of polarity proteins to the tight junctions is important in the 
ability of the tight junctions to define the apicobasal membrane domains, establishing 
and maintaining apicobasal polarity in epithelial cells. During cell migration, cells 
lose their apicobasal polarity and assume front-rear polarity instead, observed by the 
redistribution of polarity proteins.  Just as is involved in junction formation, cross-talk 
between Par polarity proteins and the RhoGTPases is involved in regulating cell 
migration.  Cdc42 recruitment and activation at the leading edge of cells following 
wounding, results in an interaction with Par6 and subsequent activation of aPKC 
(Etienne-Manneville and Hall, 2001).  Localised activation of aPKC is necessary for 
localised activation of cJun N-terminal kinase (JNK), which phosphorylates Paxillin, 
promoting migration by increasing focal adhesion dynamics (Rosse et al., 2009).  By 
retaining polarity proteins at cell-cell junctions, therefore, tight junctions may 
function in perturbing the migration of epithelial cells. 
Tight junctions and migration 
Alterations to the localisation of tight junction proteins in migrating cells has lead to 
the hypothesis that tight junction proteins may function directly in the regulation of 
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cell migration.  Occludin has been seen to localise to the leading edge of migrating 
MDCK cells and in its absence their migration was significantly reduced (Du et al., 
2010).  Without occludin, aPKC-Par3 and PATJ failed to recruit to the leading edge 
resulting in disorganisation of the microtubule network previously been shown to be 
mediated by PATJ (Shin et al., 2007).  In addition to regulating the localisation of 
polarity proteins and subsequent directional migration, occludin was also implicated 
in the regulation of lamellipodia formation by regulating leading edge activation of 
PI3K and Rac1 (Du et al., 2010).  Thus interactions between tight junction proteins 
and polarity proteins are important for both tight junction formation and regulation of 
migration.  
ZO-1 is also implicated in the regulation of directional cell migration.  At the tight 
junction, ZO-1 maintains epithelial integrity by binding transmembrane proteins 
occludin and claudins and the underlying actin cytoskeleton.  At the onset of 
migration, ZO-1 resdistributes from the tight junction to the leading edge in response 
to phosphorylation by PKC$ and interacts with #5-integrin (Tuomi et al., 2009).  
While the significance of this interaction is not yet known, depletion of ZO-1 resulted 
in elevated Rac activity and randomised migration, while loss of #5-integrin inhibited 
migration, indicating a role for ZO-1 in regulating directional cell migration from 
integrin-mediated contact points in the lamellipodia (Tuomi et al., 2009).  In addition, 
ZO-1 has also been shown to interact with the Cdc42 effector kinase MRCK! at the 
leading edge, activity of which is involved in the generation of cellular protrusions 
(Tan et al., 2008).  Furthermore, expression of the N-terminal half of ZO-3 in MDCK 
cells resulted in reduced RhoA activity, reduced amounts of stress fibres and 
increased migration in a wound healing assay (Wittchen et al., 2003), further 
indicating a role for tight junctions in the regulation of cell migration, by impacting 
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on the cytoskeleton.  While many studies, such as those mentioned above examining 
the role of ZO-1 in migration, have been performed in single cells, they also generate 
interesting information for our understanding of collective cell migration.  During 
collective cell migration, the presence of cell contacts likely means some of the 
upstream signals affecting leading edge localisation of junction proteins may be 
different from those occurring in single cells.  Nevertheless, understanding the 
capabilities of individual junctional constituents may shed light on the mechanisms 
governing both single and collective cell migration.   
Transitions between single and collective cell migration states 
As discussed, both single and collective cell migration have important roles in 
physiological and pathological processes.  In addition to the mechanisms behind each 
type of migration, however, those processes defining the migration type also need to 
be understood.  The arrangement of epithelial cells in to monolayers is necessary for 
organ homeostasis.  During epithelial-to-mesenchymal transition (EMT) cells undergo 
a series of biochemical and morphological changes taking them from a polarised 
epithelial cell to a motile, individual, mesenchymal cell.  Sometimes this process is 
advantageous, for example during development, and sometimes it is detrimental, for 
example during metastasis of cancer cells.  Various signalling pathways are involved 
in triggering EMT in different biological contexts, including epidermal growth factor 
(EGF), Wnt, hepatocyte growth factor (HGF) and members of the transforming 
growth factor ! (TGF!) family, like TGF! and bone morphogenetic protein (BMP) 
(Kalluri and Weinberg, 2009; Yang and Weinberg, 2008).  Expression of transcription 
factors in response to these signalling pathways results in downregulation of epithelial 
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markers, like E-cadherin, occludin and claudins, and increased mesenchymal markers, 
like vimentin and smooth muscle actin (for review see (Kalluri and Weinberg, 2009)). 
Tight junctions and Epithelial-to-Mesenchymal transition 
The functional importance of the link between tight junctions and cell polarity is 
exemplified by the dissolution of tight junctions and polarity during epithelial-to-
mesenchymal transition induced by TGF!.  The TGF! receptor 1 (TGF!R1) has been 
shown to localize to the tight junction via an interaction with the second extracellular 
loop of occludin (Barrios-Rodiles et al., 2005).  Interaction between TGF!R1 and 
TGF! receptor 2 (TGF!R2) in response to TGF! serves to recruit TGF!R2 to the 
tight junction, where it can then phosphorylate Par6, which in turn inhibits RhoA 
leading to disassembly of the tight junctions.  Cells expressing mutant constructs of 
occludin lacking the second extracellular loop domain or phosphorylation mutants of 
Par6, display reduced tight junction loss in response to TGF! than control cells 
indicating the importance of the interaction between occludin and TGF!R1 in TGF!-
induced tight junction loss (Barrios-Rodiles et al., 2005; Ozdamar et al., 2005).  These 
data demonstrate a functional collaboration between tight junctions and polarity 
proteins in the regulation of epithelial-to-mesenchymal transition in response to 
TGF!.  Furthermore, the dissolution of junctions during EMT facilitates a transition 
from collective to single cell migration.   
Intracellular signalling pathways 
The regulation of intracellular signalling pathways is an important mechanism by 
which cells can transduce signals from the exterior to the interior of the cell, leading 
to necessary changes in gene expression and behaviour.  Some of these pathways 
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involved in the regulation of epithelial cell proliferation and migration will now be 
discussed.  It is also apparent that in addition to their structural role, tight junctions 
serve an important function in the integration and transmission of intracellular signals 
to regulate junction function and overall cell behaviour.  Thus tight junctions not only 
receive and respond to signals to alter their own behaviour (for example, paracellular 
permeability properties), but also transmit signals to the interior of the cell to regulate 
gene transcription and control cell proliferation and differentiation (Matter and Balda, 
2003b).  Thus signalling at the tight junction occurs in a bidirectional manner (Matter 
and Balda, 2003b).  Signalling pathways involved in tight junction assembly and 
function have been discussed above, so I will now focus on those signalling pathways 
emanating from the tight junction and their ultimate effects on gene expression. 
Tight junction regulation of gene expression 
There is increasing evidence of a role for tight junctions in the regulation of gene 
expression involved in cell proliferation and differentiation. Observations of ZO-1 
downregulation in breast (Hoover et al., 1998) and colorectal cancer (Kaihara et al., 
2003) combined with in vitro studies demonstrating reduced proliferation following 
ZO-1 overexpression (Balda et al., 2003) have implicated this cytosolic tight junction 
protein in the regulation of cell proliferation and differentiation.  Identification of an 
interaction between the SH3 domain of ZO-1 and the transcription factor ZONAB 
(ZO-1-associated nucleic acid binding protein) provided a potential mechanism 
through which this regulation may take place (Balda and Matter, 2000).  Gel shift 
assays showed ZONAB to be capable of interacting with the promoters of a number 
of cell cycle regulatory proteins and facilitators of cellular differentiation, like ErbB2 
(Balda and Matter, 2000). When cells are at low confluence and ZO-1 levels are low, 
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ZONAB demonstrates dual localisation to both the tight junction and the nucleus 
where it promotes G1 to S phase transition by increasing transcription of cyclinD1 
and proliferating cell nuclear antigen (PCNA) gene products.  When cells become 
confluent and ZO-1 levels increase, interaction between ZO-1 and ZONAB serves to 
sequester ZONAB at the tight junction, reducing its nuclear activity and therefore 
inhibiting proliferation.  ZONAB also complexes with CDK4, a regulator of G1 to S 
phase transition.  Sequestration of ZONAB in the cytoplasm by ZO-1 also prevents 
nuclear localization of CDK4, further impairing proliferation (Balda et al., 2003).  
Regulation of the transcriptional activity of ZONAB has also been shown to be 
mediated by RhoA (Nie et al., 2009).  By regulating Rho GTPase signalling, 
therefore, tight junctions may be able to further influence intracellular signalling 
pathways and gene expression. 
Signalling by Rho GTPases 
The Rho family of GTPases are small GTP-binding proteins of the Ras superfamily.  
RhoA, Rac and Cdc42 are the best-characterised members of the Rho GTPase family 
in mammalian cells.  The Rho GTPases function as molecular switches by cycling 
between a GDP-bound inactive state and a GTP-bound active state.  Rho GTPases 
have intrinsic GTPase activity converting GTP to GDP and resuming an inactive 
state.  This cycling is additionally regulated by guanine-nucleotide exchange factors 
(GEFs), which catalyse the exchange of GDP for GTP, and by GTPase-activating 
proteins (GAPs), which promote GTP hydolysis to GDP (Figure 1.4).  Therefore 
GEFs serve to activate RhoGTPase signalling pathways while GAPs serve to inhibit 
them.  By acting on numerous downstream effector molecules Rho GTPases regulate 
an array of cellular processes including actin reorganisation, cell adhesion and signal 
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transduction (Etienne-Manneville and Hall, 2002; Ridley, 2001).  In doing so Rho 
GTPases help coordinate diverse cellular processes like cell migration, proliferation 
and differentiation. 
 
Figure 1.5 – Regulation of Rho GTPase activity.  Rho GTPase signalling is 
regulated by their binding to GTP (active) or GDP (inactive).  Rho GTPases display 
intrinsic GTPase activity, switching off their signalling by hydrolysing GTP to GDP.  
Switching between active and inactive states is further regulated by guanine 
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs).  As 
shown, GEFs promote the exchange of GDP for GTP, so increase GEF activity 
results in increased levels of active GTPase and increased activation of downstream 
effectors.  GAPs promote intrinsic GTPase activity and therefore serve to switch off 
GTPase signalling by promoting hydrolysis of GTP to GDP.  Rho GTPases are also 
regulated by guanine nucleotide dissociation inhibitors (GDIs), which can bind GDP-
bound GTPases and prevent nucleotide dissociation, thus negatively regulating Rho 
GTPase signalling (not shown). 
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Activation of GTPase signalling 
GEF activity is regulated by a number of different extracellular signals.  Activation of 
growth factor receptors, cytokine receptors and receptors mediating adhesion have all 
been shown to activate GEFs and, in turn, downstream GTPases.  Activation of RhoA 
in response to EGF and TNF#-induced activation of the EGFR, for example, is 
mediated by GEFH1 activation (Kakiashvili et al., 2011).  Furthermore, 
phosphorylation of GEFH1 by ERK enhances the GEF activity of GEFH1 towards 
RhoA (Fujishiro et al., 2008).  As ERK can be activated in response to EGFR 
signalling, this affords a mechanism through which growth factor signalling can 
activate the GTPase RhoA.  Activated Rho GTPases then activate a number of 
effector molecules to elicit their effects.  By activating effectors involved in both 
cytoskeletal reorganisation and intracellular signalling, active Rho GTPases may 
facilitate changes to both the actin cytoskeleton and gene expression in response to 
growth factor signalling.   The direct mechanisms behind Rho GTPase-mediated 
regulation of gene transcription, however, are only beginning to be realised. 
Regulation of gene expression by Rho GTPases 
Rho GTPases have demonstrated the potential to impact on gene expression by a 
number of different mechanisms.  By regulating actin dynamics, Rho GTPase activity 
affects the ratio of G-actin to F-actin within the cell.   MAL, a coactivator of the 
serum response factor (SRF), binds to G-actin in the cytoplasm, which prevents its 
nuclear activity.  In response to Rho-induced actin polymerisation, and subsequent 
reduction in the cytoplasmic G-actin pool, MAL redistributes to the nucleus where it 
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can regulate SRF (Miralles et al., 2003).  Thus regulating actin cytoskeletal dynamics 
may be one mechanism by which Rho GTPases can mediate gene transcription. 
In addition, as mentioned above, RhoA activation of ZONAB transcriptional activity 
enables RhoA to mediate cyclinD1 expression (Nie et al., 2009). RhoA is also 
attributed with restricting the induction of cyclinD1 to mid-G1 phase (Welsh et al., 
2001).  Binding of cyclinD1 to cyclin-dependent kinases (CDKs) 4 and 6 and 
subsequent CDK activation results in phosphorylation of the retinoblastoma protein 
(Rb), relieving the Rb-mediated inhibition of E2F-regulated genes.  E2F-mediated 
expression of cyclins E and A facilitates entry in to S-phase (Kowalik et al., 1995).  
Thus by regulating cyclinD1 expression, Rho GTPases play a pivotal role in G1 phase 
cell cycle progression.  These studies demonstrate how Rho GTPases can regulate 
gene expression by eliciting cytoskeletal changes or by feeding in to intracellular 
signalling pathways.  By signalling through Rho GTPases, therefore, cells can 
regulate both cytoskeletal changes and intracellular signalling pathways, which may 
both lead to changes in gene transcription. 
In addition to GTPases, other mechanisms that regulate gene expression have also 
been associated with the tight junction (Balda and Matter, 2009), like the interaction 
between ZO-2 and scaffold-attachment factor B (SAF-B) (Traweger et al., 2003), a 
regulator of chromatin structure.  In addition, symplekin, which is implicated in the 
regulation of polyadenylation (Takagaki and Manley, 2000), demonstrates dual 
localisation within the nucleus and at the tight junction (Keon et al., 1996).  
Furthermore, transcription factors AP1 (activator protein-1) and Myc have been 
shown to interact with ZO-2 (Betanzos et al., 2004; Huerta et al., 2007).  By 
interacting with Myc, ZO-2 mediates the down regulation of cyclinD1 (Huerta et al., 
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2007).  Overexpression of ZO-2 down regulates AP1 activity in reporter assays 
indicating a role for tight junction proteins in the regulation of this signalling 
pathway.  For the purposes of this thesis, I will now discuss AP1 signalling and its 
regulation in the cell. 
AP1 signalling 
The AP1 transcription factor is composed of hetero- or homo-dimers of Jun and Fos 
family proteins.  Activation of mitogen-activated protein kinase (MAPK) signalling 
by growth factors, stress signals and cytokines results in activation of AP1 
transcription factors and changes in gene expression (Karin et al., 2001). AP1 
transcription factors recognise and bind the DNA consensus sequence TGAGTCA 
found in the promoters of numerous genes involved in cell proliferation, survival, cell 
differentiation, migration and cell death (Shaulian and Karin, 2002), and their activity 
can be regulated transcriptionally and post-translationally by components of the 
MAPK pathway (Minden et al., 1994; Tanos et al., 2005). 
 
The mitogen-activated protein kinase pathway 
The MAPKs are serine/threonine-specific protein kinases that regulate cellular events 
in response to various extracellular signals.  There are three main groups of MAPKs; 
extracellular signal-related kinases (ERKs), cJun N-terminal kinase (JNK) and p38 
MAPKs.  The MAPKs are activated in response to activation of an intracellular 
phospho-relay in which a specific stimulus activates a MAPK kinase kinase 
(MAPKKK) at the top of the pathway followed by the sequential activation of a 
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MAPK kinase (MAPKK) and then the MAPK.  MAPKs regulate many cellular 
activities by regulating transcription factor activity affecting the expression of genes 
involved in proliferation and cell cycle progression, migration and apoptosis, and cell 
differentiation.  In addition to nuclear substrates, MAPKs can also phosphorylate 
target proteins in the cytoplasm, such as the phosphorylation of paxillin by JNK 
during cell migration (Rosse et al., 2009). 
 
A number of studies have reported a role for MAPK signalling in regulating the 
paracellular permeability properties of the tight junction.  For example, in endothelial 
cells, oxidative stress induced by addition of H2O2 disrupts the tight junction barrier 
by activating ERK (Kevil et al., 2000).  In epithelial cells, H2O2-induced barrier 
disruption is reduced following concomitant addition of EGF and this protection is 
mediated by an interaction between ERK and the C-terminus of occludin (Basuroy et 
al., 2006).  In addition, JNK activation in response to osmotic stress mediates tight 
junction disruption induced by osmotic stress, which is reduced following JNK 
inhibition (Samak et al., 2010).  These results suggest a role for the MAPK pathway 
in the regulation of paracellular permeability properties of the tight junction and 
places the tight junction downstream of MAPK activation.  An upstream role for tight 
junctions in regulating and mediating the nuclear output of MAPK signalling, 
however, has not yet been shown. 
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Figure 1.6 – Representation of the major MAP kinase signalling cascades 
found in mammalian cells.  Care should be taken to remember that MAPK 
signalling involves a degree of cross-talk between the branches of the pathway 
shown above. Taken from (Zhang and Liu, 2002). 
 
As figure 1.5 shows, MAPK signalling is activated in response to a diverse range of 
stimuli.  By relaying, amplifying and integrating information from extracellular 
signals, the MAPK cascade enables an appropriate cellular response to be initiated.  
The regulation of proliferation by the MAPK pathway involves signalling by growth 
factors, which interact with and activate their receptors on the plasma membrane.  
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Binding of epidermal growth factor (EGF), for example, induces dimerisation and 
enzymatic activation of the EGF receptor (EGFR).  Subsequent autophosphorylation 
of the cytoplasmic domain generates multiple docking sites for an array of signalling 
molecules.  In response to EGF, this leads to activation of the small GTPase Ras 
followed by activation of the MAPKKK Raf and then the activation of ERK via 
MAPKK MEK.  EGF can also lead to the activation of JNK and p38 MAPK branches 
of the MAPK pathway resulting in phosphorylation of Jun family transcription factors 
and AP1 signalling. 
MAPK activation may also occur via ligand-independent mechanisms in response to 
various cellular stresses.  Activation of JNK in response to UV light and osmotic 
shock is thought to involve the same receptors mediating activation in response to 
ligands.  Alterations in receptor conformation caused by changes to the plasma 
membrane is thought to trigger receptor clustering and internalisation as would 
normally occur in response to ligand-binding, thus activating the same downstream 
pathways (Rosette and Karin, 1996). Interestingly, JNK activation is both pro-survival 
and pro-apoptotic depending on activator, cell type or duration of its active state. 
Prolonged activation of JNK in response to UV light exposure mediates cell death 
(Liu and Lin, 2005). 
Regulation of gene expression 
By translocating to the nucleus, activated MAPKs regulate the activity of a number of 
transcription factor targets leading to changes in gene expression.  MAPK-mediated 
phosphorylation of ternary complex factor (TCF) Elk-1 enables its interaction with 
serum response factor (SRF).  In complex with SRF, Elk-1, and other TCFs, promote 
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the expression of immediate early genes like c-fos (Buchwalter et al., 2004) (Figure 
1.6).  Expression of c-fos and its binding partner c-jun results in the formation of AP1 
transcription factor dimers and facilitates the expression of AP1 responsive genes 
involved in differentiation, proliferation and apoptosis.  MAPKs can further enhance 
or impair AP1 transcription factor activity by phosphorylation, which regulates their 
DNA-binding activity (Minden et al., 1994; Tanos et al., 2005).  Genes containing 
AP1 sites within their promoters include EGFR, cyclinD1 and matrix 
metalloproteinases (MMPs), enabling MAPK signalling to regulate cell proliferation 
and migration through its regulation of AP1 signalling. 
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Figure 1.7 – Regulation of the AP1 transcription factor by the MAPK signalling 
pathway.  ERK, JNK and p38 activate Elk-1 by phosphorylation.  Binding of Elk-1, or 
other TCFs, to SRF results in binding to the serum response element (SRE) in the c-
fos promoter and increased c-fos expression.   Expression of c-jun is regulated by 
JNK and p38 MAPK signalling as shown.  Increased levels of cFos and cJun results 
in increased AP-1 transcription factors, being composed of hetero- or homo-dimers of 
the jun and fos family proteins, and increased expression of genes with AP1 
responsive elements in their promoters.  The image in this figure was taken from 
(Whitmarsh and Davis, 1996). 
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Introduction to the current study 
As the literature describes, tight junctions perform an array of functions in the cell, 
which are each attributable to the protein complement from which they are composed.  
Association of integral membrane proteins to the claudin-based strands and their 
interactions with cytosolic proteins beneath enables tight junctions to mediate 
paracellular permeability, cell polarity and intracellular signalling pathways, all of 
which are integral to the functioning of the epithelial monolayer as a whole.  In order 
to understand how tight junctions perform these functions a comprehensive 
understanding of their constituents is required.  In 2002, a novel transmembrane 
domain called the Marvel domain (MAL and related proteins for vesicle trafficking 
and membrane link) was identified and found to be present in tight junction proteins 
occludin and (though it had yet to be described) tricellulin (Sanchez-Pulido et al., 
2002).  Intriguingly, this study also highlighted two additional occludin-like proteins 
that were otherwise unknown.  These sequences correspond to two isoforms of a 
protein called MarvelD3 (Sanchez-Pulido et al., 2002).  Given the apparent 
importance of this domain at sites of membrane apposition and its presence in two 
known tight junction proteins, the aim of this thesis was to identify and characterise 
MarvelD3 and determine its relevance to the biology of the tight junction.   
 
Identification of the Marvel domain 
The Marvel domain is a novel domain with a four transmembrane-helix architecture 
first identified in proteins of the myelin and lymphocyte (MAL), physins, gyrins and 
occludin families, shown to be evolutionarily conserved between species (Sanchez-
 60 
Pulido et al., 2002).  All currently described Marvel domain-containing proteins 
demonstrate an M-shaped topology, with four transmembrane helices weaving 
through the membrane between cytoplasmic N- and C-terminal regions.  While 
putative functions for the Marvel domain have been proposed, its prevalence and 
significance within the cell is not yet fully understood. Interestingly, overexpression 
of occludin, MAL and synaptophysin results in the formation of intracellular vesicles, 
just as occurs following the overexpression of caveolin, a protein considered 
necessary for the organisation of membrane microdomains during caveolae formation 
(Razani and Lisanti, 2001; Smart et al., 1999).  Though caveolin does not possess a 
Marvel domain itself, these similar phenotypes prompted the hypothesis that the 
Marvel domain may also be involved in organisation of cholesterol-rich membrane 
domains (Sanchez-Pulido et al., 2002).  Indeed, during synaptic vesicle biogenesis, 
interaction between Marvel domain-containing synaptophysin and cholesterol has 
been implicated in facilitating the correct isolation of vesicular from plasma 
membrane constituents, as well as in the induction of vesicular curvature (Thiele et 
al., 2000). Though no direct interaction has been established, occludin and MAL 
family proteins have also been identified in membrane regions with high cholesterol 
content (Millan et al., 1997; Nusrat et al., 2000), supporting the notion that Marvel 
domains could perhaps function in the organisation of membrane domains during 
apposition events, such as those that occur during vesicular fusion, and at the tight 
junction.   
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The Marvel domain and the tight junction 
Given the implication in events where membrane apposition occurs and its presence 
in two recognized tight junction proteins occludin and tricellulin, it seems clear that 
the Marvel domain may play a significant role in the physiology of tight junctions.  
Interestingly, tricellulin has been shown to redistribute along the bicellular tight 
junctions in cells depleted of occludin (Ikenouchi et al., 2008).  This suggests that 
tricellulin may be able to compensate for some functions of occludin in occludin 
knockdown cells, and perhaps alludes to the importance of the presence of a Marvel 
domain at the tight junction.   Indeed studies conducted during this thesis and by other 
labs have suggested that Marvel domain-containing proteins of the tight junction 
perform parallel, but not redundant, functions.   
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Aims 
In consideration of reports in the literature implicating Marvel domain-containing 
proteins in membrane apposition events and the fact that two known tight junction 
proteins, occludin and tricellulin, contain a Marvel domain, MarvelD3 is thought to be 
a particularly interesting and appropriate candidate as a novel constituent of the tight 
junction.  In light of this the aims of the current study were; 
1. To initially characterise the Marvel domain-containing protein MarvelD3 by 
determining the extent of its expression in epithelial and endothelial cells and tissues, 
its localisation within the cell and, specifically to see if it localises within the 
epithelial junctional complex. 
2. To validate MarvelD3 as a functional and significant component of epithelial 
cell tight junctions through analyses of junction formation and maintenance when 
MarvelD3 is stably over-expressed and suppressed via siRNA-mediated knockdown. 
3. To investigate the role of MarvelD3 in the regulation of intracellular signalling 
pathways, which are becoming ever more associated with tight junctions and may 
provide additional insight in to how tight junction proteins can impact upon 
intracellular signalling involved in pathological conditions, like tumour progression.  
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Chapter 2: 
Materials and Methods 
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2. Materials and Methods 
All chemicals are from Sigma unless otherwise stated. 
2.1 Cell Culture 
The following cell types were cultured (Table 2.1): Caco-2, colon adenocarcinoma 
cells; HCE, immortalised corneal epithelial cells; MDCK, Madin-Darby canine 
kidney cells; PNT-1a and PNT2-C2, immortalised prostate epithelial cells; HepG2, 
hepatocellular carcinoma cells; HaCaT, spontaneously immortalised skin 
keratinocytes; MiaPaCa, human pancreatic tumour cells; ARPE-19, spontaneously 
immortalised retinal pigment epithelial cells; hCMEC/D3, immortalised brain 
endothelial cells; HCEC-B4G12, immortalised corneal endothelial cells. Caco-2, 
HCE, MDCK, HaCaT, MiaPaCa and HepG2 cells were grown in DMEM (Invitrogen, 
Paisley, UK) with 10% (HCE, MDCK, HaCaT, MiaPaca, HepG2) or 20% (Caco-2) 
foetal bovine serum (Invitrogen). PNT-1a and PNT2-C2 were cultured in RPMI 1640 
(Invitrogen) supplemented with glutamine and 10% foetal bovine serum, ARPE-19 
cells in a 1:1 mixture of DMEM and Nutrient Mixture F12 containing 10% foetal 
bovine serum and L-glutamine, hCMEC/D3 in EGM-2 medium (Cambrex 
BioScience, Wokingham, UK), and HCEC-B4G12 in human Endothelial-SFM 
containing 10 ng/ml FGF-2 (Invitrogen). MarvelD3-expressing MiaPaca cell lines 
(C2, C8 and P2) were cultured in DMEM with 10% foetal bovine serum and 30mg/ml 
G418 (PAA laboratories GmbH, Pasching, Austria).  All cell lines were grown in the 
presence of penicillin (100U/ml) and streptomycin (100µg/ml; Invitrogen) at 37°C in 
a 5% CO2 atmosphere. 
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Table 2.1 – Details of cell lines used in the current study.  The species and 
tissue of origin as well as the metastatic phenotype for all the cell lines used in the 
current study are shown.  Those cells cultured were kept as described above.  Cell 
lysates and cDNA from LnCaP, MB231, MCF10A, MCF7, Muller cells, P4E6, PC3 
and Schmac cells were kindly provided by Professor Karl Matter, UCL Institute of 
Ophthalmology.  HUVEC cDNA was kindly provided by Jay Stone, UCL Institute of 
Ophthalmology. 
2.1.1 Cell storage 
For long-term storage, cells at approximately 80% confluency were trypsinised 
completely in 1X Trypsin-EDTA (PAA laboratories GmbH) at 37°C.  Fully 
trypsinised cells were resuspended in 6ml DMEM with 10% foetal bovine serum and 
centrifuged at 1000 rpm for 5 minutes at room temperature.  The supernatant was 
removed and cell pellet gently resuspended in 3ml DMEM or RPMI 1640, each 
supplemented with 30% foetal bovine serum and 10% DMSO.  Cell suspension was 
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separated into 1ml aliquots in cryovials and frozen at -80°C overnight.  Samples were 
transferred to -150°C or liquid nitrogen for long-term storage. 
 
2.2 Transfection Methods 
2.2.1 Lipofectamine 2000 
Plasmids were transfected into Caco-2 and MDCK cells using Lipofectamine 2000 
reagent (Invitrogen).  Cells were plated in DMEM containing 10% foetal bovine 
serum without antibiotics, 24 hours prior to transfection.  For transfection, cDNA 
(Tube 1) and Lipofectamine 2000 (Tube 2) were diluted into OptiMEM, as shown in 
table 2.2, and incubated at room temperature for 5 minutes.  Tubes 1 and 2 were 
combined and incubated at room temperature for a further 20 minutes.  Finally, DNA-
Lipofectamine complexes were added to each well containing DMEM with 10% 
foetal bovine serum without antibiotics in the final volumes shown (Table 2.2).  
Transfection medium was changed after overnight incubation at 37°C.  Expression 
was analysed 48 hours after transfection. 
 
 
Table 2.2 – Lipofectamine transfection quantities.  See text for details. 
Transfection was performed in DMEM without penicillin/streptomycin antibiotics 
(w/out P/S). 
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2.2.2 JetPEI  
Plasmids were transfected into MiaPaCa cells using JetPEI reagent (Polyplus 
Transfection Inc., Illkirch, France).  Cells were plated in DMEM containing 10% 
foetal bovine serum and antibiotics (complete medium), 16 hours before transfection.  
For transfection, cDNA (tube 1) and JetPEI (tube 2) were diluted into 150mM NaCl, 
as shown in table 2.3, and vortexed gently.  The contents of tube 2 were then added to 
tube 1, vortexed gently, briefly spun and then incubated at room temperature for 30 
minutes.  The transfection mix was then added to each well containing complete  
medium in the final volumes shown (Table 2.3).  Transfection medium was changed 
after 24 hours incubation at 37°C.  
 
 
Table 2.3 – JetPEI transfection quantities. See text for details. 
 
2.2.3 Ca2+-phosphate precipitation 
Cells were plated in DMEM containing 10% foetal bovine serum with antibiotics, 24 
hours prior to transfection.  Plasmids were combined in an appropriate volume of 2X 
HEPES buffer (0.5M HEPES pH7.1, 3M NaCl, 1M NaPO4 pH7.1). This was then 
shaken vigourously as an equal volume of 0.25M CaCl2 was added drop-wise to the 
centre of the tube.  The solution was left to precipitate for 30 minutes at room 
temperature.  Medium was aspirated from cells and the precipitate added and 
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incubated for 20 minutes at 37°C.  Finally, warm complete medium was added and 
the cells incubated overnight at 37°C.  Transfection medium was replaced with fresh 
complete medium and cells returned to 37°C.  For MDCK cells, a glycerol shock was 
performed after overnight incubation.  MDCK cells were incubated with 12.5% 
glycerol (prepared in complete medium) for 2 minutes at room temperature, washed 
carefully with 1X PBS before adding back complete medium and returning to 37°C. 
 
2.2.4 Interferin 
For knockdown studies, Caco-2 and HCE cells were transfected with individual or a 
pool of siRNAs (MD3p-siRNA) specific for MarvelD3 (5’ to 3’ direction): siRNA13, 
GCGCAGGTGAACACGGAGT; siRNA14, GAGAGGAGGTGGAATATTA; 
siRNA15, CCGGAGAGAGACCAGGAGA; siRNA16, 
GCCGCAGACCCGAAAGTGA.  All four target sequences are found in the N-
terminus common to both isoforms of MarvelD3 (Thermo Scientific Dharmacon, 
Lafayette, CO). Used were On-Target plus siRNAs along with control On-Target plus 
siRNAs from the same provider. For transfections, Interferin transfection reagent 
(Polyplus Transfection Inc) was used according to the manufacturer’s instructions. 
Briefly, cells were plated 16 hours prior to transfection.  Interferin reagent was 
vortexed for 1 second and left to stand at room temperature for 10 minutes.  Interferin 
was added to OptiMEM (Invitrogen) containing siRNA in the volumes detailed below 
(Table 2.4), pipetted up and down once to mix, and incubated at room temperature for 
10 minutes.  Complete medium was added to the Interferin-siRNA-OptiMEM mix, 
inverted 3 times and added to the cells.  Transfection medium was changed after 24 
hours and expression was analysed between two and four days after transfection. 
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Efficient knockdown of MarvelD3 was achieved with a final total siRNA 
concentration of 100nM.  Other siRNAs were used in the volumes shown in Table 
2.4. 
 
 
Table 2.4 – Interferin transfection quantities. See text for details. 
 
2.3 Generation of stable cell lines 
2.3.1 Generation of MiaPaCa expressing MarvelD3_1:VSV 
VSV-tagged MarvelD3_1 was previously cloned into eukaryotic expression vector 
pCIN4 (kindly provided by Professor Karl Matter).  MiaPaCa cells were plated at 
50% confluence in complete medium with 2.5% horse serum (Invitrogen) the day 
before transfection. pCIN4-MD3_1:VSV (20µg) was transfected by Ca2+-phosphate 
precipitation.  After overnight incubation, the transfection medium was removed and 
cells incubated in 2ml complete medium for 8hours at 37°C.  Medium was aspirated 
into a 15ml centrifuge tube.  Cells were washed in 3ml PBS, which was added to the 
tube. Cells were fully trypsinised in 2ml Trypsin-EDTA, resuspended in 5ml 
complete medium and added to the 15ml tube.  Cells were then centrifuged at 1000 
rpm for 5 min and the supernatant discarded.  The cell pellet was resuspended in 25ml 
complete medium with 2.5% horse serum and 0.6mg/ml G418, to select against 
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untransfected cells, and plated onto a 15 cm plate.  Cells were incubated at 37°C for 
17 days.  After 17 days, 12 clones were picked by trypsinising until cell-cell contacts 
were lost, but cells remained adherent to the 15cm plate.  Trypsin-EDTA was then 
aspirated completely and clones were picked using a 200µl pipette tip.  Clones were 
plated onto a 24-well plate in complete medium with 2.5% horse serum and 0.6mg/ml 
G418.  Remaining colonies were resuspended in 10ml complete medium with 2.5% 
horse serum and plated onto a 6-well plate to create a pool.  Untransfected cells in the 
pool were selected against with 0.6mg/ml G418 or 3mg/ml G418.  Clones and pools 
were then observed until 80%-90% confluent.  Transfection efficiency was 
determined by immunoblotting and immunofluorescence.  Expression of 
MD3_1:VSV was established in two independent clones (C2 and C8). 
 
2.4 DNA Methods 
2.4.1 cDNA 
cDNAs coding for full length and truncated, tagged and untagged MarvelD3 isoforms 
were generated by PCR from reverse transcribed Caco-2 total RNA and from an EST 
clone obtained form Geneservice Source BioScience plc. The PCR reaction mix was 
composed of 5µl 10X buffer with MgCl2, 8µl dNTPs (each 1.25mM), 1µl forward 
primer, 1µl reverse primer, 0.5µg template DNA, 5µl DMSO, 0.5µl Taq polymerase 
and brought to a final volume of 50µl with distilled water.  The PCR was performed 
in a Thermocycler (Biometra GmbH, Germany) under the following conditions: 95°C 
for 2 minutes, a 2 hour 30 minute annealing-elongation cycle (30 seconds at 94°C – 
30 seconds at 60-65°C – 1 minute at 72°C) and then incubated at 72°C for 10 
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minutes.  Suitable annealing temperatures were determined for each pair of primers.  
Primers were designed to generate cDNAs containing the restriction sites necessary 
for cloning into a suitable expression vector, as shown in table 2.5. The resulting 
cDNA constructs were verified by sequencing.  
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Table 2.5 – Primers used to clone MarvelD3 constructs.  The forward and 
reverse primers used to generate cDNA of each construct, and the restriction sites 
used to clone constructs into each vector, are shown.  Internal restriction sites in 
VSV- and HA-tagged constructs are shown in italics.  Constructs marked with an * 
were designed but have not yet been made. 
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2.4.2 Purification of PCR products with silica beads 
PCR products were purified from a 1% low-melting agarose gel (AGTC Bioproducts, 
Hessle, UK) in 1X Tris-Acetate-EDTA (TAE) buffer (National Diagnostics, Atlanta, 
GA).  Samples were run out at 50mV until they could be clearly resolved against the 
1kb ladder.  Bands were carefully cut from the gel, and melted in 1ml 6M NaI for 10 
minutes at 70°C.  Silica beads (40µl) were added to the melted agarose, inverted and 
incubated at room temperature for 10 minutes, inverting again after 5 minutes to mix.  
Samples were centrifuged at 2000 rpm for 1 minute, the supernatant removed and 
resuspended in 1ml wash buffer (50nM NaCl, 10mM TrisHCl pH7.5, 2.5mM EDTA, 
50% v/v ethanol) and centrifuged again.  This wash step was then repeated.  After 
removing as much wash buffer as possible, beads were resuspended in 30µl water and 
incubated at 70°C for 10 minutes to elute the DNA.  A 5µl sample of the eluate was 
run on a 1% agarose gel (Bioline Ltd, London, UK) to check for recovery. 
 
2.4.3 Restriction digests 
In order to clone the PCR products into the necessary expression vectors, both the 
PCR product insert and target vector were digested with the appropriate combination 
of restriction enzymes (Table 2.4).  Restriction digests were set up on ice and 
contained 3µg vector DNA or 15µl PCR product, 3µl 10X buffer, 1µl enzyme 1, 1µl 
enzyme 2 and distilled water to give a final volume of 30µl, and then incubated at 
37°C for 2 hours.  All enzymes and buffers were supplied by New England Biolabs 
(NEB). Appropriate buffers for double digests were found by consulting the NEB 
Enzyme finder online (http://www.neb.com/nebecomm/enzymefinder.asp).  To 
prevent self-ligation, 2µl Antarctic phosphatase (NEB) and 2µl Antarctic phosphatase 
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buffer (NEB) were added to the digested vector and incubated at 37°C for a further 30 
minutes.  This reaction was stopped by adding 2µl 0.5M EDTA and incubating at 
70°C for 10 minutes. 
 
2.4.4 Agarose ligations 
The digested vectors and PCR product inserts were run out on a 1% low-melting 
agarose gel at 50mV for 1-2 hours.   PCR product bands were carefully cut from the 
gel and purified with silica beads as described above (2.4.2).  The linearised vector 
bands were cut from the gel and melted at 70°C for 10 minutes.  Vectors and inserts 
were combined in appropriate ratios in a 10µl volume, and the ligation mix 
(containing 2µl 10X ligation buffer, 7µl distilled water and 1µl T4 DNA ligase 
(Roche Diagnostics, Mannheim, Germany)) was added.  Ligations were incubated at 
room temperature for 2 hours and then left at 4°C overnight before being transformed 
into competent DH5# cells. 
 
2.4.5 Preparation of competent cells 
A single colony of the desired strain was inoculated into 5ml LB and incubated 
overnight at 37°C.  The overnight culture was then diluted 1:100 in LB and incubated 
at 25°C until OD600=0.4-0.5.  Cells were then placed on ice, centrifuged at 4000 rpm 
for 10 minutes at 4°C and gently resuspended in 200ml ice-cold TB buffer (10mM 
Pipes-KOH, pH6.7, 15mM CaCl2, 0.25M KCl, 55mM MnCl2).  Cells were 
centrifuged again and resuspended in 40ml ice-cold TB.  DMSO (3ml) was added and 
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incubated on ice for 10 minutes before aliquoting cells and snap-freezing in liquid 
nitrogen.  Efficiency was tested with the standard transformation protocol. 
 
2.4.6 Transformation of competent cells 
Competent DH5# (for preparation of cDNAs) and BL21 pLysS (for induction of 
GST-fusion proteins) were transformed according to the same standard protocol.  
First, cells were thawed slowly on ice.  Once thawed, 1.4M !-mercaptoethanol was 
added, and incubated on ice for 10 minutes.  Cells (100µl) were then incubated with 
the DNA to be transformed (1µl plasmid DNA, or 10µl for ligations) for a further 30 
minutes.  Samples were heat-shocked at 42°C for 45 seconds, returned to the ice for 3 
minutes, before adding 1ml LB and incubating at 37°C for 1 hour.  Samples were then 
plated as appropriate (100µl for cells transformed with plasmid DNA, while cells 
transformed with ligations were spun down, resuspended in 100µl and plated in full) 
onto LB agarose plates supplemented with 100µg/ml ampicillin or 50µg/ml 
kanamycin, as necessary.  Plates for BL21 pLysS cells were further supplemented 
with 34µg/ml chloramphenicol to prevent protein expression.  Plates were incubated 
at 37°C overnight to allow colony formation. 
 
2.4.7 Preparation of plasmid DNA 
To prepare plasmid DNA for transfection, colonies were picked from overnight plates 
and inoculated one colony per 5ml (for mini-prep) or 200ml (for midi-prep) LB 
containing the appropriate antibiotic.  cDNAs were then prepared using a QIAGEN 
mini- or midi-prep kit according to the manufacturers instructions (QIAGEN, Hilden, 
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Germany).  Presence of insert was determined by restriction digest and confirmed by 
sequencing (MWG Biotech). Concentrations were determined using a 
spectrophotometer (Eppendorf Biophotometer) and preparations were stored at -20°C 
until use. 
 
2.4.8 Agarose gel electrophoresis 
DNA gel electrophoresis was used to separate DNA samples according to size to 
assess the presence of inserts and prior to purification and agarose ligation.  Gels were 
made from 1% agarose (Bioline, London, UK) in 1X Tris-Borate-EDTA (TBE) buffer 
(National Diagnostics) (for confirmation purposes), or 1% low-melting agarose in 1X 
TAE buffer (for purification and agarose ligations), containing 1:20000 SafeView 
nucleic acid stain for detection purposes (NBS Biologicals Ltd, Cambridgeshire). 
Gels were run at 100mV for 1-2 hours surrounded in 1X TBE or TAE buffer, as 
made.  1% low-melting agarose gels were run at 50mV for 1-2 hours.  Gels were 
viewed in UV box (Syngene BioImaging system) or under UV lamp with wavelength 
302nm (Upland, CA). 
 
2.5 RNA Methods 
2.5.1 RNA extraction and reverse transcription PCR (RT-PCR) 
To assess the expression pattern of MarvelD3 in various cell and tissue types, total 
RNA was isolated from tissues and cultured cells using an miRNeasy Mini Kit 
(QIAGEN) according to the manufacturers instructions. Reverse transcription was 
performed at 45°C using AMV reverse transcriptase (Promega Corp, Madison, WI) 
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for 1 hour. A sample of HUVEC cDNA generated from total RNA was kindly 
provided by Jay Stone (UCL Institute of Ophthalmology, London, UK). The cDNAs 
were then amplified by PCR using FastStart Taq polymerase (Roche Diagnostics 
GmbH., Mannheim, Germany) at an annealing temperature of 63°C. The following 
primers were used (5’ to 3’ direction): human MarvelD3 
AAAAATCTAGATCAAAGAG TTCCAGACCACAG and 
AAAAATCTAGATTAAAATTCAAACATTTCTGCTGG for reverse transcription, 
and AAAAAGCTAGCAAATACTTGTGCACTGGGAGAG, AAAAAGCTAGCTC 
GGTAGCTACGCAGGGC, AAAAAGCTAGCTCGGTAGCCCTTTATGGCCA for 
PCR amplification; mouse MarvelD3  CACAAATGCAGATACTTGTGCACAGG, 
CTAAAACTCAAGCATTTCTGTGGGC, TTAGAGCGTCCCGGACCACAGGTA ; 
GAPDH (human and mouse) ATCACTGCCACCCAGAAGAC and 
ATGAGGTCCACCACCCTGTT.  
 
2.5.2 RNA extraction and microarray analysis 
Wild-type and MarvelD3-expressing MiaPaCa clones C2 and P2 were plated into 6-
well plates (1.5x105 cells/well) and grown at 37°C for 4 days, recreating the 
conditions under which the proliferation phenotype was first observed. Importantly, 
prior to RNA isolation, cells were not trypsinised thus avoiding any affects this may 
have on gene expression.  Rather, medium was removed, cells quickly washed once in 
1X PBS and QIAzol lysis reagent added to give a final volume of 700µl for each 
sample.  RNA was then isolated according to the manufacturers instructions using an 
miRNeasy Mini Kit (QIAGEN).  RNA from MarvelD3-expressing clones was 
combined.  RNA from wild-type and MarvelD3-expressing MiaPaCa cells was 
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labelled using an Affymetrix WT labelling assay to create cDNA probes which were 
then hybridised to Human Affymetrix Gene 1.0 ST Arrays (Tony Brooks, UCL 
Institute of Child Health).  Data was analysed using GeneSpring GX 11.0.1 software 
(Agilent Technologies, Santa Clara, CA) and the online bioinformatics resource 
DAVID (Huang da et al., 2009). 
 
2.6 Protein Methods 
2.6.1 Generation and purification of anti-MarvelD3 peptide antibody 
To analyse MarvelD3 expression an antibody against a peptide of the N-terminal 
cytoplasmic domain (CAPDRGPRRDTHRDAG) was generated. To purify, the same 
peptide was coupled to epoxy-activated sepharose beads by incubating 2mg peptide 
with 2g swollen sepharose in a total volume of 50ml coupling buffer (0.1M sodium 
bicarbonate (pH11)), overnight on an end-over-end shaker at 4°C.  Excess groups 
were then blocked with 1M ethanolamine, pH11, incubated overnight on an end-over-
end shaker at 4°C.  Peptide-conjugated beads were washed 3 times through a cycle of 
50ml coupling buffer, 50ml distilled water, 50ml 0.1M acetate with 0.5M NaCl, pH4 
and 50ml PBS, before being resuspended in PBS containing 0.1% NaN3.  The 
antibody-containing serum was diluted 1:5 with 10mM Tris (pH7.5), containing 
150mM NaCl, 40µg/ml PMSF and 0.1% NaN3, and centrifuged at 10,000 rpm for 15 
minutes at 4°C.  The supernatant was then added to the peptide-conjugated beads and 
incubated overnight on an end-over-end shaker at 4°C.  To elute the antibody, 
samples were spun at 3000 rpm for 10 minutes and the beads resuspended in the 
10mM Tris (pH7.5) described above.  Resuspended beads were poured onto a Pierce 
column and washed with the Tris solution until the OD280 of the eluate was <0.01.  To 
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elute the antibody, 15ml tubes containing 750µl 1M Tris (pH8) were prepared.  The 
antibody was eluted into these tubes in 7ml aliquots first with 100mM glycine 
(pH2.8) and then with 100mM triethanolamine (pH11.5).  Protein concentration was 
determined by measuring OD280 and the peak fractions were combined for each 
elution buffer.  Pools were pH6-8.5.  The antibody was then dialysed twice overnight 
against 1X PBS at 4°C.  This antibody was used in results chapter 3.!
 
2.6.2 Generation and purification of antibody against the entire N-terminus and 
two isoform-specific C-termini of MarvelD3 
To improve detection of MarvelD3, an antibody was raised against the whole N-
terminus (amino acids 1-198) and, since the sequence of the N-terminus is common to 
both MarvelD3 isoforms, against isoform-specific sequences at the C-termini (amino 
acids 384-411 isoform 1; amino acids 387-402 isoform 2).  GST-fusion proteins were 
generated and injected into rabbits.  Antibodies were purified by conjugating GST-
fusion proteins of the relevant domain of MarvelD3 to hydrated CNBr-activated 
sepharose on an end-over-end shaker overnight, at 4°C.  Antibody serum (10ml) was 
brought to a final volume of 50ml with 10mM Tris-HCl, pH7.5 containing 150mM 
NaCl, 40mg/ml PMSF and 0.1% NaN3, and then centrifuges at 10,000 rpm for 15 
minutes.    Supernatant was added to the washed beads and incubated on an end-over-
end shaker overnight, at 4°C.  Beads were then centrifuged at 3000 rpm for 10 
minutes, resuspended in 10mM Tris-HCl, pH7.5, 150mM NaCl and loaded onto a 
Pierce column with reservoir.  The column was washed with 10mM Tris-HCl, pH7.5, 
150mM NaCl until the OD280 of the eluate was below 0.01.  Antibody was then eluted 
with 100mM Glycine, pH2.8, concentration was determined by measuring OD280.  
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Peak fractions were combined and dialysed twice overnight against 1X PBS at 4°C.   
The antibody specific for the N-terminus of MarvelD3 purified in this way was used 
in results chapters 4 and 5. 
 
2.6.3 Production of GST-fusion proteins 
GST-fusion proteins were produced by transforming plasmids into competent BL21 
pLysS cells as described above (Section 2.4.6).  After overnight incubation at 37°C, 
colonies were picked, inoculated into 50ml LB containing ampicillin and 
chloramphenicol and grown overnight at 37°C on a shaker.  Protein production was 
induced by adding 200ml LB, containing 100mg/ml ampicillin and 1mM Isopropyl !-
D-1-thiogalactopyranoside (IPTG), to the overnight cultures and incubating at 25°C 
for 2 hours on a shaker.  Cells were centrifuged at 4000 rpm for 15 minutes at 4°C 
and resuspended in 10ml PBS containing 0.5% Triton X-100 (PBSTx), a cocktail of 
protease and phosphatase inhibitors (50µg/ml bezamidine, 10µg/ml aprotinin, 
10µg/ml leupeptin, 10µg/ml pepstatin A, 1mM PMSF) and 1mM DTT.  Samples were 
sonicated, centrifuged at 10,000rpm at 4°C for 10 minutes and the supernatant stored 
at -80°C until use.  Recovery of fusion protein was determined by adding a 300µl 
sample to 40µl 40% glutathione bead suspension and incubating for 1 hour on an end-
over-end shaker at 4°C.  Beads were washed 3 times with 1ml 0.5% PBSTx and once 
with 1X PBS before being resuspended in 30µl SDS sample buffer (see below, 
Section 2.6.5) and incubated at 70°C for 5 minutes.  Presence of the fusion protein 
was assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE).  After running samples on a 12% gel, the gel was stained with coomassie 
blue (for 500ml; 1.25g coomassie blue, 450ml 1:1 methanol:H2O, 50ml acetic acid) 
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for 30 minutes and then destained over night with destaining solution (20% methanol, 
7.5% acetic acid) at room temperature with gentle agitation.  GST-fusion proteins 
with an expected molecular weight could be identified with reference to the molecular 
weight marker.!
!
2.6.4 Purification of GST-fusion proteins 
For antibody production, GST-fusion proteins were purified from bacterial lysates.  
Lysates were thawed on ice and brought to 30ml with 0.5% PBSTx containing 1mM 
DTT and fresh protease and phosphatase inhibitors.  Samples were centrifuged at 
10000 rpm for 10 minutes at 4°C.   The supernatant was incubated with 3ml 40% 
glutathione bead suspension for 2 hours on an end-over-end shaker at 4°C.  Beads 
were then loaded on to Pierce columns (Thermo Scientific, Rockford, IL) and washed 
with 0.5% PBSTx until the OD280 of the eluate was <0.01.  GST-fusion protein was 
eluted with 25mM reduced glutathione prepared in 1M Tris (pH8) and the 
concentration determined by measuring OD280. 
 
2.6.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Polyacrylamide gels were prepared using a MightySmall II gel electrophoresis system 
(Hoefer, Holliston, MA) and contained polyacrylamide, 0.1% ammonium persulphate, 
0.1% SDS and TEMED.  Stacking gels were prepared at 5% with Tris-HCl, pH6.8.  
Resolving gels were prepared at 12%, 10% or 8%, as necessary, with Tris-HCl, 
pH8.8. Whole cell lysates were collected by adding SDS sample buffer (3% SDS, 
15% glycerol, 0.0015% bromophenol blue, 0.25M Tris HCl containing 150mM DTT 
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and 6M Urea) to samples pre-washed once in 1X PBS. The samples were incubated 
for 30 minutes at room temperature and then homogenised through a 25G needle 
before analysis by SDS-PAGE.  Samples were transferred to nitrocellulose membrane 
(LI-COR Biosciences, Lincoln, NE) for western blotting at 100V, restricted to 450mA 
for 120-150 minutes depending on protein size.  Transfer buffer contained 20% 
methanol and 1X SDS-Tris-Glycerol (National diagnostics, Atlanta, GA). 
 
2.6.6 Immunoblotting 
Nitrocellulose membranes were stained with 0.1% amido black for 30 seconds 
followed by agitated destaining in 20% methanol, 7.5% acetic acid for 15 minutes at 
room temperature.  Nitrocellulose membranes were blocked in 5% milk prepared in 
TBST (1M Tris-HCl pH7.4, 3M NaCl, 0.5% Tween) and containing 0.1% NaN3, for 
30 minutes. Primary antibodies were incubated overnight in 5% milk-TBST with 
0.1% NaN3 at room temperature (see table 2.6 for primary antibody information).  
Secondary antibodies were incubated for 2 hours in TBST at room temperature 
without 0.1% NaN3.  MarvelD3 protein levels were detected with a horseradish 
peroxidase-conjugated donkey anti-rabbit antibody (1:5000) and enhanced 
chemiluminescence detection system (ECL; Amersham, Corp. Arlington Heights, IL).  
All other protein levels were detected using an Odyssey detector and IRDye-680- and 
IRDye-800CW-conjugated donkey anti-rabbit, donkey anti-mouse and donkey anti-
goat secondary antibodies (LI-COR Biosciences; 1:5000). 
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2.6.7 Methanol Fixation 
Cells grown on glass coverslips or filters (Fisher Scientific, Loughborough, UK), as 
specified, for at least 3 days were either fixed directly in methanol or first extracted 
on ice with 0.1% Triton X-100 in BB buffer (100mM KCl, 3mM MgCl2, 1mM CaCl2, 
200mM sucrose, 1mM Hepes, pH7.1) for 1 minute and then fixed in methanol at -
20°C for 10 minutes.  Cells were rehydrated in PBS for 5 minutes and blocked for 15 
minutes with 0.5% BSA in PBS (PBS-0.5%BSA).   
 
2.6.8 Paraformaldehyde Fixation 
Cells were grown on glass coverslips for at least 3 days prior to fixing.  Cells were 
fixed in 4% PFA for 20 minutes at room temperature before being permeabilised in 
0.1% Triton in PBS-0.5%BSA for 5 minutes at room temperature.  Coverslips were 
washed twice in 1X PBS before blocking and quenching in PBS-0.5%BSA containing 
20mM Glycine for 10 minutes at room temperature.  Samples were kept in PBS-
0.5%BSA until processed for immunofluorescence. 
 
2.6.9 Immunofluorescence 
Coverslips fixed in either methanol or PFA were incubated with primary antibodies 
(Table 2.6) for 2 hours at room temperature, washed three times with PBS-0.5%BSA 
and incubated with secondary antibody and Hoechst nuclear stain for 1 hour at room 
temperature.  Filters were incubated in primary antibody overnight at room 
temperature in a moist atmosphere, washed three times with PBS-0.5%BSA and 
incubated in donkey Cy3- or FITC-, anti-rabbit, anti-rat or anti-mouse secondary 
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antibodies (1:300; Jackson Immunoresearch, West Grove, PA) with Hoechst (1:4000) 
for 1.5 hours at room temperature.  Where necessary FITC- and Cy3-phalloidin 
(1:4000) were incubated with the secondary antibodies and nuclear stain. Coverslips 
and filters were then washed two times with PBS-0.5%BSA and once with PBS 
before being mounted onto glass microscope slides with ProLong Gold mounting 
medium (Invitrogen). Images were acquired using a Leica Image capture 
epifluorescent microscope and a Zeiss LSM510UV confocal microscope with 63x oil 
immersion lenses.  Brightness and contrast were adjusted with Adobe Photoshop CS4 
software.   
 
2.6.10 Primary antibodies 
Antibodies to detect MarvelD3 were generated as described above (2.6.1 and 2.6.2).  
Antibodies against all other proteins were previously described or were from 
commercial sources (Table 2.6). 
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Table 2.6 – Primary antibodies.  Details of antibody, species of origin and dilutions 
used for immunofluorescence (IF) and immunoblotting (IB) are shown. 
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2.7 Experimental Assays 
2.7.1 Ca2+-switch, paracellular permeability and transepithelial resistance (TER) 
measurements 
Caco-2 cells were transfected with control, pool or individual siRNAs against 
MarvelD3 in 6-well plates.  The day after transfection, cells were trypsinised and 
plated at confluent density on Transwell filters (Corning Inc., Corning, NY) in 
quadruplicates, either in low calcium medium, for Ca2+ switch, or directly into 
DMEM++.  After 24 hours, the medium was changed for fresh DMEM++ and cells 
were incubated at 37°C for 10 minutes before starting to measure TER.  TER was 
recorded every 2 hours for the first 12 hours, then at 24, 36 and 48 hours by applying 
an AC square wave current of ± 20 µA at 12.5 Hz with a silver electrode and 
measuring the voltage deflection elicited with a silver/silver-chloride electrode using 
an EVOM (World Precision Instruments, Sarasota, FL), as previously described!
(Balda et al., 1996).  To measure paracellular flux, 1 hour before the experiment, 
medium was replaced with 1000µl DMEM++ on the basolateral side and 250µl on the 
apical side and the cells returned to 37°C.  Tracer solution containing 4kD FITC-
dextran and 70kD Rhodamine-B-dextran was added to the apical side and incubated 
at 37°C for 4 hours (Matter and Balda, 2003a).  200µl samples were collected from 
the basolateral side and fluorescence was determined using a FLUOstar OPTIMA 
microplate reader (BMG LabTech, Offenburg, Germany).  Fluorescence of the apical 
solutions was used to determine total values. 
 
 
 87 
2.7.2 Proliferation assay 
Wild-type and MarvelD3-expressing MiaPaCa cells were plated in triplicate onto 96-
well plates at various cell densities and incubated at 37°C for 3 days. For knockdown 
experiments, Caco-2 cells were transfected with control, two individual siRNAs or a 
pool of siRNAs against MarvelD3 in 48-well plates and incubated at 37°C for 3 days. 
In both experiments, medium was removed after 3 days by inverting the plates onto 
paper towels and the samples immediately frozen at -80°C.  Cell proliferation was 
determined the following day using a CyQUANT Cell Proliferation Assay Kit 
(Invitrogen).  A 5X CyQUANT-GR solution, enabling a linear detection range 
extending to 250,000 cells, was prepared in nuclease-free distilled water containing 
1X cell lysis buffer, and 200µl added to each well of the 96-well plate.  Samples were 
gently pipetted up and down 3 times to mix and incubated for 5 minutes, protected 
from light.  Fluorescence was determined using a microplate reader and converted 
into cell numbers against a reference standard curve for each cell type.  In some 
experiments additional EGF (Peprotech) was prepared in water and added to complete 
medium at the concentrations described. 
 
2.7.3 Flow cytometry 
The effect of MarvelD3 on apoptosis was quantified by FACS analysis.  First, 1.5x105 
cells were plated in a 6-well plate in complete medium and incubated at 37°C for 4 
days.  Cell culture medium was removed and collected in a 50ml tube.  Cells were 
washed once in 1X PBS and the PBS added to the 50ml tube.  Cells were then 
completely trypsinised with 1X Trypsin-EDTA.  Trypsinisation was terminated with 
2ml complete medium and cell suspensions transferred to the 50ml tube and 
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centrifuged at 1500 rpm for 5 minutes at room temperature.  Medium was removed, 
cells gently resuspended in 2ml ice-cold 70% ethanol in PBS and incubated at 4°C for 
30 minutes.  Fixed cells were then pelleted at 1500 rpm for 5 minutes at 4°C and 
resuspended in 800µl PBS.  A homogenous suspension was made by passing the cells 
through a 25G needle 10 times before adding 40µg/ml propidium iodide and 
0.1mg/ml RNase and incubating at 37°C for 1 hour.  Samples were then run through a 
FACSCalibur (Becton Dickinson) and analysed using CellQuest Pro. 
 
2.7.4 Migration assay 
To assess cell migration, MiaPaCa and Caco-2 cells were applied to both 0.22mm2 
chambers of a 9mm x 9mm x 5mm µ-Dish35mm, high culture-insert (Ibidi GmbH) in 70µl 
complete medium.   The outer area of the dish was filled with 2ml complete medium 
to prevent drying out.  Cells were plated in triplicate for each experiment.  Cells were 
incubated at 37°C resulting in a confluent monolayer after 48 hours.  For knockdown 
experiments, Caco-2 cells were transfected with control or two individual siRNAs 
against MarvelD3 in 24-well plates.  Twenty-four hours after transfection, cells were 
trypsinised, added to the Ibidi culture inserts and incubated at 37°C until confluent 
(48 hours later).  In all experiments, the culture insert was then gently removed 
generating a 500µm cell-free gap between monolayers, and the medium replaced with 
fresh complete medium containing mitomycin c to inhibit proliferation. When 
necessary, 20µM SP600125 or DMSO was added to the cells 3 hours before insert 
removal.  Complete medium containing 20µM SP600125 or DMSO was then used for 
the duration of the experiment. Brightfield images were taken at regular time points 
(0, then every 2 hours up to 8 hours, and every 2 hours from 20 hours until the most 
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rapidly migrating cells showed approximately 80% wound closure) using an 
epifluorescent microscope to observe the migration of cells in to the cell-free space.  
ImageJ software was used to determine the area of cell-free space and subsequently 
enable % wound closure to be calculated at each time point (% wound closure =  100 
– [(cell-free area at end-point)/(cell-free area at time 0)*100]. 
 
2.7.5 Reporter assay 
Caco-2, MDCK and wild-type MiaPaCa cells were plated in triplicate or 
quadruplicate into 96-well plates in complete medium the day before transfection.  
After 24 hours, MDCK cells were transfected by Ca2+-precipitation and Caco-2 and 
MiaPaCa cells were transfected with JetPEI reagent. In both cases, transfection mix 
was changed for fresh complete medium 24 hours after transfection.  Luciferase 
luminescent signals were determined 24 hours later using a Dual luciferase reporter 
assay kit (Promega).  Medium was removed from all cells and MDCK and Caco-2 
cells were washed once with 1X PBS.  MiaPaCa cells were not washed with PBS to 
prevent cell loss.  Cells were lysed with 20µl lysis buffer (stock provided) and 
incubated at room temperature on a shaker for 20 minutes.  Cell extract (12µl) was 
transferred to a white 96-well plate and the luciferase and renila luminescence signals 
measured sequentially using OPTIMAFluorostar microplate reader (BMG Labtech).  
Relative promoter activity was calculated by making a ratio between luciferase and 
renila luminescent signals, and then normalizing to the control. 
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2.7.6 Hyperosmotic shock 
HCE and Caco-2 cells were plated into 24-well plate or on to glass coverslips and 
grown for 3 days at 37°C.  For knockdown experiments, HCE cells were reverse 
transfected using Interferin reagent.  Caco-2 cells were transfected 16 hours after 
plating, also with Interferin reagent.  Three days after transfection, cells were 
incubated in the presence of hyperosmotic DMEM (containing 600mosM NaCl) or 
hypo-osmotic DMEM (containing 150mosM NaCl) for 15 minutes, 30 minutes, 1 
hour or 2 hours.  Cells incubated in isotonic DMEM (300mosM NaCl) were used as a 
control.  After treatment, cells were fixed for immunofluorescence or harvested for 
analysis of protein levels by SDS-PAGE.  Where necessary, cells were incubated with 
inhibitors, or diluent for controls, overnight prior to hyperosmotic shock (Table 2.7).  
Inhibitors/diluent were also present throughout the subsequent incubation with 
hyperosmotic medium. 
 
 
Table 2.7 – Inhibitors used in hyperosmotic shock experiments.  Final 
concentration refers to the concentration of the inhibitor present in the experiment.  
Controls were made by adding equal volume of the diluent to control cells.  
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2.7.7 Pulldowns 
To identify potential interaction partners of MarvelD3 and the domains responsible, 
pulldown experiments were performed with GST-fusion proteins of the N-terminus 
and the isoform specific C-termini of MarvelD3.  Caco-2 cells were grown on 15cm 
cell culture dishes at 37°C for 5 days.  Pulldown beads were prepared by incubating 
purified GST-fusion proteins with 40µl glutathione beads on an end-over-end shaker, 
at 4°C for 2 hours.  Beads were washed 3 times with 0.5% PBSTx and once with 1X 
PBS.  Cell lysates were prepared quickly, on ice, in 0.1% PBSTx.  Non-specific 
binding was reduced by incubating lysates with negative glutathione beads. Cell 
lysates were incubated with fusion protein-conjugated beads for 1.5 hours at 4°C.  
0.1% PBSTx-harvested samples were either washed with 0.1% PBSTx followed by 
1X PBS, or twice with 1X PBS.  GB buffer-harvested samples were washed twice 
with 1X PBS. After the final wash, 50µl sample buffer was added to the beads and 
boiled at 70°C for 5 minutes before separating on by SDS-PAGE. 
 
2.7.8 GTPase activation assay (G-LISATM) 
To assess the effect of MarvelD3 on RhoA GTPase activity, control and MarvelD3-
expressing MiaPaCa cells were in triplicate on 12-well plates and left to grow until 
70% confluent.  A G-LISA was performed to assess the relative levels of active RhoA 
in each sample according to the manufacturers protocol (Cytoskeleton).  Briefly, 
samples were washed on ice with cold 1X PBS and lysed.  The protein concentration 
of each sample was determined and equalised by addition of lysis buffer.  Cell lysate 
was then added to wells of a 96-well plate containing a Rho-GTP-binding protein and 
incubated at 4°C for 30 minutes with gentle agitation.  Samples were washed twice 
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with wash buffer to remove inactive, unbound RhoA.  Bound RhoA was detected with 
an anti-RhoA primary antibody (1:250) and HRP-conjugated secondary antibody 
(1:62.5; both provided).  Adding HRP detection reagent and measuring absorbance at 
490nm determined the degree of RhoA activity.  Subtracting background absorbance 
from all absorbance values and then normalising mean absorbance values to the 
control calculated relative RhoA activity. 
 
2.7.9 Impedance analysis 
Impedance was measured in response to hyperosmotic shock using Electric Cell-
Substrate Impedence Sensing (ECIS) Model 1600R (Applied BioPhysics).  Control 
and MD3p-siRNA transfected Caco-2 cells were plated in to ECIS electrode array 
containing 10 electrodes per well (8W10E; Applied BioPhysics).  Array plates were 
prepared by addition of 200µl 10mM cysteine for 10 minutes and then washed three 
times with 1X PBS. Cells were plated in quadruplicate and grown at 37°C for 48 
hours until confluent.  Basal impedance across the monolayer was measure at 37°C 
for 1 hour.  Complete medium was then replaced with DMEM containing 600mosM 
NaCl and measurements of impedance was taken at 2 minute intervals for a further 9 
hours.  Impedance values for each group (control or MD3p-siRNA) were normalised 
to readings taken before exposure to hyperosmotic shock. 
 
2.7.10 Statistics 
All statistical analyses were performed using Microsoft Excel.  Statistical significance 
was calculated with a two-tailed Student’s t-test. 
 93 
2.8 Xenopus laevis Methods 
 
2.8.1 Egg collection and fertilisation 
Xenopus were injected with 500 units human chorionic gonadotropin (HCG) 5 days 
after injection with 50 units pregnant mare serum gonadotropin (PMSG).  After 24 
hours, Xenopus were placed in 1X egg laying solution (ELS; pH7.6).  For 
fertilization, freshly laid eggs were collected using a Pasteur pipette and placed in a 
7cm dish.  ELS was removed and eggs were washed 3 times in 1X Modified Barth’s 
solution (MBS), removing as much MBS as possible following the final wash.  Eggs 
were fertilized by direct application of isolated testes extract prepared in 1X MBS.  
After 5 minutes, 0.1X MBS was added to facilitate sperm entry.  Fertilised eggs were 
placed at 14°C to develop. Embryos were staged according to Niewkoop and Faber 
(1994). All embryo manipulations were in accordance with the UK Home Office 
regulations and guidelines. 
 
2.8.2 De-jellying 
The jelly coat was removed 1 hour after fertilization by addition of 2% cysteine 
solution, pH7.6-7.8, for 5 minutes at 14°C.  Embryos were then washed 3 times in 
0.1X MBS to remove all traces of cysteine and allowed to develop at 14°C in 0.1X 
MBS until required. 
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2.8.3 RNA extraction from embryos and RT-PCR 
To determine the expression pattern of MarvelD3 during Xenopus development, total 
RNA was extracted from whole embryos at representative stages of development and 
subjected to semi-quantitative RT-PCR analysis. Embryos from the same fertilization 
were collected (20 embryos per developmental stage), snap-frozen in dry-ice and 
stored at -80°C until RNA extraction. Immediately before RNA extraction, embryos 
were thawed on ice and lysed in 1200µl RLT lysis buffer (provided in RNeasy kit 
detailed below) supplemented with 140mM !-mercaptoethanol.  Embryos were 
homogenised mechanically by passing through a 23G needle 10 times, then 
centrifuged for 3 minutes at 13200rpm to clear the lysate.  RNA extraction was then 
performed using an RNeasy mini-kit (QIAGEN) according to the manufacturers 
instructions. Reverse transcription was performed at 45°C using AMV reverse 
transcriptase (Promega) for 1!"#$%&!The cDNAs were then amplified by PCR using 
FastStart Taq polymerase (Roche Diagnostics Gmb.) at an annealing temperature of 
62°C (Xenopus MarvelD3; xMD3) and 58°C (Xenopus ornithine decarboxylase; 
xODC).!!!Primers used for this study were as follows (5’ to 3’ direction): xMarvelD3 
CGGAGCAGCAGATCAGGATCAG for reverse transcription and 
ACAAACCCCATAATAGAAATTTGCC and 
TTCAACATATTCCATATTCGAGCC for PCR amplification; ODC forward 
CAGCTAGCTGTGGTGTGG and reverse CAACATGGAAACTCACACC as 
previously described (Daniels et al., 2004). 
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2.8.4 in vitro transcription of mRNA 
mRNA of the human MD3 isoform 2 was generated for microinjection, to both 
attempt to rescue the phenotype observed following morpholino injection, and to 
perform gain of function studies.  Human MarvelD3 isoform 2 is most similar to the 
xenopus sequence.  GFP and !-galactosidase mRNA for control injections and 
identification of injection sites, respectively, were synthesized in the same way.  First, 
pCS2 vector containing the relevant cDNA was linearised by digestion with NotI 
restriction enzyme for 3 hours at 37°C.  DNA was then purified from a 1% low-
melting agarose gel.  The in vitro transcription reaction was assembled at room 
temperature containing 1µg linearised DNA in a total volume of 20µl, using reagents 
from Ambion Message Machine kit (Ambion).  The reaction was allowed to run for 2 
hours at 37°C.  Template DNA was removed by 15 minute incubation with TURBO 
DNase  at 37°C and stopped by addition of ammonium acetate stop solution 
(Ambion).  RNA was recovered by phenol/chloroform extraction and stored at -80°C 
until use. 
 
2.8.5 Phenol/chloroform extraction of RNA 
An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) was added to the in 
vitro transcription mix, vortexed and centrifuged at 13200 rpm for 2 minutes at 4°C.  
The aqueous phase was collected and 80µl RNase-free water added to the 
phenol/chloroform layer, vortexed and centrifuged again, and as much aqueous phase 
collected as possible.  An equal volume of ice-cold isopropanol was then added, 
vortexed and left at -20°C overnight.  RNA was pelleted by centrifugation at 13200 
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rpm for 30 minutes at 4°C and washed in 70% ethanol.  Finally, RNA was 
resuspended in RNase-free water and stored at -80°C until use. 
 
2.8.6 Microinjection 
Morpholinos (MO) and mRNAs were injected into embryos at the 2-cell stage 
according to the same protocol.  Borosilicate glass capilleries (1.2mm OD x 0.94mm 
ID; Harvard Apparatus, Kent, UK) were pulled into needles using a P-97 
Flaming/Brown micropipette puller (Sutter Instrument Co., USA).  Eggs were 
fertilised and de-jellied prior to injection.  Embryos at the 2-cell stage were placed in 
injection dishes with 4% Ficoll solution (4% Ficoll with 50µg/ml Gentomicin in 0.2X 
MBS).  Morpholinos and mRNAs were diluted to the necessary concentrations in 
RNase-free water and injected with 200pg !-galactosidase.  A standard control 
morpholino was injected with 200pg !-galactosidase as a control in loss of function 
experiments.  GFP mRNA was injected with 200pg !-galactosidase as a control in 
gain of function experiments.  The xMD3 morpholino 
(AGACCCAAATCTTCCTTTTGTTCCC) and control morpholino were obtained 
from Gene Tools LLC (Philomath, OR).  After injection embryos were placed at 14°C 
overnight.  Ficoll solution was replaced with 0.1X MBS the following morning, and 
embryos returned to 14°C to monitor development. 
 
2.8.7 Fixation  
Embryos were fixed with MEMFA (3.7% formaldehyde (Fisher Scientific), 1X 
MEM; 0.1M MOPS, pH7.4, 2mM EGTA, 1mM MgSO4) for 1 hour at room 
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temperature with gentle rocking.  Embryos were then washed 3 times in 1X PBS and 
once with methanol.  Fixed embryos were stored in methanol at -20°C. 
 
2.8.8 !-galactosidase staining 
Injection of !-gal mRNA alongside control and xMD3 morpholinos enabled us to 
identify successfully injected embryos by positive !-galactosidase staining. It also 
enabled us to identify the side of injection.  Embryos were fixed in MEMFA for 1 
hour at room temperature under gentle rotation.  Embryos were washed 3 times in 1X 
PBS and pre-incubated in PBS containing 2mM MgCl2 for 15 minutes at room 
temperature. !-galactosidase staining was then developed by placing embryos in X-
Gal mixer solution (5.35mM K3Fe(CN)6, 5.35mM K4Fe(CN)6.3H2O, 1.2mM MgCl2, 
0.01% sodium deoxycholate, 0.02% NP40 in 1X PBS) containing 1mg/ml X-Gal at 
37°C for 30 minutes.  Embryos were then washed twice in 1X PBS and stored in 
methanol at -20°C.  
 
2.8.9 In situ hybridisation 
To investigate the effect of MarvelD3 on neural crest cell migration, in situ 
hybridisation of whole embryos was performed on unilaterally xMD3-MO-injected 
embryos fixed at stages 20 and 23.  Embryos were placed into baskets and the in situ 
hybridisation performed using a Biolane HTI automated incubation liquid handler 
(Holle and Huttner) at 22°C.  Embryos were gradually rehydrated with 75% methanol 
for 10 minutes, and 50% and 25% methanol for 5 minutes each, before being washed 
4 times in PBS containing 0.1% Tween-20 (PBST), for 5 minutes each.  Embryos 
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were then incubated in 1.32µg/ml Proteinase K in PBST for 5 minutes.  Incubation of 
embryos in 0.1M triethanolamine (TEA), pH7-8 and 0.1M TEA containing 0.5% 
acetic acid, for 5 and 10 minutes respectively was used to block reactive groups in the 
embryonic tissue by acetylation and therefore reduce background staining.  Finally, 
embryos were refixed in 4% formaldehyde for 20 minutes and washed 6 times 5 
minutes in PBST.   Embryos were pre-hybridised at 60°C in hybridisation buffer 
(50% formamide, 5X (SSC), 1X Denhardts, 0.1% Tween-20, 0.1% CHAPS, 1mM 
EDTA, 1mg/ml torula RNA, 100µg/ml heparin) before being transferred to 
hybridisation buffer containing DIG-labelled RNA probes and incubated at 60°C 
overnight, with gentle rocking.  Probes were previously synthesised and optimised in 
the Ohnuma lab and kindly donated for these experiments.  Post-hybridisation, 
embryos were washed with 2X SSC pre-warmed to 65°C, incubated in 1µg/ml 
RNaseA in 2X SSC for 20 minutes at 37°C and washed in 0.2X SSC also pre-warmed 
to 65°C.  Embryos were then washed in 1X MAB for 3 times 30 minutes before being 
blocked in 1X MAB containing 2% blocking solution (Roche) and 20% lamb serum 
(GIBCO) for 2 hours at 22°C.  After blocking, embryos were incubated in the 
presence of anti-DIG AP Fab fragments (Roche) for 12 hours in 1X MAB containing 
2% blocking solution and 20% lamb serum at 4°C.  Embryos were then washed 
thoroughly in 1X MAB for 10 times 30 minutes before being transferred to glass 
vials.  In glass vials, DIG probes were detected by adding BM Purple substrate in the 
presence of alkaline phosphatase (AP) buffer (0.1M Tris-HCL, pH9.5, 0.1M NaCl, 
50mM MgCl2, 0.1% Tween-20, supplemented with 2mM Levamisole).  When the 
colour reaction was complete, embryos were washed in methanol for 30 minutes and 
fixed overnight in MEMFA at room temperature.   
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2.8.10 Depigmentation of embryos after in situ hybridisation 
After development of in situ hybridisation probes, embryonic pigmentation was 
removed by bleaching to enable the staining pattern to be seen more clearly.  Embryos 
were washed three times in PBST for 5 minutes each.  They were then transferred to 
bleaching solution (5% Formamide, 1X SSC, 3% H2O2) and placed in a light box until 
bleached.  Bleaching solution was then removed, embryos washed three times in 
PBST for 5 minutes each, and stored at room temperature in ME MFA. 
 
2.8.11 Imaging 
For imaging, embryos were handled in 1X PBS and photographed using a Leica M80 
microscope and Leica DFC420C camera. 
 
2.8.12 Preparation of samples for immunoblotting 
Embryos were collected, snap-frozen in dry ice and stored at -80°C.  Whole embryo 
lysates were prepared by adding lysis buffer (20mM Tris-HCl, pH8.0, 150mM NaCl, 
2mM EDTA, 1% NP40 containing protease inhibitors) to embryos thawed on ice 
(10µl lysis buffer per embryo) and pipetting up and down to mix.  Lysates were then 
centrifuged at 12000 rpm at 4°C for 5 minutes, and the clear middle layer removed 
and added to an equal volume of 3X sample buffer.  Samples were then analysed by 
SDS-PAGE according to the standard protocol. 
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2.8.13 Additional solutions for Xenopus laevis experiments 
For clarity, the recipes of some of the solutions used in Xenopus laevis experiments 
have not been included in the main body of text and are, instead, detailed below. 
MBS: To prepare 4L of 10X MBS 205.2g NaCl, 3g KCl, 8g NaHCO3, 95.2g Hepes, 
8g MgSO4•7H2O, 3.12g Ca(NO3)2•4H2O, 3.2g CaCl2•6H2O was dissolved in water.  
Adjusted to pH7.6 with NaOH.  Solution was then autoclaved and stored at 4°C until 
use. 
 ELS: To prepare 4L of 8X ELS, 205.71g NaCl, 4.77g KCl, 2.72g Na2HPO4•2H2O, 
5.815g Tris base, 5.38g NaHCO3, 16.149 MgSO4•7H2O was dissolved in water.  
Adjusted to pH7.6 with glacial acetic acid. Stored at 4°C until use. 
Denhardt’s Solution: To prepare 100ml of 100X stock, 2g Ficoll 400, 2g 
polyvinylpyrrolidone, 2g  BSA was dissolved in water and filter sterilised. 
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Chapter 3: Identification of MarvelD3 at the Tight Junction 
Some results in this chapter have been published in reference (Steed et al., 2009)  
Introduction 
In their identification of the Marvel domain, Sanchez-Pulido and colleagues 
highlighted MarvelD3 as an as yet unknown Marvel domain-containing protein of the 
occludin family (Sanchez-Pulido et al., 2002).  Since occludin and tricellulin are also 
MARVEL domain-containing proteins and both components of the tight junction, I 
wanted to determine whether MarvelD3 is also a component of the tight junction.   
This chapter describes the identification of MarvelD3 at the tight junction using 
bioinformatics analysis and a range of cell and molecular biology techniques.  
Transepithelial resistance and paracellular permeability assays were also used to 
determine the role of MarvelD3 in the fundamental “barrier” properties of the tight 
junction.   
These analyses showed that MarvelD3 is expressed in various epithelial and 
endothelial cells, and shows a broad tissue expression pattern.  MarvelD3 colocalises 
with the tight junction protein occludin, apically to the adherens junction marker E-
cadherin, suggesting a specific localisation to the tight junction within the apical 
junctional complex.  Depletion of MarvelD3 does not affect the paracellular 
permeability properties of the tight junction, but does result in increased TER, 
suggesting MarvelD3 expression may have a role in regulating the ion conductance 
properties of the tight junction. 
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Results 
Identification of two human isoforms of MarvelD3 by bioinformatic analysis  
To begin these studies, a number of basic bioinformatic analyses were performed to 
gain further insight into the molecular properties of the MarvelD3 protein.  Database 
searches were also conducted to see if and how it has been conserved through 
evolution.   
 
Bioinformatics analysis revealed the existence of two human MarvelD3 isoforms: 
isoform 1 contains 410 amino acids [Genbank: NM_001017967] and isoform 2 401 
amino acids [Genbank: NM_052858] (Figure 3.1). A membrane topology analysis 
with Phobius and TMpred confirmed that both isoforms are predicted to contain four 
transmembrane domains and to expose their N- and C-terminal domains to the cytosol 
(Figure 3.2). The two isoforms represent splice variants and share the predicted N-
terminal cytoplasmic domain of 198 amino acids, but differ in their C-terminal halves 
that contain the transmembrane domains. Both MarvelD3 isoforms are predicted to 
possess only short C-terminal cytoplasmic domains (30aa isoform1; 18aa isoform 2) 
with no apparent similarities to the comparatively long C-terminal cytoplasmic 
domains of tricellulin and occludin that contain their ZO-1 binding sites (Riazuddin et 
al., 2006) (Fanning et al., 1998).  
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Figure 3.1 – Identification and alignment of the two human MarvelD3 isoforms 
(A) The cytosolic domains are highlighted in blue, the transmembrane domains in 
orange, and the extracellular domains in green. The splice junction between the N-
terminal domain shared by both isoforms and the alternative domains is indicated by 
two arrows.  (B) Representation of the two human isoforms of MarvelD3.  The 
transmembrane (Marvel) domains are represented by dark blue (isoform 1; MD3_1) 
and dark green (isoform 2; MD3_2) shading.  The presence of a common N-terminus 
is highlighted. 
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Figure 3.2 – Membrane topology analysis of human MarvelD3 isoforms 1 and 2.  
Amino acid sequences of each MarvelD3 isoform were entered into online membrane 
topology prediction programmes Phobius and TMpred.  The predicted domains are 
summarised from each programme for each isoform  (A, isoform 1; C, isoform 2).  
Hydrophobicity plots generated from the TMpred predictions are also shown (B, 
isoform 1; D, isoform 2).   
 
Database searches revealed that MarvelD3 is expressed in chicken, Xenopus and 
various mammalian species, but not in any invertebrates, suggesting that it is 
expressed by vertebrates only (Figure 3.3 and Table 3.1). Alternatively spliced 
isoforms were only found in mammalian species. In contrast, the chicken genome 
contains two distinct MarvelD3 genes, variant A and B, which reside on different 
chromosomes. Variant A is more similar to mammalian isoform 2. Although variant 
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B is more similar to isoform 1 than 2, the two chicken proteins show a similar degree 
of conservation with mammalian isoform 1. It thus seems that mammalian isoform 2 
and the variant A gene found in birds, fish and amphibians represent the MarvelD3 
form common to all vertebrates. 
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Figure 3.3 – Analysis of vertebrate MarvelD3 sequences. (A) Human, mouse and 
dog isoform 1 and chicken variant B; and (B) human, mouse and dog isoform 2 and 
chicken, Xenopus laevis and zebrafish variant A were aligned with ClustalW using 
default settings. The amino acid residues conserved in mammalian MarvelD3 
sequences are highlighted in yellow. Conservation is labelled according to ClustalW 
definitions: identical residues (*); conserved substitutions (:); semi-conserved 
substitutions (.). 
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Table 3.1 – Alignment scores of MarvelD3 sequences from different 
vertebrates.  MarvelD3 sequences were retrieved from Genbank and aligned using 
ClustalW (see Fig. 3.3 for a selection of the alignments). Indicated are all Genbank 
accession numbers. The scores reflect percent identity. For mammals, the two 
alternatively spliced isoforms were used. Two different MarvelD3 genes, variants A 
and B, exist in chicken.  Only variant A was found in X. laevis and zebrafish.  
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Generation of antibodies against MarvelD3 
To enable detection of MarvelD3 for analysis of protein expression, an antibody was 
generated against a peptide of the N-terminal cytoplasmic domain.  Expression was 
analysed in two epithelial cell lines derived from different types of epithelia: Caco-2, 
a human colon adenocarcinoma cell line, and an immortalised human corneal 
epithelial cell line (HCE).  Total cell extracts were generated from control cells as 
well as cells transfected with control siRNAs or a pool of four siRNAs targeting 
MarvelD3. All four targeted sequences are part of the common exon encoding the N-
terminal cytoplasmic domain; hence, mRNAs encoding both isoforms should become 
degraded.  Figure 3.4 shows that the antibody recognised a band of about 40 kD in 
both cell lines, as expected. The band became weaker with increasing concentrations 
of MarvelD3 siRNA, indicating that the band indeed corresponded to MarvelD3.  
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Figure 3.4 – Detection of endogenous MarvelD3 in a Caco-2 and HCE cells.  Caco-2 and 
HCE cells were transfected with the indicated concentrations of siRNAs, using a pool of the 
four MarvelD3-directed siRNAs, or a control siRNA (lane 0). Three days after transfection, cell 
extracts were prepared and expression levels of MarvelD3 and #-tubulin were analysed by 
immunoblotting. Arrows indicate band corresponding to MarvelD3. An anti-#-tubulin antibody 
was used as loading control. 
Deconvolution of the MarvelD3 siRNA pool revealed that siRNAs 14 and 16 were the 
most effective of the four sequences and were hence used individually, or together as 
a pool, for all subsequent analyses (Figure 3.5). 
 
Figure 3.5 – Deconvolution of MarvelD3 siRNA pool.  Caco-2 cells were transfected with 
100nM control siRNA or each of the individual constituents of the MarvelD3-specific siRNA 
pool.  Three days after transfection, cell extracts were prepared and analysed for 
effectiveness of MarvelD3 depletion by immunoblotting. An anti-#-tubulin antibody was used 
as loading control. 
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In an attempt to detect MarvelD3 in an isoform-specific manner antibodies were also 
raised against the complete C-terminal sequences of each isoform.  Immunoblotting 
showed these antibodies were able to detect MarvelD3 when overexpressed in Caco-2 
cells, but not the endogenous protein (Figure 3.6).  Thus MarvelD3 protein was 
detected in a non-isoform-specific manner, using the antibody directed against the N-
terminus, in all subsequent experiments in this thesis.   
 
Figure 3.6 – Antibodies directed against the isoform-specific C-termini of 
MarvelD3 isoforms can only detect over-expressed MarvelD3 protein.  Caco-2 
cells were transfected with cDNAs encoding MarvelD3 isoform 1 (A) and isoform 2 
(B).  Three days after transfection, cell extracts were prepared and run on 10% SDS-
PAGE gels.  Immunoblotting was performed with antibodies against the C-terminus 
of MarvelD3 isoform 1 (A) and isoform 2 (B).  Antibodies were able to detect the 
overexpressed protein, but not the endogenous protein, even after prolonged 
exposure. An anti-#-tubulin antibody was used as loading control. 
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Expression pattern of MarvelD3 isoforms 
Since the MarvelD3 antibody was found to recognise both isoforms, reverse 
transcription PCR was used to determine the expression of MarvelD3 isoforms in 
different cultured epithelial and endothelial cell lines, as well as different tissues. 
Figure 3.7 shows that both isoforms are widely expressed by different epithelial and 
endothelial cells. Similarly, most tested adult mouse tissues expressed both isoforms 
(Figure 3.8). Both MarvelD3 isoforms are thus widely expressed and are found in 
different types of epithelial and endothelial cells. Nevertheless, apparent differences 
in isoform expression profiles were detected as, for example, both liver and the 
hepatocyte-derived cell line HepG2 only expressed isoform 1. 
 
 
Figure 3.7 – Expression of MarvelD3 in epithelial and endothelial cells. Reverse 
transcription PCR was used to analyse the expression of MarvelD3 isoforms in 
cultured human epithelial and endothelial cells. HUVEC cDNA was kindly provided by 
Jay Stone, UCL Institute of Ophthalmology. Primers were used to specifically amplify 
human MarvelD3 isoforms or, as a control, GAPDH. 
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Figure 3.8 – Expression of MarvelD3 in mouse tissue.  RT-PCR was performed 
on RNA extracted from adult mice (RNA was kindly provided by Prof. Maria Balda, 
UCL Institute of Ophthalmology) to analyse the expression of MarvelD3 in different 
tissue types.  Primers were used to specifically amplify mouse MarvelD3 isoforms or 
GAPDH, as a control. 
 
Localisation of MarvelD3 to the epithelial cell tight junction 
Indirect immunofluorescence was used to determine the intracellular localisation of 
MarvelD3 in epithelial cells. As the antibody only recognises the human protein, we 
used Caco-2 and HCE cells for the localisation experiments as they form well-
developed junctional complexes and are derived from two different types of epithelia. 
Confluent and semi-confluent cultures of the two cell lines were fixed in methanol 
and processed for double immunofluorescence using the rabbit anti-MarvelD3 
antibody and a mouse monoclonal antibody against occludin. The samples were first 
analyzed by epifluorescence microscopy. 
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Figure 3.9 – MarvelD3 localises to cell-cell contacts in Caco-2 and HCE cells.  
Caco-2 and HCE cells were plated on to glass coverslips and grown at 37°C until 
cells were confluent (A).  Cells were then fixed in methanol and immunofluorescence 
was performed with antibodies against MarvelD3 (red) and occludin (green).  
Hoechst (blue) was used as a nuclear stain.  MarvelD3, like occludin, can be seen to 
localise to points of cell-cell contact in both cell types. Bars, 10µm. 
 
Figure 3.9 shows that the anti-MarvelD3 antibody stained cell-cell contacts in Caco-2 
and HCE cells. There was also some cytoplasmic and nuclear staining. However, the 
junctional staining was specific as it disappeared when MarvelD3 was depleted by 
RNA interference (see below). In both cell lines, MarvelD3 and occludin co-localised, 
suggesting that MarvelD3 is a component of the apical junctional complex.  To 
analyse the specific junctional localisation of MarvelD3 samples were further 
analysed by confocal microscopy. Figures 3.10A and B show that MarvelD3 and 
occludin co-localised at cell junctions and in the same focal plane (note that the 
staining patterns of the two proteins enter and leave the focal plane at the same sites) 
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in Caco-2 cells. In contrast, MarvelD3 and the adherens junction marker E-cadherin 
localised in different focal planes (Figure 3.11). The concentration of MarvelD3 at the 
apical end of the lateral membrane together with occludin, apical to the lateral E-
cadherin staining, was also observed in z-projections reconstituted from serial z line 
scans (Figure 3.10B and 3.11B).  These data thus demonstrate that MarvelD3 co-
localises with occludin, but not E-cadherin, at the junctional complex, indicating 
specific association with tight junctions. 
 
 
Figure 3.10 – MarvelD3 colocalises with occludin in the apical junctional 
complex.  Caco-2 cells were grown on filters until confluent, fixed in methanol and 
processed for immunofluorescence with antibodies against MarvelD3 and occludin. 
The samples were then analyzed by confocal microscopy. (A) xy sections from 
different samples taken at the interface between the tight and adherens junctions.   
Occludin and MarvelD3 can be seen to follow each other in and out of the focal 
plane. (B) is a reconstitution of serial z line scans. Bars, 10µm. 
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Figure 3.11 – MarvelD3 localises apically to E-cadherin in the apical junctional 
complex. Caco-2 cells were grown on filters until confluent, fixed in methanol and 
processed for immunofluorescence with antibodies against MarvelD3 and E-
cadherin. The samples were then analyzed by confocal microscopy. (A) Shows two 
xy sections from different samples taken at the interface between the tight and 
adherens junctions.  MarvelD3 and E-cadherin do not occupy the same focal plane 
(B) is a reconstitution of serial z line scans showing MarvelD3 to localise apically to 
E-cadherin in the apical junctional complex. Bars, 10µm. 
 
Finally, to further confirm the localisation observed for the endogenous MarvelD3 
protein, cDNAs encoding the two full-length isoforms untagged, as well as VSV- and 
HA-tagged full-length isoforms, were prepared and transfected into Caco-2 and 
MDCK cells.  Figure 3.12 shows expression of all full-length MarvelD3 constructs in 
MDCK cells.  Isoform 1 constructs were seen to run at a slightly higher molecular 
weight than isoform 2 constructs, which is in keeping with the slightly longer amino 
acid sequence of isoform 1 (410 amino acids) in comparison to isoform 2 (401 amino 
acids).  HA-tagged constructs of both isoforms ran slightly higher than their untagged 
and VSV-tagged counterparts.  The reason behind this is unknown, but has been 
observed for other HA-tagged constructs in the lab (K. Matter, personal 
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communication).  Immunofluorescence analysis of transfected cells shows that both 
isoforms were enriched at cell-cell contacts (Figure 3.13), supporting the staining 
observed for endogenous protein in Caco-2 and HCE cells. Control MDCK cells did 
not reveal any staining for MarvelD3, possibly due to the species difference as the 
antibody was made against a sequence of the human protein that shows little 
conservation in the canine protein.  
 
 
Figure 3.12 – Expression of full-length MarvelD3 constructs in MDCK cells. 
MDCK cells were transfected with cDNAs encoding the full-length isoforms of 
MarvelD3.  Three days after transfection, cells were prepared for analysis by SDS-
PAGE. Immunoblotting was performed with an antibody against MarvelD3 and anti-#-
tubulin as a loading control.   All constructs contain the full-length sequence of the 
specified MarvelD3 isoform and are shown as follows: MD3_1, untagged isoform 1; 
MD3_2, untagged isoform 2; MD3_1:VSV, C-terminally VSV-tagged isoform 1; 
MD3_2:VSV, C-terminally VSV-tagged isoform 2; HA:MD3_1, N-terminally HA-
tagged isoform 1; HA:MD3_2, N-terminally HA-tagged isoform 2.  
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Figure 3.13 – MarvelD3 constructs localise to the cell periphery in MDCK and 
Caco-2 cells.  Caco-2 and MDCK cells were transfected with cDNAs encoding the 
full-length, untagged isoforms of MarvelD3.  Three days after transfection, cells were 
fixed in methanol and processed for immunofluorescence using antibody against 
MarvelD3 and Hoechst as a nuclear stain. Exogenously expressed MarvelD3 
isoforms 1 and 2 can be seen to localise to the cell periphery in both MDCK and 
Caco-2 cells. Bars, 10µm. 
 
Furthermore, expression of N-terminally HA-tagged MarvelD3 isoforms in Caco-2 
and MDCK cells also resulted in staining of cell-cell contacts with anti-HA and anti-
MarvelD3 antibodies (Figure 3.14).  Unfortunately, C-terminally VSV-tagged 
constructs could not be detected by immunofluorescence with anti-VSV antibody, 
though the presence of the tag was confirmed by sequencing.  These data indicate that 
both isoforms of MarvelD3 localise to cell-cell contacts in epithelial cells. 
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Figure 3.14 – HA-tagged constructs of MarvelD3 localise to the cell periphery 
in MDCK and Caco-2 cells.  Caco-2 and MDCK cells were transfeted with cDNAs 
encoding full-length MarvelD3 isoforms tagged at the N-terminus with a HA tag.  
Three days after transfection, cells were fixed in methanol.  Immunofluorescence was 
performed with antibodies against MarvelD3 and HA.  Hoechst was used as a 
nuclear stain.  HA-tagged constructs of each isoform localise to the cell periphery in 
both MDCK and Caco-2 cells. Bars, 10µm. 
 
Occludin and tricellulin have both been shown to interact with ZO-1 via their 
cytoplasmic C-termini (Furuse et al., 1994; Riazuddin et al., 2006).  In the case of 
occludin, this interaction has been implicated in its localisation to the tight junction 
(Furuse et al., 1994).  To determine whether MarvelD3 may also interact with ZO-1, 
pulldown assays were performed with GST-fusion proteins of MarvelD3 N- and C-
terminal domains from whole Caco-2 cell lysates.  Immunoblotting with anti-ZO-1, -
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ZO-2 and –ZO-3 showed no interaction between the cytoplasmic N- and C-termini of 
MarvelD3 isoforms and any of the ZO proteins (Figure 3.15).  Immunoblotting with 
an anti-occludin antibody, however, showed a potential interaction between occludin 
and the N-terminus of MarvelD3.  This suggests MarvelD3 and occludin may interact 
heterotypically within the tight junction. 
 
 
Figure 3.15 – Pulldown assays suggest an interaction between MarvelD3 and 
occludin, but not ZO-1, -2 or -3 in Caco-2 cells.  Purified GST-fusion proteins of 
the N-terminus and two isoform-specific C-termini of MarvelD3 were loaded onto 
GST-agarose beads in equal quantities.  Beads conjugated to the GST tag alone 
were used as a negative control.  Pulldown assays using whole Caco-2 cell lysates 
demonstrated an interaction between the N-terminus of MarvelD3 and occludin, but 
not with any of the ZO proteins. The input lane shows all probed proteins were 
present in the original lysates. 
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Functional characterisation of MarvelD3 at the tight junction 
To begin to address a functional role of MarvelD3 at the tight junction, the effect of 
siRNA-mediated depletion of MarvelD3 on the localisation and expression levels of 
other protein constituents of the apical junctional complex was assessed.  Efficient 
knockdown of MarvelD3 was achieved with a pool of siRNAs as well as the two 
individual siRNAs identified above (Figure 3.16A). Depletion of MarvelD3 on 
immunoblots was mirrored by the absence of junctional staining by 
immunofluorescence (Figure 3.16B), indicating that knockdown of MarvelD3 was 
sufficient to efficiently deplete the junctional pools of MarvelD3.   Transfection with 
MD3p-siRNA also caused reduced cytoplasmic staining suggesting some MarvelD3 
may also exist in a cytoplasmic pool. 
 
Figure 3.16 – Knockdown of MarvelD3 depletes the junctional pools of 
MarvelD3 in Caco-2 cells. Caco-2 cells were transfected with the indicated siRNAs 
and then processed for immunoblotting (A) or immunofluorescence. (A) Cells were 
immunoblotted with antibodies against MarvelD3 and  #-tubulin.  (B) 
Immunofluroescence was performed with an antibody against MarvelD3 and Hoechst 
was used as a nuclear stain.  Depletion of MarvelD3 following siRNA transfection 
resulted in loss of junctional MarvelD3. Bar, 10µm. 
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The effect of MarvelD3 on the expression levels of other junctional proteins was then 
tested. Expression of the tight junction proteins occludin, tricellulin, claudin-1, GEF-
H1, ZO-1, ZO-2 and ZO-3 (Figure 3.17), and the adherens junction proteins E-
cadherin and !-catenin remained unchanged (Figure 3.18). Similarly, 
immunofluorescence analysis did not reveal any effects of MarvelD3 depletion on the 
distribution of the junctional proteins occludin, tricellular, GEF-H1, ZO-1, ZO-2, ZO-
3, E-cadherin and !-catenin (Figure 3.19: shown is occludin). Although minor 
alterations cannot be excluded based on these data, depletion of MarvelD3 does not 
seem to affect the overall distribution of major junctional components.  
 
 
Figure 3.17 – Depletion of MarvelD3 does not affect expression of tight 
junction proteins occludin, claudin-1, GEFH1, ZO-1, ZO-2, ZO-3 or tricellulin.  
Cell extracts prepared from MarvelD3-depleted cells were separated by SDS-PAGE 
and probed with antibodies against various tight junction proteins.  Extracts blotted 
for occludin, claudin-1 and GEFH1 were from cells grown on filters.  Extracts blotted 
for ZO-1, ZO-2, ZO-3 and tricellulin were from cells grown on plastic.  Note that the 
expression levels of none of the tight junction proteins were affected by MarvelD3 
depletion, independent of whether filter- or plastic-grown samples were analysed.  All 
blots are representative of at least three independent experiments. 
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Figure 3.18 – Depletion of MarvelD3 does not affect expression of adherens 
junction proteins !-catenin and E-cadherin.  Immunoblotting MarvelD3-depleted 
cell extracts for adherens junction proteins !-catenin and E-cadherin showed no 
effect of MarvelD3 depletion on expression of these proteins. 
 
 
Figure 3.19 – Depletion of MarvelD3 does not affect occludin localisation. 
Caco-2 cells transfected with a pool of siRNAs against MarvelD3 (MD3p-siRNA) 
were fixed in methanol and processed for immunofluorescence with antibodies 
against MarvelD3 and occludin.  Occludin distribution appears unaltered by MarvelD3 
depletion. Bar, 10µm. 
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MarvelD3 and the regulation of ion conductance and paracellular permeability 
An important function of tight junctions is the generation of a tight seal between 
neighbouring cells of the monolayer, which restricts the movement of ions and solutes 
through the paracellular pathway (Cereijido et al., 2004).  To determine whether or 
not MarvelD3 plays a role in the assembly of the barrier or in the regulation of ion 
permeability, the TER of monolayers formed by control Caco-2 cells was compared 
to those formed by Caco-2 cells depleted of MarvelD3.  To follow assembly and 
monolayer formation of the junction, cells were seeded first on plastic for transfection 
of the siRNA. 24 hours after transfection, the cells were re-plated onto permeable 
supports either in normal tissue culture medium (direct plating) or at low Ca2+ 
concentrations, which are insufficient to support junction formation. Junction 
assembly was then initiated 24 hours after plating by switching the cells to normal 
Ca2+ concentrations (Ca2+ switch) (Gonzalez-Mariscal et al., 1985), by which time 
depletion had already occurred. The monolayers were followed for a further 48 hours 
by measuring TER and then analysed for protein expression and paracellular tracer 
permeability. Figure 3.20A shows that MarvelD3 was still efficiently depleted at the 
end of the incubation period. Similarly, no effects on monolayer morphology and 
localisation of junctional proteins were observed (Figure 3.20B: shown are occludin 
and ZO-1).  
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Figure 3.20 – Depletion of MarvelD3 and tight junction assembly. (A) Control 
and siRNA-transfected Caco-2 cells were plated on filters one day after transfection. 
The cells were lysed three days later and expression of MarvelD3 and #-tubulin was 
determined by immunoblotting. (B) Cells treated as those in panel A were fixed and 
processed for immunofluorescence at the end of the incubation period. Shown are 
epifluorescence images of samples labelled for the tight junction markers occludin 
and ZO-1. Note, depletion of MarvelD3 did not affect monolayer integrity and 
appearance. Bar, 10µm. 
 
TER measurements revealed that formation of functional tight junctions still occurred 
at similar kinetics as in control cells (Figure 3.21A), suggesting MarvelD3 is not 
necessary for the formation of tight junctions. However, MarvelD3 depleted cells 
reached higher resistance values. Determination of tracer permeability using 4kD and 
70kD fluorescent dextrans did not suggest any defects in barrier formation or 
significant alterations in tracer diffusion (Figure 3.21B). Cells that were directly 
plated in normal medium, and were hence 24 hours longer in normal Ca2+ medium, 
also formed functional tight junctions and reached stable TER values by the end of 
the incubation time (Figure 3.21C and D). As the Ca2+ switch cells, directly plated 
MarvelD3 depleted cells had reached 25% higher electrical resistance values than 
control cells.  Taken together, these results indicate that MarvelD3 depletion does not 
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affect the formation of functional tight junctions, but that MarvelD3 levels are a 
determinant of paracellular ion conductivity. 
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Figure 3.21 - Depletion of MarvelD3 and epithelial barrier properties.  Caco-2 
cells were cultured as in figure 3.20 either using the Ca2+ Switch (A, B) or Direct 
plating (C, D) protocol.  TER and fluorescent dextran permeability using 4kD and 
70kD dextran were measured as indicated. The amount of dextran diffused to the 
basolateral side of the monolayer was normalised against the average value 
obtained from control cells.  Shown are averages ± 1 standard deviation of 
quadruplicate samples of a typical experiment. The indicated p values were obtained 
with a t-test comparing knockdown with control values; in panel A, the p values refer 
to the final TER values. Note, MarvelD3 knockdown had no significant effect on 
diffusion of either dextran tracer across monolayers in either the Ca2+ switch 
experiment (B) or those plated directly into complete culture medium (D).  
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Claudins are the main constituent of tight junction strands and thought to be the main 
regulators of ion conductance properties of the tight junction.  Since MarvelD3 
depletion caused an increase in TER, the effect of MarvelD3 depletion on claudin 
expressed was determined by immunoblotting.  Figure 3.22 shows that MarvelD3 
depletion does not effect expression levels of claudin-1, but may lead to increased 
expression of claudin-4, as detected by immunoblotting. 
 
Figure 3.22 – Effect of MarvelD3 depletion on expression levels of claudin-1 
and claudin-4. (A) Cell extracts prepared from control and MarvelD3-depleted cells 
grown on filters were separated by SDS-PAGE and probed with antibodies for 
claudin-4 and claudin-1.  (B) Levels of claudin-4 were slightly, but not significantly, 
increased in MarvelD3-depleted cells, while there was no change in the expression 
levels of claudin-1, when compared to controls. Claudin-1 and claudin-4 levels were 
quantified relative to #-tubulin from three independent experiments. An anti-#-tubulin 
antibody was used as a loading control. 
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Discussion 
MarvelD3 is a novel component of the epithelial cell tight junction 
In the current chapter, MarvelD3 is identified as a novel component of the epithelial 
cell tight junction (Steed et al., 2009).  MarvelD3, a four-pass transmembrane protein, 
co-localises with the tight junction protein occludin, apical to the adherens junction 
protein E-cadherin, indicating that MarvelD3 is a tight junction-associated Marvel 
domain protein. MarvelD3 has also been shown to localise to tight junctions in 
epithelial tissues from mouse (Raleigh et al., 2010) suggesting the presence of this 
protein at tight junctions may be of physiological relevance. Depletion of MarvelD3 
using RNA-interference resulted in reduced junctional and cytoplasmic staining 
suggesting MarvelD3 exists in both a junctional and a cytoplasmic pool.  A functional 
analysis using RNA interference-mediated depletion indicates that MarvelD3 is not 
essential for junction assembly or the formation of a functional paracellular diffusion 
barrier, but the observed increase in TER in depleted cells indicates that MarvelD3 is 
a determinant of paracellular ion permeability.  The data presented demonstrate that 
MarvelD3 associates with the junctional complex of intestinal and corneal epithelial 
cells, and its expression was detected in multiple mouse tissues and cultured epithelial 
and endothelial cell lines. MarvelD3 thus seems to be a widely expressed protein and 
hence is likely to be a component of tight junctions with different functional 
properties. 
 
MarvelD3 is expressed as two isoforms due to alternative splicing and translation of 
exon 4 (isoform 1) or exon 3 (isoform 2) (Raleigh et al., 2010).  Both isoforms were 
recruited to the cell periphery when transfected into Caco-2 or MDCK cells in a 
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manner similar to the endogenous protein, suggesting that both isoforms associate 
with junctions. Attempts to generate isoform-specific antibodies, which are required 
to study endogenously expressed isoforms at the protein level, have so far failed. 
Based on reverse transcription PCR results, however, both isoforms seem to be 
widely expressed.   The majority of epithelial and endothelial cell lines tested 
expressed both isoforms of MarvelD3, though some isoform-specific expression 
patterns were observed. The liver cell line HepG2, for example, expressed the 
transcript for MarvelD3 isoform 1, but not isoform 2.  Interestingly, analysis of liver 
tissue from healthy mice also showed MarvelD3 isoform 1 to be expressed, but not 
isoform 2 (also observed in Raleigh et al., 2010), suggesting an expression preference 
for isoform 1 in the liver.  In keeping with Raleigh et al., (2010), neither transcript of 
MarvelD3 was detected in the spleen, which contains little epithelial tissue. It would 
be interesting for future studies to be able to differentiate between MarvelD3 isoforms 
at the protein level and to determine whether there are any isoform-specific 
differences in expression, localisation and/or function, as has been suggested for 
occludin (Ghassemifar et al., 2002; Muresan et al., 2000).  Intriguingly, the two 
MarvelD3 isoforms share a common N-terminal sequence and differ from their first 
transmembrane domain to the C-terminus, thus the sequences of their Marvel domains 
are not the same. In contrast, splice variants of occludin (occludin and occludin 1B) 
share the same Marvel domain, but differ at their N-terminus (Muresan et al., 2000).  
Tricellulin isoforms also share the same Marvel domain, but show differences in their 
cytosolic domains mediating interactions with potential signalling partners.  This 
suggests the conservation of the N-terminal sequence between isoforms of MarvelD3 
may be important in mediating the primary function of MarvelD3 at the tight junction, 
perhaps via interactions with cytoplasmic scaffolding or signalling proteins, while the 
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Marvel domain or differences at the C-terminus may be responsible for differential 
expression patterns. Perhaps the different Marvel domains of MarvelD3 isoforms 1 
and 2 afford propensity for insertion into membranes with slightly different 
properties, or affect the stability/dynamics of the protein within the membrane.  
Indeed, analysis of the dynamic behaviour of MarvelD3 has shown isoform 1 to be 
more stable at tricellular junctions, while isoform 2 appears more stable along 
bicellular junctions (Raleigh et al., 2010).  Under such a hypothesis, the existence of 
two isoforms would enable differential expression or cellular localisation based on 
membrane properties, without impairing the as yet unknown primary function 
regulated by the common N-terminal domain.  
 
Occludin and tricellulin not only localise to tight junctions, but have been shown to 
associate with the junctional intramembrane strands observed in freeze fracture 
replicas (Fujimoto, 1995; Ikenouchi et al., 2005).  The association of MarvelD3 with 
these structures and whether the Marvel domain, which is found in all three proteins, 
is important for strand association, has not been addressed here.  It would be 
interesting for subsequent studies to use electron microscopy to see if MarvelD3 
localises to the tight junction strands and, in combination with RNA interference, 
determine the effect it and other Marvel domain-containing proteins have on strand 
morphology.   
 
The regulation of paracellular diffusion and ion conductance is an important property 
of the tight junction.  Measurements of TER in MarvelD3-depleted monolayers 
revealed that formation of functional tight junctions occurred at similar kinetics as in 
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control cells.  This is in contrast to Raleigh et al. (2010) who reported a delay in 
barrier formation following MarvelD3 depletion.  Both of these studies were 
performed in Caco-2 cells, however unknown differences in the experimental set-ups 
make it difficult to comment on how the discrepancies between the two data sets may 
have arisen. More recently, MarvelD3 depletion has been shown to reduce TER and 
increase permeability to dextran tracers across pancreatic cell monolayers (Kojima et 
al., 2011), suggesting there could be cell type-specific differences in the response to 
MarvelD3 depletion.  To further clarify the importance of MarvelD3 in junction 
formation it would be beneficial to generate an inducible MarvelD3 knockdown cell 
line which would enable more stable knockdown of MarvelD3 than is possible using 
siRNA.  In their study, Raleigh et al. (2010) monitered TER for 9 days while the 
maximum knockdown in the system used in the current study is achieved at just 3 
days, and could perhaps be the important difference between the two studies.  
 
Since occludin overexpression was previously seen to increase TER (Balda et al., 
1996), it was tested whether the increased TER observed in the present study could be 
attributable to elevated levels of occludin expression.  Immunoblotting cell lysates 
from MarvelD3 knockdown cells however showed occludin levels, as well as levels 
of ZO-1, ZO-2 and ZO-3, to be unchanged.  Neither were any significant changes in 
the distribution of these proteins observed by immunofluorescence.  However, at this 
point it cannot be excluded that more subtle changes in occludin distribution might 
have caused the increase in TER. Given the importance of claudin family members 
for paracellular ion permeability (Van Itallie and Anderson, 2006; Krause et al., 2008; 
Angelow et al., 2008), it is possible that MarvelD3 depletion affected claudin 
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expression or function.  Indeed, occludin knockdown has been shown to reduce 
expression levels of claudins 1 and 7 and increase levels of claudins 3 and 4 in 
MDCK cells (Yu et al., 2005) and, in the present study, depletion of MarvelD3 
resulted in slightly elevated levels of claudin-4, which has been shown to cause 
increases in TER when overexpressed (Van Itallie et al., 2001).   Aside from altering 
protein expression levels, depletion of MarvelD3 could also affect ion conductivity by 
altering the dynamics of other tight junction proteins, which would not have been 
seen with the approaches used here.  In a recent study, the phosphorylation state of 
occludin at serine residue 408 (S408) has been shown to regulate paracellular 
permeability by affecting the dynamics of other tight junction proteins (Raleigh et al. 
2010).  Phosphorylation of occludin S408 weakened the interaction between occludin 
and ZO-1 and subsequently reduced the association between occludin and claudins 1 
and 2.   This promoted the assembly of claudin-1 and -2-based pores and subsequently 
promoted cation flux (Raleigh et al., 2011).  When unphosphorylated at S408, 
occludin interaction with claudin molecules, mediated by ZO-1, impairs pore 
formation and reduced ion conductance.  Thus by regulating the interactions and 
mobility of claudin-1, claudin-2 and ZO-1, the phosphorylation state of occludin can 
regulate paracellular permeability properties of the tight junctions (Raleigh et al., 
2011).  Pulldown assays showed the N-terminal domain of MarvelD3 was able to 
interact with occludin, supporting co-immunoprecipitation experiments, which have 
demonstrated an interaction between occludin and MarvelD3 (Raleigh et al., 2010), 
and extending them further by mapping the interaction to the N-terminal domain of 
MarvelD3.  Perhaps interactions with MarvelD3 may also be able to influence the 
dynamic properties of occludin-based tight junction complexes, or additional 
complexes based on MarvelD3 alone.  Identification of interactions between 
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MarvelD3, claudins and/or adaptor molecules other than ZO-1 may be needed to 
ascertain the mechanism behind MarvelD3 regulation of tight junction ion 
conductance. 
 
Despite the lack of interaction between MarvelD3 and the ZO proteins in this and 
another independent study (Raleigh et al., 2010), it is possible that the fusion proteins 
used may prevent some interactions from occurring during the pulldown assay.  
Though generated independently, both experimental setups utilised a GST-fusion 
protein with the GST tag at the N-terminal end of the MarvelD3 N-terminal sequence.  
The presence of this tag may impair interactions occurring at distal regions of the N-
terminus of MarvelD3, which would be freely exposed to the cytoplasm in vivo.  To 
address this issue, efforts were made to generate a GST-fusion protein with the GST-
tag at the C-terminal end of the N-terminus, but these unfortunately failed.  It is 
important to note, however, that a different strategy may enable interactions between 
MarvelD3 and the ZO proteins, or other proteins, to be observed, despite no evidence 
of such interactions being reported here.   
 
In conclusion, the experiments in this chapter identify MarvelD3 as a novel member 
of the occludin family, a subgroup of the Marvel domain proteins.  MarvelD3 is 
expressed as two isoforms that each shows a broad tissue distribution. Similarly to 
occludin, normal MarvelD3 expression is not essential for tight junction formation. 
Nevertheless, knockdown of MarvelD3 affects the paracellular ion conductance 
properties of tight junctions by mechanisms that still have to be identified.  The 
importance of MarvelD3 as an integral membrane component of the tight junction has 
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also been realised in additional studies performed during the preparation of this thesis 
(Kojima et al., 2011; Raleigh et al., 2011; Raleigh et al., 2010).  
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Chapter 4: 
Role of MarvelD3 in the regulation of 
proliferation and migration in epithelial 
cells 
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Chapter 4: Role of MarvelD3 in the regulation of proliferation 
and migration in epithelial cells 
Introduction 
In the previous chapter, MarvelD3 was identified as a novel component of the tight 
junction.  Since MarvelD3 appeared to have a relatively minor role in the regulation 
of ion conductance properties, and not in paracellular permeability, the work in this 
chapter aimed at determining what the primary function of MarvelD3 at the tight 
junction might be.  In addition to providing a structural role to the cell and performing 
the well characterised barrier and fence functions, tight junctions are further 
appreciated for their role in the regulation of intracellular signalling pathways and 
gene transcription.   
 
The work in this chapter addresses the idea that the primary function of MarvelD3 
may be in the regulation of intracellular signalling pathways from the tight junction.  
Indeed, the majority of the work implicating tight junctions in intracellular signalling 
pathways considers cytoplasmic proteins of the tight junction and not the integral 
membrane proteins themselves (Balda et al., 2003; Huerta et al., 2007). Exposed to 
both the cell exterior and interior, the transmembrane proteins are ideally situated to 
elicit the transmission of signals from the extracellular space or neighbouring cell to 
the cell interior.  That the cytoplasmic tails of these proteins interact with numerous 
cytoplasmic proteins implicated in intracellular signalling, further suggests the 
transmembrane proteins themselves could play an important role in the regulation of 
intracellular signalling pathways.  Such a role has been touched on for occludin in the 
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sensing and extrusion of apoptotic cells from the monolayer (Rosenblatt et al., 2001), 
but remains relatively uninvestigated for other proteins and other processes. 
This chapter demonstrates how expression of MarvelD3 protein is lost in a number of 
metastatic tumour cell lines and its exogenous expression in the metastatic pancreatic 
tumour cell line MiaPaCa results in a more epithelial-like phenotype and reductions in 
both cell proliferation and migration. In keeping, depletion of endogenous MarvelD3 
in Caco-2 cells results in increased proliferative and migratory behaviours.  
Microarray analysis identified altered expression of epidermal growth factor receptor 
(EGFR) pathway components following MarvelD3 expression in MiaPaCa cells.  
Thus suggesting cross talk between MarvelD3 and the EGFR signalling pathway.  
Inhibition of AP1 promoter activity by MarvelD3 expression suggests MarvelD3 may 
regulate the EGFR via AP1.  Taken together, data in this chapter implicates MarvelD3 
in the regulation of epithelial proliferation and migration, suggesting its absence may 
contribute, at least in part, to the uncontrolled proliferation and propensity for 
migration observed in the tumourogenic process. 
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Results 
To first address whether MarvelD3 may play a role in epithelial tumourigenesis, a 
number of benign and metastatic tumour cell lines were analysed for expression of 
MarvelD3 protein.  Immunoblotting showed MarvelD3 to be expressed in 
immortalised and benign tumour cell lines, including human mammary epithelial cells 
MCF10A and MCF7. MarvelD3 protein was reduced or absent in metastatic cell 
lines, like MB231 cells and MiaPaCa cells (Figure 4.1).  In prostate cell lines, 
reduction in MarvelD3 expression appeared to correspond with cells developing an 
invasive phenotype, just as reduced occludin levels have been shown to correspond 
with the progression of endometrial carcinoma (Tobioka et al., 2004) and breast 
cancer (Martin et al., 2010).    This suggests that loss of MarvelD3 expression may 
play a role in tumour pathogenesis. 
 
Figure 4.1 – Expression of MarvelD3 in tumour cell lines.  Whole cell lysates 
prepared from a number of tumour cell lines were processed for immunoblotting with 
an antibody against the N-terminus of MarvelD3.  MarvelD3 expression appears 
reduced in cells with a metastatic phenotype (-, non-metastatic; +, metastatic).  #-
tubulin was used as a loading control. 
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Expression of MarvelD3 in MiaPaCa cells results in the formation of cell-cell 
contact sites and a more epithelial-like phenotype 
In order to begin to understand a possible function of MarvelD3 in tumourigenesis 
and in normal physiology, the human pancreatic carcinoma cell line MiaPaCa was 
used, in which endogenous MarvelD3 protein could not be detected.   Semi-
quantitative RT-PCR demonstrated that MarvelD3 transcript is greatly reduced in 
MiaPaCa cells in comparison to healthy pancreas (Figure 4.2A).  As the pancreas 
expresses MarvelD3 isoform 1, but not isoform 2, MiaPaCa cell lines stably 
expressing a VSV-tagged construct of MarvelD3 isoform 1 (MD3_1:VSV) were 
generated.  To compensate for possible clonal variations two independent clones were 
established (C2 and C8), both of which expressed MarvelD3 transcript and protein 
(Figure 4.2B). 
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Figure 4.2 – Expression of MarvelD3 in MiaPaCa cell lines.  (A) RT-PCR of RNA 
extracted from healthy pancreas and control MiaPaCa cells shows MarvelD3 isoform 
1 (MD3_1) is expressed in healthy pancreas but not in MiaPaCa cells.  MarvelD3 
isoform 2 (MD3_2) is not expressed in healthy pancreas.  RT-PCR (A) and 
immunoblotting (B) demonstrates that the MiaPaCa clones C2 and C8 express 
MarvelD3 isoform 1 at the transcript and protein level.  Images are representative of 
three independent experiments.  RNA from human pancreas was purchased from 
Clonetech. 
 
Indirect immunofluorescence was used to determine the localisation of exogenously 
expressed MarvelD3 in MiaPaCa cells.  Figure 4.3 shows that anti-MarvelD3 and 
anti-VSV antibodies detected the MarvelD3 construct at cell-cell contact sites in C2 
and C8 MiaPaCa cells, at both low and high cell densities, consistent with the 
localisation pattern of the endogenous protein. Immunofluorescent staining also 
showed that MarvelD3-expressing MiaPaCa cells appeared more epithelial-like than 
control MiaPaCa cells.   
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Figure 4.3 – MD3_1:VSV localises to cell-cell contact sites when constitutively 
expressed in MiaPaCa cells.  Control and MarvelD3-expressing MiaPaCa cells 
were plated onto glass coverslips and grown for 3 days at 37°C.  Cells were fixed in 
methanol and processed for immunofluorescence using anti-MarvelD3 and anti-VSV 
antibodies.  Images were taken of cells at low density, to show early junctions, and 
high density, to show more mature junctions within the monolayer.  Exogenously 
expressed MarvelD3 showed the same localisation pattern as that seen in cells 
expressing the endogenous protein (e.g. Caco-2 cells). Bars, 20µm. 
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Imaging by light microscopy confirmed that cells expressing MarvelD3 grew in 
defined colonies with an epithelial-like appearance in contrast to the fibroblast-like, 
migratory appearance of the control cells (Figure 4.4).   Since endogenous MarvelD3 
was not detectable in control MiaPaCa cells, expression of MarvelD3 may be 
responsible for the more epithelial-like phenotype observed. 
 
 
Figure 4.4 – Expression of MarvelD3 results in a more epithelial-like phenotype 
in MiaPaCa cells.  Phase-contrast images were taken of control and MarvelD3-
expressing MiaPaCa cells grown in complete medium for 48 hours.  MarvelD3-
expressing C2 and C8 cells grow in colonies characteristic of adhesive epithelial cells 
in comparison to the fibroblast-like appearance of control MiaPaCa cells. 
 
In order to understand the nature of the cell-cell contact sites established following the 
expression of MarvelD3 in MiaPaCa cells, the effect of MarvelD3 expression on the 
expression and localisation of other junctional proteins was determined.  As figure 4.5 
shows, ZO-1 is recruited to early points of cell-cell contact following MarvelD3 
expression while transmembrane components of the tight and adherens junctions, 
occludin and E-cadherin, were not.  Both occludin and E-cadherin demonstrated an 
intracellular vesicular-like staining pattern in control MiaPaCa cells, which was still 
present following expression of MarvelD3.  Immunoblotting showed expression 
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levels of occludin to be decreased in MarvelD3-expressing cells, while ZO-1 and E-
cadherin levels were unchanged (Figure 4.5B).  This suggests that exogenously 
expressed MarvelD3 can integrate into the membrane and partially restore the 
epithelial nature of MiaPaCa cells. The recruitment of ZO-1 (Figure 4.5C), but not 
occludin or E-cadherin, suggests these MarvelD3-based contact sites are simple points 
of cell-cell contact which may enable the specific functions of MarvelD3 to be looked 
at more closely, away from the complexity of the endogenous apical junctional 
complex.  It will be important to combine such observations, however, with studies in 
epithelial cells expressing the endogenous protein, in case the presence or correct 
localisation of other junctional components are required for MarvelD3 functions. 
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Figure 4.5 – Effect of MarvelD3 expression on occludin, ZO-1 and E-cadherin in 
MiaPaCa cells.  (A) Control and MarvelD3-expressing MiaPaCa cells were 
processed for immunofluorescence with anti-MarvelD3, anti-occludin, anti-ZO-1 and 
anti-E-cadherin antibodies.  ZO-1 can be seen to recruit to points of early cell-cell 
contact in MD3-expressing cells (arrowheads).  E-cadherin and occludin retain the 
vesicular-like staining seen in control cells, following MarvelD3 expression.  (B) 
Immunoblotting shows the effect of MarvelD3 on junctional protein expression levels. 
(C) Images taken at increased magnification show the colocalisation between 
MarvelD3 and ZO-1 at cell-cell contact points in MarvelD3-expressing C2 MiaPaCa 
cells.  For clarity, only control and MarvelD3-expressing C2 MiaPaCa cells are 
shown.  MarvelD3 expression had the same effect in C8 MiaPaCa cells (not shown). 
Bar, 20µm. 
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MarvelD3 expression regulates epithelial cell proliferation and migration 
As tight junction formation inhibits proliferation, it was first asked whether MarvelD3 
expression was sufficient to suppress proliferation of MiaPaCa cells.   MiaPaCa cells 
were plated at a number of different cell densities and left to grow at 37°C for 4 days. 
The increase in cell number demonstrated by control MiaPaCa cells was greatly 
reduced in cells expressing MarvelD3 (Figure 4.6A).  To determine whether this 
reduction was attributable to an increase in apoptosis, sub-confluent control and 
MarvelD3-expressing MiaPaCa were prepared for FACS analysis.  Quantification of 
the numbers of fragmented nuclei, a sign of apoptosis, showed no significant increase 
in MarvelD3-expressing cultures than in control cells (Figure 4.6B).  Furthermore, 
extensive immunofluorescent analyses, across a number of experiments, highlighted 
no observable increase in apoptotic nuclei following expression of MarvelD3 than in 
control cells.  Taken together, this suggests the attenuation in cell number increases 
over time following expression of MarvelD3 in MiaPaCa cells may be due to an 
inhibition of cell proliferation, rather than an increase in apoptosis. 
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Figure 4.6 – Effect of MarvelD3 expression on cell number increases in 
MiaPaCa cells.  MiaPaCa control cells and MarvelD3-expressing clones C2 and C8 
were plated in quadruplicate at a number of different cell densities and a CyQUANT 
proliferation assay kit used to determine the cell number after 4 days.  (A) The 
increase in cell number shown by control MiaPaCa cells is greatly reduced in cells 
expressing MarvelD3. Shown are mean cell numbers after 4 days (n=4) ± standard 
deviation (B) FACS analysis demonstrated there was no significant difference in the 
proportion of apoptotic cells following the expression of MarvelD3.  20,000 cells of 
each group were counted.  **p<0.01 by Student"s t-test.  
 
To confirm this effect on proliferation was due to MarvelD3 expression and not a 
non-specific effect of overexpression or the presence of the VSV tag, Caco-2 cells, 
plated at the same cell density, were either transfected with a control siRNA, a pool of 
siRNAs, or two individual siRNAs to deplete the endogenous MarvelD3 protein. 
Quantification of cell numbers after 3 days at 37°C showed an approximately 20% 
increase in cell number following MarvelD3 depletion in comparison to control cells 
(Figure 4.7A). Immunoblotting confirmed good knockdown of the endogenous 
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MarvelD3 protein by all MarvelD3-siRNA treatments (Figure 4.7B).  Work in the 
previous chapter demonstrated that tight junctions and adherens junctions are still 
present following siRNA-mediated knockdown of MarvelD3, ruling out the 
possibility that MarvelD3 depletion increases proliferation by breaking cell-cell 
contacts.  Thus MarvelD3 may play a specific role in the regulation of proliferation in 
epithelial cells. 
 
 
Figure 4.7 – MarvelD3 depletion results in increased proliferation of Caco-2 
cells.  Caco-2 cells were plated in quadruplicate at the same cell density and 
transfected with control or MarvelD3-specific siRNAs.  Cell number was quantified 
after 3 days using a CyQUANT proliferation assay kit.  (A) Caco-2 cells depleted of 
MarvelD3 show significantly increased cell numbers in comparison to control cells.  
Shown are mean cell numbers plus standard deviation (n=4) representative of 3 
independent experiments. (B) Immunoblotting for MarvelD3 was used to confirm 
depletion of the endogenous protein. Significance was determined by Student's t-test 
*p<0.05, **p<0.01. 
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Since metastasis is also an important part of the tumourigenic process and given the 
recently reported role for occludin in regulating migration (Du et al., 2010), the effect 
of MarvelD3 expression on cell migration was also determined.  This question was 
first addressed using the control and MarvelD3-expressing MiaPaCa cells under the 
assumption that an effect on migration would be most apparent in this highly 
migratory cell type.  Cells were plated in to cell culture inserts, which, upon reaching 
confluency, were removed to reveal a 500µm cell-free space.  Migration of the cells 
into the cell-free space was monitored at regular intervals by brightfield microscopy 
until the most migratory cells showed approximately 80% wound closure. 
Quantification of wound closure showed control MiaPaCa cells to migrate into the 
cell-free space more rapidly than MarvelD3-expressing cells (Figure 4.8).  In the time 
it took control cells to close the wound by 80%, MarvelD3 expressing clones C2 and 
C8 demonstrated approximately 6% and 40% closure, respectively.  Thus MarvelD3 
expression appears to inhibit migration in MiaPaCa cells. 
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Figure 4.8 – MarvelD3 expression reduces migration in MiaPaCa cells.  
MiaPaCa cells (control and MarvelD3-expressing clones) were plated into cell culture 
inserts and grown until confluent.  Inserts were then removed and cell migration 
monitored by light microscopy. (A) Phase-contrast images show reduced migration 
into the cell-free space by MarvelD3-expressing C2 and C8 cells in comparison to 
control MiaPaCa cells.  (B) Quantification of migration shows control cells to begin 
migrating into the cell-free space more rapidly than MarvelD3-expressing cells, and 
result in significantly greater closure of the wound area, also represented in (C).  
Images were quantified using ImageJ software.  Shown are mean values (n=3) from 
a single representative experiment.  Error bars represent the standard deviation.  
Significance was calculated by Student"s t-test; **p<0.01, *p<0.05. 
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It is important to note that control MiaPaCa cells do not form cell-cell contacts and 
migrate as single cells, while the cell-cell contacts formed following expression of 
MarvelD3 means C2 and C8 cells migrate collectively.  The difference in migration 
speeds between these two groups, therefore, could be due to the transition from single 
to collective cell migration and not necessarily a MarvelD3-specific effect.  To see if 
MarvelD3 may have a signalling role in the regulation of migration, the migration 
assay was repeated with Caco-2 cells depleted of MarvelD3, which retain cell-cell 
contact, but lack MarvelD3 at the tight junction.  Migration in to the cell-free space 
following insert removal showed MarvelD3-depleted cells to migrate more rapidly 
than control cells (Figure 4.9). Migration assays were performed in the presence of 
10µg/ml Mitomycin c to ensure the effect seen is due to increased migration, and not 
increased proliferation, which is also thought be regulated by MarvelD3.  Brightfield 
imaging showed MarvelD3-depleted cells kept their sheet-like morphology like 
control cells, and knockdown of MarvelD3 did not result in cells breaking free from 
the monolayer and migrating in to the cell-free space.  This suggests loss of MarvelD3 
results in increased collective migration of Caco-2 cells. 
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Figure 4.9 – Depletion of endogenous MarvelD3 increases migration in Caco-2 
cells.  Caco-2 cells transfected with control or two individual MarvelD3-specific 
siRNAs (14 and 16) were plated into cell culture inserts to reach confluency after 2 
days.  (A) Brightfield microscopy was used to track migration of cells into the cell-free 
space following insert removal.  (B) Immunoblotting was used to confirm knockdown 
of the endogenous MarvelD3 protein, with #-tubulin as a loading control. (C) Cell 
migration was quantified by calculating the area of the cell-free space at each time 
point and represented as a % of the original area.  MarvelD3-depleted cells can be 
seen to migrate more rapidly into the space than control cells, to cover a greater 
proportion of the original cell-free space by the end of the experiment, also 
represented in (D). Migration images were quantified using ImageJ software.  Shown 
are the means (n=3) of a single representative experiment, plus the standard 
deviation.  Significance was calculated with a Student"s t-test; *p<0.05. 
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Since junctions are maintained in the absence of MarvelD3, these data together 
suggest that MarvelD3 may function in the regulation of intracellular signalling 
pathways in order to regulate epithelial cell proliferation and migration from the tight 
junction.  The rest of this chapter is dedicated to elucidating a mechanism through 
which this may be achieved. 
 
MarvelD3 expression regulates the expression of genes involved in cell 
proliferation and migration 
To begin to address how MarvelD3 may be regulating epithelial cell proliferation and 
migration, a microarray was performed comparing changes in mRNA transcripts 
between control and MarvelD3-expressing MiaPaCa cells, to obtain a profile of the 
potential signalling pathways affected by expression of MarvelD3.  The microarray 
was performed by Tony Brooks, UCL Institute of Child Health, and of a list of 
significant genes provided from this analysis, data was analysed further using 
GeneSpring and DAVID software. These analyses revealed that expression of 
MarvelD3 in MiaPaCa cells resulted in changes in the expression of a number of 
genes involved in proliferation and migration, among others.  Focusing on genes 
involved in proliferation and migration, or otherwise relevant to the tight junction, 
figure 4.10 shows genes affected by MarvelD3 expression.  Pathway analysis using 
GeneSpring software based on 170 genes that were at least 2-fold differentially 
regulated further revealed the importance of EGFR signalling and Wnt signalling, 
both heavily implicated in tumourigenesis.  Potential hits of the microarray were 
validated by immunoblotting cell lysates using antibodies already available in the lab.  
MiaPaCa cells grown in the same way as those harvested for RNA prior to microarray 
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analysis were used for this validation.  Figure 4.10B confirms EGFR, integrin-linked 
kinase (ILK), ETS1, Stat3, Smurf1, CDK6 and (phospho-)Smad3/1 are changed at the 
protein level, as well as at the level of the transcript.  To confirm the functional 
importance of reduced EGFR expression following MarvelD3 expression the 
proliferation of control, MD3-MiaPaCa C2 and MD3-MiaPaCa C8 cells in response 
to EGF was quantified. MarvelD3-expressing MiaPaCa cells did not increase their 
proliferation in response to addition of EGF, but control cells did (Figure 4.10C).  
This suggests MarvelD3 expression reduces responsiveness to EGF, likely by 
reducing expression of the EGFR. 
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Figure 4.10 – Genes regulated by expression of MarvelD3 in MiaPaCa cells.  (A) Shown 
is a list of genes involved in proliferation and migration affected by MarvelD3 expression in 
MiaPaCa cells.  Fold changes are shown and colour-coded; green for increased expression, 
blue for reduced expression.  (B) For validation purposes, MiaPaCa control and MarvelD3-
expressing cell lysates were separated by SDS-PAGE and immunoblotted for differentially 
expressed proteins identified in the microarray.    #-tubulin was used as a loading control.  (C) 
Reduced EGFR expression leaves MD3-MiaPaCa C2 and C8 cells unresponsive to EGF in 
CyQuant proliferation assay.  Only control cells increased cell number in response to EGF. 
Shown are mean cell numbers normalised to control for each MiaPaCa cell type (n=4) plus 
normalised standard deviation.  Significance was calculated by Student's t-test; *p<0.05 
compared to control (i.e. without EGF). 
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Regulation of transcription factor-specific promoter activity by MarvelD3 
expression 
The microarray analyses performed in MiaPaCa cells alluded to the ability of 
MarvelD3 expression to regulate the expression of genes involved in proliferation and 
migration.  It was therefore reasoned that expression of MarvelD3 must somehow 
modulate the transcriptional activity of certain promoters in order to elicit these 
effects of gene expression.  To test this hypothesis, transcription factor-specific 
reporter plasmids, consisting of transcription-factor-responsive promoter elements 
reading in to a firefly luciferase reporter gene and a separate, eBM2 mutant promoter 
upstream of a renilla luciferase reporter gene, were cotransfected into cells alongside 
a plasmid encoding MarvelD3 isoform 1 (MD3_1) or isoform 2 (MD3_2), occludin or 
a control plasmid.  Occludin overexpression was used to determine the specificity of 
promoter regulation to MarvelD3.  The ability of MarvelD3 and occludin expression 
to affect promoter activity was first assessed in MDCK cells due to their ease of 
transfection.  Figure 4.11 shows the effect of expressing each isoform of MarvelD3 or 
occludin on the activity of a number of transcription-factor-specific promoters relative 
to the promoter activity in control MDCK cells.  Expression of both MarvelD3 
isoforms resulted in reduced activity of promoters regulated by the serum response 
element (SRE), AP1, myc, cyclinD1 and ZONAB, but not at the TCF promoter, 
suggesting some specificity in the effects of MarvelD3.  Since ZONAB is a repressor 
of this promoter, the reduction in promoter activity illustrates an increase in ZONAB 
signalling following expression of MarvelD3.  Interestingly, AP1 signalling, 
cyclinD1, SRE, ZONAB and myc all have previously reported roles in cell 
proliferation and/or cell migration.  In addition, the presence of AP1-binding sites in 
the promoters of cyclinD1 and myc, and the ability of AP1 signalling to regulate the 
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activity of the SRE suggested regulation of the AP1 promoter could be the significant 
role of MarvelD3 in regulating gene expression. Furthermore, occludin expression 
significantly reduced activity of the SRE, cyclinD1 and myc promoters, but not of 
AP1, suggesting this regulation may be specific for MarvelD3. 
 
 
Figure 4.11 – Regulation of transcription factor-specific promoters by 
MarvelD3 isoforms and occludin.  MDCK cells were plated on to 96 well plates and 
transfected with cDNAs encoding MarvelD3 isoform 1, isoform 2, occludin or a 
control plasmid, alongside a luficerase reporter construct and a renilla control 
plasmid.  Promoter activity was detected using a Dual luciferase reporter assay kit 
and luminescence signals for firefly and renilla luciferase activity were measured 
sequentially on a microplate reader.  Ratios of firefly luciferase to renilla luciferase 
activity were calculated, averaged (n=3) and normalised to control-transfected cells 
to give relative promoter activity values.  Expression of both isoforms of MarvelD3 
attenuated SRE, AP1, myc, and cyclinD1 promoter activity.  TCF promoter activity is 
not affected by MarvelD3 expression in MDCK cells.  Error bars represent the 
standard deviation.  Significance was calculated by Student"s t-test; **p<0.01 
compared to promoter activity in control cells. 
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Regulation of the AP1 promoter by MarvelD3 
To confirm regulation of the AP1 promoter by MarvelD3, the luciferase reporter 
assay was repeated in Caco-2 and MiaPaCa cells.  Consistent with the observations 
made in MDCK cells, expression of either isoform of MarvelD3 caused a significant 
reduction in AP1 promoter activity when compared to control cells (Figure 4.12).  
AP1 promoter activity was not affected by expression of occludin.  It is also notable 
that MD3_2 appeared to reduce AP1 promoter activity more than MD3_1 in all cell 
types tested.  While isoform-specific differences have not been a focus of this thesis, 
it is interesting that the isoforms appear to display slightly different properties, 
especially when the differential tissue expression patterns are considered.   
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Figure 4.12 – MarvelD3 regulates AP1 promoter activity in Caco-2 and MiaPaCa 
cells.  Caco-2 and MiaPaCa cells were transfected with control plasmid or that 
encoding MarvelD3 isoform 1 or isoform 2, alongside the AP1-firefly reporter plasmid 
and a Renilla control.  Detection of firefly and Renilla luciferase luminescent signals 
showed AP1 promoter activity to be reduced in both cell types following expression of 
both isoforms of MarvelD3, but not occludin.   Relative promoter activity was 
calculated as previously described (n=3) and error bars represent standard deviation.  
Significance was calculated by Student's t-test; *p<0.05, ***p<0.001. 
 
Since the reporter assays performed so far have relied upon over-expressing 
MarvelD3, it was asked if depletion of MarvelD3 resulted in increased transcriptional 
activity.  To address this question, Caco-2 cells were plated into 96-well plates and 
transfected with control or MarvelD3-specific siRNAs according to the standard 
transfection protocol.  Reporter plasmids were then transfected 48 hours later.  
Medium was changed after overnight incubation in transfection mix, and promoter 
activity was assayed after a further 6 hours.  Interestingly, depletion of MarvelD3 did 
not result in an increase in AP1 promoter activity (data not shown), despite the 
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consistent and substantial reductions following MarvelD3 overexpression.  Since 
these studies were performed in unstimulated cells, it is possible that, if MarvelD3 
acts as a brake on AP1 signalling, loss of MarvelD3 alone may not be enough to 
potentiate AP1 promoter activity.  Perhaps, MarvelD3 depletion in combination with 
the addition of an inducer of AP1 activity is necessary in order to be able to observe 
the effect of loss of MarvelD3.   
In addition to EGFR expression being transcriptionally regulated by AP1 signalling 
(Johnson et al., 2000), AP1 is also a major downstream target of signalling induced by 
EGF (Whitmarsh and Davis, 1996). The microarray analysis above implicated 
MarvelD3 expression in the regulation of the EGFR pathway and MiaPaCa cells 
expressing MarvelD3 failed to respond to EGF in a proliferation assay.  Taken 
together with the observation that MarvelD3 expression reduces AP1 promoter 
activity and the presence of multiple AP1 sites in the EGFR promoter, it was 
hypothesised that MarvelD3 may function in regulating expression of the EGFR via 
regulation of AP1 signalling.  Despite there being no potentiation in AP1 promoter 
activity in MarvelD3-depleted cells, however, immunoblotting cell lysates suggested 
increased levels of EGFR protein following loss of MarvelD3 and increased AP1 
promoter activity in response to EGF (Figure 4.13).  Therefore, MarvelD3 expression 
in Caco-2 and MiaPaCa cells appears to regulate expression of the EGFR and 
subsequently affects AP1 activity and proliferation in response to EGF. Furthermore, 
depletion of MarvelD3 resulted in increased levels of cyclinD1 protein and activity of 
the cyclinD1 promoter, a previously reported downstream target of the EGFR (Figure 
4.14). While the mechanism behind the increased EGFR levels remains to be 
determined, these data allude to a function for MarvelD3 in the regulation of the 
EGFR pathway. 
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Figure 4.13 – Effect of MarvelD3 depletion on EGFR expression and AP1 
promoter activity in response to EGF.  (A) Immunoblotting MarvelD3-depleted 
Caco-2 cell lysates showed an increase in EGFR protein in comparison to controls. 
Con-siRNA and MD3p-siRNA samples were run on the same gel and are shown with 
#-tubulin as a loading control. (B) Quantification of band intensities from 3 
independent experiments using ImageJ software confirmed increased EGFR protein 
in cells depleted of MarvelD3.  (C) Control and MarvelD3-depleted Caco-2 cells 
expressing AP1-firefly luciferase and Renilla luciferase control reporter constructs 
were incubated with 0.2µg/ml EGF or the appropriate volume of water (control) for 24 
hours at 37°C. Detection of firefly and Renilla luciferase luminescent signals showed 
AP1 promoter activity to be potentiated in response to 0.2µg/ml EGF in the absence 
of MarvelD3, but not in control cells. All treatments were performed in quadruplicate 
and shown are mean values of a representative experiment.  Significance was 
calculated by Student"s t-test, *** p<0.01, *p<0.05, n.s. = not significant. 
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Figure 4.14 – Effect of MarvelD3 on cyclinD1 expression.  (A) Caco-2 cells 
depleted of MarvelD3 show increased levels of cyclinD1 protein when compared to 
control transfected cells.  (B) Activity of the cyclinD1 promoter is increased following 
depletion of MarvelD3 by two independent siRNAs. Shown are mean values 
representative of three independent experiments (n=4), plus the standard deviation. 
Significance was determined by Student"s t-test. **p<0.01 (C) MarvelD3 expression 
reduces the level of cyclinD1 protein in MiaPaCa cells.  #-tubulin is used as a loading 
control in both immunoblots.   
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MarvelD3 regulates cytoskeletal rearrangements during cell migration 
Reorganisation of the actin cytoskeleton is a critical event involved in cell migration.  
Since MarvelD3 appears to play a role in migration of Caco-2 and MiaPaCa cells, it 
was hypothesised that alterations in MarvelD3 expression may affect rearrangements 
of the cytoskeleton conducive to migration.  To address this, control and MarvelD3-
depleted Caco-2 cells monitored during the migration assay on Ibidi cell culture 
inserts were fixed after 26 hours and stained with phalloidin to observe the effect of 
MarvelD3 depletion on arrangement of the actin cytoskeleton.  Although 26 hours 
was the end point of the migration assay, the most migratory cells showed 
approximately 80% wound closure after this time (see above, Figure 4.9) and cells 
were therefore still considered to be migrating at the time of fixation.  Depletion of 
MarvelD3 resulted in increased numbers of protrusions into the cell-free space from 
the monolayer (Figure 4.15), suggesting that MarvelD3 may regulate migration by 
regulating the formation of a constructive leading edge.   
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Figure 4.15 – Effect of MarvelD3 depletion on the actin cytoskeleton in 
migrating Caco-2 cells.  Caco-2 cells transfected with control or MarvelD3-specific 
siRNA were fixed on Ibidi cell culture inserts 26 hours after the onset of migration.  
(A) Representative F-actin staining shows the actin cytoskeleton in control and 
MarvelD3-depleted cells.  Cells transfected with MD3-siRNA appeared to have more 
protrusive structures than control cells. (B) Quantification of cell protrusions into the 
cell-free space shows an increase following depletion of MarvelD3.  Counts were 
made by determining the ratio of cells with protrusions into the cell-free space 
compared to the total number of cells with an edge exposed to the cell-free space 
along the full length of the ibidi insert.  Shown are the mean values plus the standard 
deviation from three different plates.  ***, p<0.001 by Student"s t-test. Bar, 10µm. 
 
To further confirm a role in regulation of leading edge formation, migrating MiaPaCa 
cells were fixed and stained with Cy3-phalloidin to observe the arrangement of the 
actin cytoskeleton following expression of MarvelD3.  Interestingly, while there were 
protrusive structures in both C2 and C8 MarvelD3-expressing cells, they did not 
resemble the actin-rich lamellipodia seen in the control cells (Figure 4.16A). 
Quantification confirmed a reduced number of cell protrusions in both MarvelD3-
expressing cells when compared to the controls (Figure 4.16B).  Since this 
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quantification was made of any structure that appeared to protrude from the migration 
front, they have been termed “protrusions” rather than “leading edges” and may not 
all be structures supportive of migration.  Thus this quantification is likely to be an 
underestimate of the effect of MarvelD3 on the cytoskeletal rearrangements necessary 
for cell migration.  The reduced number of leading edges in MarvelD3-expressing 
cells, however, supports the hypothesis that MarvelD3 may play a role in leading edge 
formation, which is an integral part of the cell migration process.   
 
 
Figure 4.16 – Effect of MarvelD3 expression on the actin cytoskeleton in 
migrating MiaPaCa cells. (A) Migrating MiaPaCa cells were fixed and stained with 
phalloidin to observe the arrangement of the actin cytoskeleton following the 
expression of MarvelD3.   Actin-rich lamellipodia can be seen in control MiaPaCa 
cells, but not in MarvelD3-expressing C2 or C8 clones.  C2 and C8 cells show some 
protrusive structures at the migration front.  (B) Quantification of immunofluorescence 
images shows a reduction in protrusive structures following expression of MarvelD3 
in comparison to controls.  n=112, 114 and 259 for control, C2 and C8 cells 
respectively.  Bar, 5µm. 
 
Taken together, the data presented suggests a role for MarvelD3 in the regulation of 
epithelial cell proliferation and migration by affecting the expression of genes 
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involved in these processes and regulating the cytoskeletal rearrangements involved 
in cell migration.  To appreciate how this is achieved, the next step will be to 
elucidate the events upstream that link MarvelD3 at the cell membrane to events in 
the nucleus and underlying cytoplasm. 
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Discussion 
The experiments described above suggest a role for MarvelD3 in the regulation of 
epithelial proliferation and migration.  Loss of MarvelD3 from metastatic tumour cell 
lines and the increased proliferation and migration observed following siRNA-
mediated depletion of MarvelD3 suggests MarvelD3 may function as a tumour 
suppressor at the tight junction.  Consistently, expression of MarvelD3 in tumour cells 
lacking the endogenous protein resulted in the formation of a more epithelial, sheet-
like morphology and cells became less migratory and less proliferative.  As 
MarvelD3-depleted cells retain cell-cell contacts but lack MarvelD3 at the tight 
junction, it is proposed that MarvelD3 regulates these processes via intracellular 
signalling pathways and not indirectly by breaking cell-cell contacts.  Reduced 
expression levels of the EGFR following MarvelD3 expression in MiaPaCa cells 
prompted the hypothesis that MarvelD3 may regulate both proliferation and migration 
by impacting on the activity of EGFR signalling.  Reporter assays suggested 
inhibition of AP1 promoter activity following MarvelD3 expression.  As the EGFR 
both regulates and is regulated by AP1 signalling, impacting upon AP1-mediated 
gene expression could be one mechanism by which MarvelD3 inhibits proliferation 
and migration. 
 
Exogenous expression of MarvelD3 results in a partial restoration of epithelial 
morphology in MiaPaCa cells 
The reduction or loss of MarvelD3 in a number of metastatic tumour cell lines tested 
suggested that MarvelD3 may play a role as a tumour suppressor.  To investigate this 
further, exogenous MarvelD3 isoform 1 (MD3_1:VSV) was expressed in MiaPaCa 
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cells, which lack the endogenous protein expressed in the healthy pancreas.  
Strikingly, MarvelD3 expression induced an epithelial-like morphology with 
MarvelD3 expressing cells growing in distinct colonies and remaining in contact with 
their neighbours in contrast to the single cell behaviour of control MiaPaCa cells.  
MarvelD3 expression, however, did not lead to redistribution of other junctional 
proteins to contact sites, with occludin and E-cadherin retaining the cytoplasmic, 
vesicular-like staining observed in untransfected cells.  Interestingly, despite there 
being no interaction between MarvelD3 and ZO-1 in pulldown assays, ZO-1 is 
recruited to early sites of cell contact in MarvelD3-expressing MiaPaCa cells.  Thus 
expression of MarvelD3 appears to be sufficient for the formation of basic cell-cell 
contacts and maybe be capable of initiating the formation of simple protein 
complexes.   
 
Regulation of proliferation and migration by MarvelD3 
Analysis of proliferation and migration in response to MarvelD3 expression levels 
demonstrated that MarvelD3 inhibits proliferation and migration of both MiaPaCa 
and Caco-2 cells.  Interestingly, depletion of MarvelD3 in Caco-2 cells resulted in 
increased proliferation and migration without disrupting cell-cell contacts, suggesting 
MarvelD3 may possess some signalling activity that enables this regulation rather 
than an indirect effect of breaking down cell-cell junctions. 
 
Microarray analyses of RNA extracted from MarvelD3 expressing and control 
MiaPaCa cells demonstrated that many genes involved in proliferation and migration 
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were affected by MarvelD3 expression.  The microarray was performed as an initial 
strategy to identify potential pathways that may be being regulated by MarvelD3.  As 
described above, the protein assemblies formed at the cell-cell contact sites following 
MarvelD3 expression in MiaPaCa cells are less complex than those found at 
endogenous tight junctions.  It is possible, therefore, that some signalling 
partners/modules may not be present and subsequently downstream signalling 
pathways that may normally be regulated by MarvelD3 may have been missed.  In 
recognition of this, the microarray was used to initially highlight potential pathways 
of interest that could then be investigated further using additional protocols and in 
other cell types.  The microarray data was also a useful resource to confirm results 
found by other approaches.  
 
Initial pathway analysis of microarray data highlighted the EGFR signalling pathway 
as being significantly altered following MarvelD3 expression in MiaPaCa cells.  
Elevations in EGFR activation due to increased receptor expression levels or 
increased availability of its ligands, including EGF and TNF#, confers significant 
growth and survival advantages and is reported in numerous types of cancer, 
including pancreatic cancer (Korc et al., 1992).  The high levels of EGFR displayed 
by MiaPaCa cells in the current study were greatly reduced upon expression of 
MarvelD3 at both the transcript and protein levels.  This reduction in EGFR 
significantly diminished the responsiveness of MiaPaCa cells to EGF in a 
proliferation assay.  The increase in EGFR levels following siRNA-mediated 
depletion of MarvelD3 further suggested that MarvelD3 might regulate EGFR 
signalling by regulating the expression of the EGFR itself.  It would be interesting to 
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test this hypothesis by determining whether or not expression levels of MarvelD3 and 
EGFR correlate in tumour cell lines and primary tumour samples. 
 
The promoter of the EGFR contains multiple AP1 response elements that ensure its 
expression in response to AP1 signalling (Johnson et al., 2000).  Since EGFR 
activation itself activates AP1 signalling, this establishes a positive feedback loop that 
further amplifies the activity of the EGFR pathway in response to ligand binding 
(Grose, 2003).  Inhibition of AP1 activity by MarvelD3 may therefore result in the 
attenuated expression of the EGFR gene and protein observed in MiaPaCa cells.  This 
could be confirmed by performing reporter assays with the wild-type EGFR promoter 
and those with mutated AP1 binding sites and assaying the effect of MarvelD3 on 
promoter activity.  If MarvelD3 regulates EGFR expression via AP1, only those 
constructs containing the responsive AP1 binding sites should be affected by 
MarvelD3 expression.  AP1-mediated regulation of EGF signalling could be how 
MarvelD3 regulates epithelial cell proliferation and migration. The increased EGFR 
protein levels in unstimulated MarvelD3 knockdown cells without increased AP1 
promoter activity, however, suggests there could be additional factors by which 
MarvelD3 regulates EGFR expression.  Smad3 and Smad4 have been shown to 
cooperate with AP1 to mediate gene transcription induced by TGF! (Zhang et al., 
1998).  Therefore, while overexpression of MarvelD3 may be sufficient to inhibit 
JNK activity and AP1 activity, loss of MarvelD3 and the proposed increase in JNK 
activity may not be sufficient to increase AP1 signalling if the activities of 
cooperation partners are not equally upregulated.  Addition of AP1-promoting signals, 
like TGF!, to control and MarvelD3-depleted cells may enable the identification of 
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potential signalling pathways that could converge with MarvelD3-regulated JNK-
MAPK pathway at promoter sites regulated by AP1. 
 
It has also been reported that inhibition of the EGFR in pancreatic cancer cells results 
in reduced nuclear localisation of ZO-1 (Takai et al., 2005).  Interestingly, ZO-1 was 
recruited to cell-cell contact sites in MarvelD3-expressing MiaPaCa cells despite 
there being no interaction between MarvelD3 and ZO-1 in pulldown assays.  
Inhibition of EGFR signalling by MarvelD3, therefore, may also regulate proliferation 
by altering the localisation of ZO-1 and perhaps its binding partner and regulator of 
proliferation, ZONAB (Balda and Matter, 2000).  Somewhat surprisingly, reporter 
assay data demonstrated an increase in ZONAB signalling following expression of 
MarvelD3 isoforms 1 and 2.  Since increased ZONAB signalling is associated with 
increased proliferation, this was unexpected and suggests MarvelD3 does not mediate 
its inhibition of proliferation via ZONAB.  The functional significance of MarvelD3-
mediated increases in ZONAB transcriptional activity, however, requires further 
investigation.  Immunoflourescent analysis of the nuclear to junctional ratios of ZO-1 
and ZONAB with respect to MarvelD3 expression may help to determine how 
MarvelD3 impacts on the ZO-1-ZONAB signalling pathway.   
 
Cell cycle regulators were also highlighted in the microarray. Immunoblotting cell 
lysates from unsynchronised MiaPaCa cell cultures demonstrated reductions in CDK6 
and cyclinD1 protein levels in MarvelD3-expressing MiaPaCa cells.  MarvelD3 
expression also reduced cyclinD1 promoter activity in MDCK cells, thus regulation of 
cell cycle progression by reducing the availability/formation of cyclinD1/CDK6 
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complex could be another mechanism through which MarvelD3 regulates 
proliferation.  In keeping with this hypothesis, depletion of MarvelD3 potentiated 
cyclinD1 promoter activity and increased the amount of cyclinD1 protein in Caco-2 
cells.  Since MarvelD3 depletion was not sufficient to increase AP1 promoter activity, 
however, it is possible that MarvelD3 regulates the cyclinD1 promoter by a 
mechanism other than AP1.  Interestingly, activated Stat3 has previously been shown 
to correlate with elevations in cyclinD1 protein levels (Leslie et al., 2006).  In the 
current study, MarvelD3 expression reduced the levels of Stat3 transcript and protein, 
and therefore could explain the reduced levels of cyclinD1 in MarvelD3-expressing 
MiaPaCa cells.  Levels of Stat3 in MarvelD3-depleted cells should be assessed to 
determine if MarvelD3 could be regulating cyclinD1 promoter activity via Stat3.  The 
effect of MarvelD3 expression on Stat3 localisation in response to EGFR activation 
should also be determined.  Though further work is required to determine the 
underlying mechanism, the regulation of cyclinD1 and progression through the cell 
cycle is another mechanism by which MarvelD3 may regulate cell proliferation. 
 
The inhibition of epithelial cell migration following MarvelD3 expression suggests 
MarvelD3 and occludin have opposite effects on the regulation of migration.  
Depletion of occludin reduced the rate of wound closure of MDCK cells (Du et al., 
2010), while MarvelD3 knockdown in the current study increased Caco-2 cell 
migration.  In addition, occludin depletion resulted in reduced numbers of cellular 
protrusions (Du et al., 2010), while MarvelD3 depletion appeared to promote 
protrusion formation, implicating both proteins in the regulation of the actin 
cytoskeleton during migration.  The activation and localisation of Rac1 at the leading 
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edge, which regulates lamellipodia formation during cell migration, was attenuated in 
occludin-depleted cells, implicating occludin in the localised activation of this 
RhoGTPase (Du et al., 2010).  Preliminary studies have suggested that Rac1 may be 
inhibited following the expression of MarvelD3 in MiaPaCa cells (data not shown), 
but this needs to be confirmed.  It is also important to realise that the effects of 
occludin and MarvelD3 upon migration have been studied in different cell types and 
therefore require some standardisation before firm conclusions can be drawn.  Based 
on current observations, however, it is interesting to speculate that occludin and 
MarvelD3 may serve opposing roles in regulation of the actin cytoskeleton during cell 
migration.   
 
In conclusion, loss of MarvelD3 expression, which is observed in a number of 
metastatic tumour cell lines, resulted in increased proliferation and migration of Caco-
2 cells.  Microarray analysis suggested MarvelD3 expression might regulate these 
processes by impacting on, and inhibiting, the activity of the EGFR signalling 
pathway.  In keeping, alterations in MarvelD3 expression levels appeared to affect 
signalling pathways downstream of the EGFR, with MarvelD3-expressing MiaPaCa 
cells being less responsive to EGF and MarvelD3-depleted cells displaying elevated 
AP1 promoter activity following addition of EGF.  Furthermore, depletion of 
MarvelD3 resulted in elevation of cyclinD1 levels, which can also be regulated in 
response to EGFR signalling. The mechanism behind MarvelD3-mediated regulation 
of EGFR expression, however, is not yet known.  In consideration of the results 
presented here, however, MarvelD3 may serve a function in maintaining homeostasis 
of the monolayer in response to growth factor signalling.  Absence of this MarvelD3-
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mediated inhibition in tumour cells may contribute to the exacerbation of the 
tumourogenic state.  Understanding the timing of loss of MarvelD3 expression during 
tumour progression may also be useful to see if MarvelD3 is a potential therapeutic 
target.   
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Chapter 5 – Regulation of AP1 signalling by MarvelD3 
Introduction 
The results described in the previous chapter suggested a role for MarvelD3 in the 
regulation of epithelial cell proliferation and migration.  Further analyses suggested 
this could be mediated by changes in the levels of EGFR signalling components in 
response to MarvelD3 expression.  Furthermore, reporter assays demonstrated that 
MarvelD3 expression inhibits AP1 promoter activity.  As EGFR expression can be 
regulated by AP1 signalling (Johnson et al., 2000), this could be a potential 
mechanism through which MarvelD3 impacts upon the EGFR pathway.  In addition, 
due to the presence of AP1 sites in the promoters of a large number of genes involved 
in a variety of cellular processes, the regulation of AP1 could be a significant cellular 
function of MarvelD3.  To better appreciate this potential function, work in this 
chapter aimed to elucidate the events upstream of AP1, that link MarvelD3 at the cell 
membrane to events in the nucleus.   
 
In this chapter, pulldown assays identified an interaction between the N-terminus of 
MarvelD3 and the MAP kinase kinase kinase MEKK1.  The N-terminus of MarvelD3 
is also shown to be sufficient for the inhibition of AP1 promoter activity alluding to 
the importance of this domain in the signalling properties of MarvelD3.  In addition, 
MarvelD3 expression is shown to result in reduced levels of active JNK, which is 
necessary for proliferation and migration of MiaPaCa cells and suggests MarvelD3 
preferentially regulates the JNK branch of the MAPK signalling pathway, over p38 or 
ERK.   
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Results 
Levels of active JNK are reduced in MarvelD3-expressing MiaPaCa cells 
To first determine whether MarvelD3 may regulate AP1 promoter activity via the 
MAPK pathway, cell lysates from control and MarvelD3-expressing MiaPaCa cells 
were immunoblotted for levels of phosphorylated (active) and total ERK1/2, JNK and 
p38 MAPKs.  The levels of phospho-JNK were reduced in MiaPaCa cells expressing 
MarvelD3 in comparison to control cells, while total levels of JNK remained constant 
(Figure 5.1).  Levels of phospho-p38 and phospho-ERK were unchanged in response 
to MarvelD3 expression (Figure 5.1). This suggests that, in unstimulated cells, 
increased MarvelD3 expression may inhibit signalling via the JNK branch of the 
MAPK pathway. 
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Figure 5.1 – Expression of MarvelD3 results in reduced levels of active JNK in 
MiaPaCa cells.  Control and MarvelD3-expressing MiaPaCa cell lysates were 
immunoblotted for total and active forms of ERK1/2, JNK and p38 MAPKs.  Levels of 
phospho-JNK are reduced in MarvelD3-expressing MiaPaCa clones C2 and C8 in 
comparison to control cells.  Levels of active p38 and ERK do not change following 
expression of MarvelD3 in MiaPaCa cells.  Immunoblotting is representative of at 
least 3 independent experiments.  #-tubulin was used as a loading control. 
 
JNK activity is necessary for MiaPaCa cell migration and proliferation 
JNK activity is heavily implicated in the regulation of cell proliferation and survival 
and is known to be required for migration in a number of cell types (Huang et al., 
2003; Kavurma and Khachigian, 2003).  Before investigating whether JNK may be 
responsible for the proliferation and migration phenotypes observed following 
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manipulation of MarvelD3 expression levels, the importance of JNK activity for 
proliferation and migration in control MiaPaCa cells was first determined.   First, 
MiaPaCa cells were incubated in the presence of the JNK inhibitor SP600125 for two 
hours to determine an appropriate inhibitor concentration in order to inhibit JNK 
activity.  Immunoblotting whole cell lysates revealed 20µM SP600125 was sufficient 
to reduce levels of active cJun, a JNK substrate, without increasing apoptosis, as was 
apparent with the higher 50µM concentration (observation made visually). Thus 
20µ% SP600125 was used in the subsequent experiments (Figure 5.2A).    
 
In order to determine the importance of JNK activity on MiaPaCa cell proliferation, 
cells were plated at an equal cell density on to a 96 well plate and allowed to adhere 
overnight.  Cells were incubated with the JNK inhibitor SP600125 (20µM) or DMSO 
for 48 hours before quantifying cell number.  As expected, inhibition of JNK activity 
resulted in reduced cell numbers in comparison to control-treated cells (Figure 5.2B).  
Verification that extended incubation with SP600125 did not result in cell death was 
made visually by labelling nuclei with Hoechst; no increase in fragmented nuclei was 
apparent between control cells and those incubated with 20µM SP600125.  To further 
determine a role for JNK in MiaPaCa cell migration, control MiaPaCa cells were 
plated in to cell culture inserts and grown until confluent.  They were then incubated 
with the JNK inhibitor SP600125 (20µM) or DMSO for two hours before insert 
removal to inhibit JNK activity prior to the onset of migration. As expected, MiaPaCa 
cell migration was significantly reduced following JNK inhibition in comparison to 
control treated cells.  This suggests JNK activity is involved in the regulation of 
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MiaPaCa cell migration and proliferation, just as has been observed previously in 
other cell types. 
 
 
Figure 5.2 – Inhibition of JNK activity reduces proliferation and migration in 
MiaPaCa cells. (A) Immunoblotting cell lysates for phospho-cJun, a downstream 
target of JNK, shows reduced levels after 2 hours of SP600125 incubation, 
suggesting efficient inhibition of JNK. (B) SP600125 reduced increases in cell 
number of MiaPaCa cells (n=4). (C) MiaPaCa cells were plated onto cell culture 
inserts and grown until confluent.  When confluent, cells were incubated with 20µM 
SP600125 for two hours prior to insert removal.   SP600125 inhibited the migration of 
MiaPaCa cells following insert removal (n=3).  Confirmation that the 20µM SP600125 
dose did not cause apoptosis was made visually. 
 
To determine whether JNK activity is important for the regulation of cell migration by 
MarvelD3, control and MarvelD3-depleted Caco-2 cells were allowed to migrate in 
the presence and absence of the JNK inhibitor SP600125.  As figure 5.3 shows, 
inhibition of JNK inhibits the migration of control Caco-2 cells and prevents the 
increase in migration caused by depletion of MarvelD3.  This suggests JNK activity is 
necessary for the increased migration caused by MarvelD3 depletion, and alludes 
further to the possibility that MarvelD3 may be regulating migration via JNK.  
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Figure 5.3 – JNK activity is necessary for increased cell migration following 
MarvelD3 depletion.  Caco-2 cells transfected with control or MarvelD3-specific 
siRNAs were plated on to cell culture inserts, as previously described.  Upon 
reaching confluency, cells were incubated with 20µM SP600125 for 2 hours before 
insert removal.  Cell migration with or without SP600125 was then monitored for 26 
hours using brightfield microscopy (A) and quantified with ImageJ software (B).  
Quantification shows mean values of wound closure (n=3) plus standard deviation.  
Inhibition of JNK prevented migration of control Caco-2 cells.  Depletion of MarvelD3 
was not able to increase migration in the absence of JNK activity.  Significance was 
calculated by Student's t-test between groups as shown; *p<0.05, **p<0.01. 
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The N-terminus of MarvelD3 can interact with MEKK1 
The data shown so far suggests MarvelD3 expression inhibits JNK activation and 
perturbs proliferation and migration in MiaPaCa cells.  JNK inhibition also appears to 
prevent the increased migration resulting from depletion of MarvelD3, which further 
suggests MarvelD3 may function to inhibit migration by restricting JNK activity.  To 
ascertain how MarvelD3 may achieve this, it was determined how MarvelD3 may 
feed in to the MAPK pathway.  Pulldown assays were performed with GST-fusion 
proteins of N- and C-termini of MarvelD3 and identified a clear interaction between 
the N-terminus of MarvelD3 and MEKK1 from Caco-2 cell lysates, but not with other 
kinase kinase kinases MEKK3 or MLK3 (Figure 5.4A).  Though some degradation of 
the N-terminal domain GST protein can be seen, this does not appear to affect the 
ability of the N-terminus of MarvelD3 to interact with MEKK1.  To check the 
potential relevance of this interaction in vivo, Caco-2 cells were processed for 
immunofluorescence with antibodies against MEKK1 and occludin as a marker of the 
tight junction.  In addition to the previously reported cytoplasmic localization of 
MEKK1, MEKK1 was seen to colocalize with occludin at points of cell-cell contact 
(Figure 5.4B).  Immunostaining MarvelD3-depleted cells with anti-MEKK1 antibody 
showed the continuous peripheral MEKK1 staining to be disrupted or lost following 
depletion of MarvelD3 by siRNA, suggesting MEKK1 may require MarvelD3 for its 
localization to cell contacts and further supporting the hypothesis of an interaction 
between these two proteins (Figure 5.4C).  Thus MarvelD3 may be able to regulate 
AP1 signalling and JNK activity via an interaction with MEKK1. 
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Figure 5.4 – MEKK1 interacts with the N-terminus of MarvelD3 and localizes to 
cell-cell contacts in a MarvelD3-dependent manner.  (A) Caco-2 cell lysates were 
incubated with GST-fusion proteins attached to glutathione beads for 1.5 hours.  
Immunoblotting of pulldown samples shows a clear interaction between the N-
terminus of MarvelD3 and MEKK1, but not MEKK3 or MLK3. An anti-GST antibody 
was used as a loading control. (B) MEKK1 can be seen to colocalise with occludin at 
the edge of the cell. (C) Localisation of MEKK1 to cell-cell contact sites seen in 
control cells is disrupted following siRNA-mediated depletion of MarvelD3.  All are 
representative images of three independent experiments. Bars, 10µm. 
 
Regulation of AP1 promoter activity by the N-terminus of MarvelD3 
Since MEKK1 is an upstream regulator of AP1 signalling, and MarvelD3 has been 
shown to inhibit the activity of the AP1 promoter, the significance of the N-terminus 
in MarvelD3-mediated regulation of the AP1 promoter was assessed. First, Caco-2 
cells were transfected with cDNAs encoding full-length MarvelD3 isoform 1 
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(MD3_1), full-length VSV-tagged MarvelD3 isoform 1 (MD3_1:VSV), a VSV-
tagged N-terminal construct (NTD:VSV) or a VSV-tagged MarvelD3 isoform 1 
construct lacking the N-terminus (&N_1:VSV), alongside the AP1 promoter firefly 
luciferase reporter plasmid and the Renilla luciferase control.  Relative promoter 
activity was determined 3 days after transfection.  Expression of the full length 
constructs reduced AP1 promoter activity consistent with previous observations 
(Chapter 4, Figure 4.12).  Expression of the N-terminal domain of MarvelD3 was 
sufficient to reduce AP1 promoter activity.  Interestingly, the &N_1:VSV construct 
reduced promoter activity, but this reduction did not reach significance.  It is possible 
that the &N_1:VSV construct disrupts endogenous MarvelD3 signalling by integrating 
into the same complexes as the endogenous protein, but failing to regulate the same 
signalling pathways.  To investigate this further, the N-terminal constructs 
(NTD:VSV and &N_1:VSV) were transfected in to MiaPaCa cells, which do not 
express endogenous MarvelD3 and presumably therefore do not assemble the same 
multi-protein junctional complexes found in Caco-2 cells.  In the absence of 
endogenous junctions, expression of NTD:VSV significantly reduced AP-1 promoter 
activity, but &N_1:VSV did not (Figure 5.5), suggesting the N-terminal domain is 
responsible for the AP1-inhibitory activity of the full length MarvelD3 molecule.  As 
the N-terminal region interacts with MEKK1, this further supports the hypothesis that 
the interaction with MEKK1 is significant in the signalling properties of MarvelD3. 
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Figure 5.5 – Regulation of the AP-1 promoter by the N-terminus of MarvelD3.  
(A) Caco-2 cells were transfected with control plasmid, or plasmid encoding various 
constructs of MarvelD3 (as mentioned in main text), alongside the AP1 firefly 
luciferase reporter plasmid and a Renilla luciferase control.  Detection of the 
luciferase and Renilla luminescent signals were made in triplicate and showed AP1 
promoter activity to be significantly reduced by the full-length and N-terminal 
constructs, and less so in the absence of the N-terminal domain.  (B) Transfection of 
N-terminal constructs in to MiaPaCa cells showed the N-terminus to be necessary 
and sufficient to reduce AP1 promoter activity. Results are presented as mean 
luminescent signals normalised to the control, ± standard deviation. Significance was 
calculated by Student"s t-test.***p<0.001, ** p<0.01, * p<0.05, in comparison to 
control. 
 
In addition to its role in regulating transcription, MEKK1 is necessary for 
transcription-independent stress fibre formation in migrating epithelial cells.  
Activation of RhoA in response to TGF! induces stress fibre formation and requires 
MEKK1 (Zhang et al., 2005b).  To further address the existence of a functional 
interaction between MarvelD3 and MEKK1, and since MarvelD3 expression appears 
to regulate the cytoskeleton during migration, the effect of MarvelD3 expression on 
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the arrangement of the cytoskeleton was analysed more closely.  It was proposed that, 
if MarvelD3 reduces MEKK1 activity, there should be few or no stress fibres in 
MarvelD3-expressing cells.  Indeed, immunofluorescence showed fewer stress fibres 
and more lateral actin in MD3-MiaPaCa C2 cells than in control MiaPaCa cells 
(Figure 5.6A).  To see whether this was due to differences in RhoA activity, a GLISA 
was performed to ascertain the abundance of active RhoA in MiaPaCa cell extracts.  
As expected from the reduced stress fibres, there was less active RhoA in MarvelD3-
expressing cells than control MiaPaCa (Figure 5.6B).  Depletion of MarvelD3 in 
Caco-2 cells did not significantly increase the amount of stress fibres when compared 
to control cells (Figure 5.6C). Consistent with the suspected elevations in active 
RhoA, however, MarvelD3-depleted cells exhibited higher levels of phospho-MLC 
staining associated with the stress fibre structures. This data offers further support for 
a functional interaction between MarvelD3 and MEKK1, suggesting MarvelD3 may 
regulate cytoskeletal rearrangements coordinated by RhoA and MEKK1.  
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Figure 5.6 – Effect of MarvelD3 expression on RhoA-mediated cytoskeletal 
rearrangements. (A) Control and MarvelD3-expressing MiaPaCa clone C2 were 
fixed and processed for immunofluorescence during migration.  Phalloidin staining 
shows more lateral actin and less stress fibre-like structures following MarvelD3 
expression than in control cells. (B) RhoA activity levels were quantified in control 
and MarvelD3-expressing MiaPaCa clone 2.  RhoA activity was significantly reduced 
following expression of MarvelD3.  Shown are mean values (n=4) plus the standard 
deviation. (C) Stress fibres in MarvelD3-depleted Caco-2 cells stain positively for 
phospho-MLC, in contrast to controls. Significance was determined by Student's t-
test; **p<0.01. Bars, 10µm. 
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Discussion 
The aim of this chapter was to begin to understand the mechanism through which 
MarvelD3 elicits its inhibitory effects on the AP1 promoter, as observed in chapter 4.  
Results presented here suggest this could be mediated by an inhibitory interaction 
between the N-terminus of MarvelD3 and MEKK1, a promoter of AP1 signalling.  
For the first time, MEKK1 was shown to localize to cell-cell contacts and this 
localization was dependent on MarvelD3.  The inhibition of AP1 promoter activity by 
the N-terminus of MarvelD3 and the reduced abundance of stress fibres following 
MarvelD3 expression in MiaPaCa cells, is consistent with an inhibitory role for 
MarvelD3 over MEKK1 activity.  MarvelD3 expression also caused reductions in the 
levels of active JNK, which is downstream of MEKK1 in the MAPK pathway.  
Inhibition of JNK activity with the inhibitor SP600125 prevented MiaPaCa cell 
migration and proliferation, and migration increases caused by loss of MarvelD3. 
Thus a hypothetical model is proposed in which MarvelD3 regulates AP1 activity via 
an interaction with MEKK1.  Furthermore, the subsequent regulation of the JNK 
MAPK pathway and the actin cytoskeleton may offer an additional influence of 
MarvelD3 over epithelial cell proliferation and migration. 
 
The MAP kinase pathway functions in the transmission of extracellular stimuli, like 
growth factors or cellular stress, through the cytoplasm to the nucleus, and is known 
to regulate AP1 signalling.  Pulldown assays identified an interaction between the N-
terminus of MarvelD3 and the MAPKKK MEKK1, and levels of active JNK were 
reduced following the expression of MarvelD3 in MiaPaCa cells.  Furthermore, the 
absence of any change in levels of active ERK or p38 suggested MarvelD3 might 
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specifically function in the regulation of the JNK branch of the MAPK pathway, a 
preference that is also shown by MEKK1 (Yujiri et al., 1999).  Immunofluorescence 
analyses of Caco-2 cells showed a clear enrichment of MEKK1 at cell-cell contacts, 
which was perturbed or lost in MarvelD3-depleted cells.  Thus MarvelD3 regulates 
the junctional localisation of MEKK1 and perhaps its activity. Impaired embryonic 
eyelid closure in MEKK1-/- mice implicated MEKK1 in the regulation of epithelial 
cell migration where it was shown to be necessary for phosphorylation of c-Jun in the 
migrating epithelium (Zhang et al., 2003).  The interaction with MEKK1, the 
inhibition of JNK activation by MarvelD3 and the reduced cell migration phenotype, 
strongly suggests MarvelD3 could regulate migration by impacting on this pathway.  
Indeed, MEKK1 downregulation leads to reduced JNK activation and reduced wound 
healing by keratinocytes (Deng et al., 2006).  Thus by reducing MEKK1 activity, 
MarvelD3 could function in the transmission of signals involved in cell migration.   
 
In order to understand the significance of the interaction between the N-terminus of 
MarvelD3 and MEKK1, regulation of AP1 promoter activity by the N-terminus of 
MarvelD3 was examined.  It was hypothesised that if MEKK1 is inhibited by 
interacting with the N-terminus of MarvelD3, AP1 promoter activity should be 
reduced when the N-terminus of MarvelD3 is present, but not in its absence.  As 
expected, expression of a MarvelD3 N-terminal construct was sufficient to inhibit 
AP1 signalling in MiaPaCa and Caco-2 cells, suggesting the N-terminus alone is 
capable of interacting with MEKK1 and preventing its activation of AP1 signalling.  
Furthermore, in the absence of its N-terminus, MarvelD3 did not inhibit AP1 
promoter activity in MiaPaCa cells, further demonstrating the importance of the N-
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terminal domain in this signalling pathway.  In contrast, however expression of the 
same MarvelD3 construct lacking the N-terminus (&N_1:VSV) caused partial, though 
not significant, reduction of AP1 promoter activity in Caco-2 cells.  This discrepancy 
may have arisen due to the differences in junctional complexes present in these two 
cell types. The tight junction in Caco-2 cells is a complex structure involving many 
protein-protein interactions.  Addition of an exogenous protein to such a system may 
interrupt endogenous protein complexes and subsequently affect their downstream 
signalling.  For example, if &N_1:VSV were to replace endogenous MarvelD3 in a 
number of protein complexes, it may liberate the endogenous protein making more of 
it available to interact and inhibit MEKK1, which could be responsible for the partial 
reduction in AP1 promoter activity by &N_1:VSV in Caco-2 cells observed here.  
Such effects are difficult to confirm, but cannot occur in a system devoid of the 
endogenous protein, like in MiaPaCa cells, which do not possess endogenous cell-cell 
junctions and therefore provide a more simple system in which to address the 
functional properties of individual protein domains.  Taken together, these results 
suggest the N-terminus of MarvelD3 is necessary for the inhibition of AP1 promoter 
activity.  As the N-terminus interacts with MEKK1, an activator of AP1 signalling, it 
is proposed that this interaction serves to inhibit MEKK1 activity and ultimately its 
downstream signalling.  Further work should focus on elucidating the mechanism of 
inhibition.  Does MarvelD3 interact with MEKK1 in its inactive form and prevent its 
activation? Or does MarvelD3 sequester activated MEKK1 thus preventing activation 
of its downstream targets?  This could be addressed by probing cell lysates from 
pulldown or co-immunoprecipitation assays with antibodies specific for various 
phosphorylated forms of MEKK1 to identify the nature of the MEKK1 molecules 
interacting with MarvelD3.  In addition, kinase assays should be performed to 
 192 
determine the effect of MarvelD3 on MEKK1 kinase activity in the presence and 
absence of the N-terminal domain.  
 
The MEKK1/JNK pathway is also thought to regulate the actin cytoskeleton, with 
MEKK1 being required for actin stress fibre formation (Zhang et al., 2003).  
Interestingly, there are fewer stress fibres in MarvelD3-expressing MiaPaCa cells than 
control cells, perhaps due to reduced MEKK1 activity in the presence of MarvelD3. 
Stress fibre formation is regulated by activity of the small GTPase RhoA, the activity 
of which is greatly reduced following expression of MarvelD3 in MiaPaCa cells, and 
has previously been implicated in promoting tumour cell migration (Joshi et al., 2008; 
Kamai et al., 2003).  In the absence of MarvelD3 the amount of stress fibres in Caco-2 
cells does not appear to change, but increased phospho-MLC staining suggests they 
are more contractile than those in control cells.  As RhoA-induced phosphorylation of 
MLC and subsequent contractility is thought to drive stress fibre formation, the 
increased phospho-MLC staining could be indicative of a more dynamic stress fibre 
cycle of assembly (and therefore disassembly) in MarvelD3-depleted in comparison 
to control cells.  Increased stress fibre turnover is supportive of increased migration.   
 
While the MEKK1/JNK cascade has not been implicated in the regulation of 
proliferation directly, demonstrations have been made of the cross-talk between RhoA 
and EGFR signalling pathways mediated by MEKK1 (Li et al., 2009; Zhang et al., 
2003).  In light of the observations made in chapter 4, therefore, it is possible that 
MarvelD3 regulates proliferation through the EGFR signalling pathway via its 
interaction with MEKK1.  So far, changes in the levels of ERK activity have not been 
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seen in response to changes in MarvelD3 expression, despite an effect of MarvelD3 
on EGFR signalling.  While activation of ERK by EGFR may be stimulus specific 
and MEKK1-mediated activation of ERK doesn’t occur in all cell types (Xu et al., 
1995), it could be that MarvelD3 regulates ERK in response to specific stimuli that 
have not been identified here.  Therefore, future studies could look more closely in to 
the potential role of MarvelD3 in regulating ERK, possibly via MEKK1-mediated 
cross-talk with the EGFR pathway. 
 
In conclusion, the data presented in the last two chapters suggests MarvelD3 regulates 
proliferation and migration by affecting activity through the EGFR signalling 
pathway.  By interacting with MEKK1, it is proposed that MarvelD3 prevents 
activation of JNK and, subsequently, restricts AP1 promoter activity.  Reduced AP1 
promoter activity may then be responsible for the reduced expression of EGFR in 
MarvelD3-expressing cells.  Reduced AP1 activity and/or EGFR signalling may then 
attenuate cyclinD1 expression levels, which in turn perturbs cell cycle progression.  
Future studies should examine the effect of MarvelD3-MEKK1 on localized JNK 
activation, which has been shown to be necessary at the leading edge for migration 
(Rosse et al., 2009).  Alongside analysis of the effects of MarvelD3 on Rac and 
Cdc42 activity, this may enable the mechanism behind MarvelD3-mediated 
protrusion formation to be better understood. 
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Chapter 6 – Regulation of the cellular response to hyperosmotic shock 
by MarvelD3 
Introduction 
Results in this thesis have so far implicated MarvelD3 in the regulation of epithelial 
cell proliferation and migration via a proposed inhibitory interaction with MEKK1.  
In addition to a role in migration, MEKK1 has been shown to protect cells from 
apoptosis when activated by stresses that alter cell shape and the arrangement of the 
cytoskeleton (Yujiri et al., 1998).  To see if MarvelD3 regulates MEKK1 in other 
contexts and to further examine the nature of this regulation, this chapter looks at the 
role of MarvelD3 in the cellular response to hyperosmotic shock, which is known to 
cause significant rearrangement of the actin cytoskeleton and involve activity of 
MEKK1 (Yujiri et al., 1998). 
Hyperosmotic shock occurs when the solute concentration surrounding cells is 
suddenly increased, resulting in rapid cell shrinkage as water moves out of the cell in 
to the hypertonic surroundings.  The cells of the kidney, for example, are frequently 
physiologically exposed to hyperosmotic conditions due to the accumulation of NaCl 
and urea during antidiuresis.  Also, in dry-eye syndrome, increased evaporation of 
tears or abnormal tear composition results in cells of the cornea being exposed to 
hypertonic conditions. When cells are exposed to a level of hyperosmotic stress that is 
either too great or for too long, apoptosis may be induced and the integrity of the 
monolayer becomes compromised.  It is important, therefore, that cells activate 
protective mechanisms in response to hyperosmotic exposure that enable restoration 
of cellular integrity and maintenance of monolayer homeostasis. 
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Epithelial cell responses to hyperosmotic shock can be classified into three main 
groups; the activation of ion transport systems, the rearrangement of the cytoskeleton 
and the changes in the expression of osmosensitive genes, such as aldose reductase 
(AR). Further, it has been proposed that changes to the cytoskeleton may be necessary 
for the facilitation of the other osmoadaptive processes, like recovery of osmotic 
balance by various ion transporters in the plasma membrane, which are thought to 
require an intact actin cytoskeleton in order to be able to function (Henson, 1999; 
Pedersen et al., 2001). 
 
Cell shrinkage in response to hypersmotic conditions in mammalian cells results in 
activation of the small GTPases Rac and Cdc42 and their translocation to the cell 
periphery where they recruit cortactin and Arp2/3, resulting in localised actin 
polymerisation and the subsequent reinforcement of the cell cortex (Di Ciano et al., 
2002).  In addition, hypersomotic shock-induced activation of RhoA has been shown 
to induce myosin light chain (MLC) phosphorylation and the dephosphorylation of 
cofilin, leading to further reinforcement of the cytoskeletal reorganizations (Di Ciano-
Oliveira et al., 2003; Miranda et al., 2010).  The levels of F-actin increase in 
mammalian cells in response to hyperosmotic shock (Pedersen et al., 1999). 
 
In addition to offering mechanical protection to the cell, the cytoskeleton may also 
participate in the hyperosmotic response by mediating intracellular signalling 
cascades.  In response to hyperosmotic shock, Rac-positive actin ruffles are seen to 
recruit a signalling module consisting of Rac, OSM (osmosensing scaffold for 
MEKK3), MEKK3 and MKK3, which facilitates the activation of p38 (Uhlik et al., 
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2003). p38 is thought to regulate the osmoprotective transcription factor 
TonEBP/OREBP, which in turn regulates expression of osmoprotective genes like AR 
and the betaine transporter (BGT1) (Nadkarni et al., 1999).  Thus p38 is involved in 
re-establishing cellular volume and inhibition of p38 impairs the ability of cells to 
restore cell volume following hyperosmotic insult (Bustamante et al., 2003).  In 
addition to p38, cell shrinkage has also been shown to stimulate the activation of JNK 
MAP kinases (Rosette and Karin, 1996). Expression of mammalian JNK in yeast 
rescues defects in growth of yeast grown on hyperosmotic media suggesting JNK may 
function in the regulation of the hyperosmotic response in mammalian cells too 
(Galcheva-Gargova et al., 1994).  In the absence of MEKK1, JNK fails to be activated 
in response to hyperosmotic shock (Yujiri et al., 1998), but the consequence of this 
has not yet been realized. 
 
Despite the physiological relevance of this process, relatively little is known about the 
mechanisms behind the mammalian cell response to hyperosmotic shock.  In this 
chapter, I have identified a function for MarvelD3 in regulating activation of JNK 
MAPK signalling and the cytoskeletal response of epithelial cells to hyperosmotic 
conditions.  This could provide a novel mechanism through which changes in the 
extracellular environment can be communicated to the cell interior, facilitating the 
changes necessary in order for the cell to adapt, and provides additional support to the 
hypothesis that regulation of MEKK1 and JNK by MarvelD3 is of functional 
significance. 
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Results 
Effect of hyperosmotic shock on MarvelD3 localisation 
To first assess if MarvelD3 may participate in the epithelial cell response to 
hyperosmotic shock, Caco-2 and HCE cells exposed to hyperosmotic conditions 
(600mosM NaCl) were processed for levels of MarvelD3 expression and localization.   
Immunofluorescent analysis revealed that both Caco-2 and HCE cells exposed to 
hyperosmotic conditions showed a redistribution of MarvelD3 from the junction to 
the cytoplasm within 15 minutes of exposure (Figure 6.1, Caco2; Figure 6.2, HCE).  
In Caco-2 cells, junctional staining of MarvelD3 began to return after 2 hours of 
hyperosmotic shock and, after 8 hours, demonstrated a linear staining pattern similar 
to that observed prior to hyperosmotic shock, indicating cells might have adapted to 
the increased osmotic conditions at this later time.  In contrast to MarvelD3, occludin 
showed junctional disruption at the 30-minute, 1-hour and 2-hour time points, but 
remained at the cell-cell junction, and this was again corrected by 8 hours.  
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Figure 6.1 – MarvelD3 redistributes to the cytoplasm in response to 
hyperosmotic shock in Caco-2 cells.  Caco-2 cells were plated on to glass 
coverslips and grown until confluent.  Medium containing 600mosM NaCl was added 
for the times shown and then fixed in methanol.  Staining with anti-MarvelD3 and 
anti-occludin antibodies shows redistribution of MarvelD3 to the cytoplasm, but not 
occludin, in response to hyperosmotic shock. Images are representative of at least 3 
independent experiments. Bar, 10µm. 
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In HCE cells, junctional MarvelD3 could still be seen alongside the increased 
cytoplasmic signal (Figure 6.2).  Figure 6.2 shows occludin staining is also less 
disrupted in HCE cells than in Caco-2 cells.  What is more, both MarvelD3 and 
occludin staining appears normal again after just 2 hours of hyperosmotic exposure, 
suggesting the kinetics of the hyperosmotic response is quicker in HCE cells when 
compared to Caco-2 cells.  Due to the more obvious phenotype in Caco-2 cells and 
the longer time course in which to dissect it, these cells were used for subsequent 
studies into the effects of hyperosmotic shock and the role of MarvelD3 therein. 
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Figure 6.2 – Redistribution of MarvelD3 to the cytoplasm in HCE cells exposed 
to hyperosmotic conditions.  HCE cells were plated on to glass coverslips and 
grown until confluent.  Cells were incubated in medium containing 600mosM NaCl 
(hyperosmotic) for the times shown and then processed for immunofluorescence with 
anti-MarvelD3 and anti-occludin antibodies on separate coverslips.  MarvelD3 
staining gives an increased cytoplasmic signal following hyperosmotic exposure.  
Occludin remained in the cell membrane.  Images are representative of 3 
independent experiments. Bars, 10µm. 
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Regulation of MAPK signalling by MarvelD3 in response to hyperosmotic shock 
The internalization of MarvelD3 in response to hyperosmotic shock, while occludin 
remained within the membrane, provoked the idea that MarvelD3 may have a 
function in the regulation of the hyperosmotic response.  As an interaction between 
MarvelD3 and MEKK1 was identified in the previous chapter, and as MEKK1 has 
been shown by others to be involved in the response to hyperosmotic shock (Yujiri et 
al., 1998), I wanted to determine if MarvelD3 regulates MEKK1 in response to 
hyperosmotic shock.  To address this, antibodies against phosphorylated forms of 
MEKK1 were kindly donated by Dr Ewen Gallagher, Imperial College London. The 
levels of total MEKK1 protein were unaffected by hyperosmotic shock or MarvelD3 
depletion, but an antibody specific for MEKK1 phosphorylated at serine residue 1455 
(Ser1455; now termed phospho-MEKK1) gave an increased signal 15 minutes after 
hyperosmotic shock in control and MarvelD3-depleted cells, suggesting MEKK1 is 
regulated in response to hyperosmotic shock (Figure 6.3A). Quantification of 
phospho-MEKK1 levels, compared to total MEKK1 levels, from three independent 
experiments demonstrated that levels of phospho-MEKK1 were elevated more greatly 
in the absence of MarvelD3 and, in addition, this elevation appeared to be more 
prolonged (Figure 6.3B).  Immunofluorescence showed some junctional staining of 
phospho-MEKK1 in control cells (Figure 6.3C).  MarvelD3 depletion also resulted in 
more rapid induction and prolonged activation of JNK in response to hyperosmotic 
shock (Figure 6.3D and E).  In control cells, levels of active JNK peaked after 1 hour 
exposure to hyperosmotic shock.  In contrast, JNK activation was more rapidly 
induced after 15 minutes hyperosmotic exposure of MarvelD3-depleted cells, peaking 
after 2 hours exposure and was still present after 8 hours.  Thus MarvelD3 appears to 
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regulate the activity of MEKK1 and JNK in response to hyperosmotic shock induced 
by 600mosM NaCl. 
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Figure 6.3 – Regulation of MEKK1 and JNK phosphorylation by MarvelD3 in 
response to hyperosmotic shock. (A) Control and MarvelD3-depleted Caco-2 cells 
were exposed to hyperosmotic shock for the times shown.  Immunoblotting with an 
antibody specific for MEKK1 phosphorylated at S1455 showed increased 
phosphorylation in response to hyperosmotic shock in control and MarvelD3-depleted 
cells.  This phosphorylated form persisted longer in MarvelD3-depleted cells.  
Hyperosmotic shock did not effect total levels of MEKK1. (B) Levels of phospho-
MEKK1 in comparison to total MEKK1 levels were quantified using ImageJ software 
from 3 independent experiments. (C) Immunofluorescence of control (untreated) 
Caco-2 cells showed localization of MEKK1 and partial localization of phospho-
MEKK1 (p-MEKK1) to cell-cell contacts.  (D) MarvelD3 depletion affects the level and 
duration of JNK phosphorylation in response to hyperosmotic shock, without 
increasing total JNK. (E) Levels of phospho-JNK in comparison to total JNK levels 
were quantified using ImageJ software from 3 independent experiments.   
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The initiation of intracellular signalling pathways in response to hyperosmotic shock 
enables cells to activate adaptive programmes in order to be able to survive in 
hyperosmotic conditions.  In yeast, activation of the Hog1 MAPK pathway is the 
primary mechanism through which the activation of osmoresponsive genes is thought 
to occur.  In mammalian cells, the Hog1 homologue p38 is activated in response to 
sorbitol-induced hyperosmotic shock and facilitates long-term adaptation through 
regulation of cytoskeletal remodeling proteins and transcription of osmoprotective 
genes (Bell et al., 2000; Uhlik et al., 2003).  Since this study utilizes NaCl to induce 
hyperosmotic shock, it was important to determine whether p38 was also activated 
and accumulated in the nucleus and whether MarvelD3 was involved in the regulation 
of this MAPK pathway.  Prior to addition of hyperosmotic shock, p38 showed weak 
nuclear staining in Caco-2 cells.  Figure 6.4 shows that addition of 600mosM NaCl to 
Caco-2 results in an increase in active, phosphorylated p38 and its increased 
accumulation in the nucleus.  Immunofluorescence analysis suggested this nuclear 
accumulation may initially be slowed in MarvelD3-depleted cells (comparing 15 
minute time points), but immunoblotting suggested no difference in the total levels of 
phospho-p38 between control and MarvelD3-depleted cells following exposure to 
hyperosmotic shock.  Similarly, the activation of ERK, which is sometimes found 
downstream of MEKK1, was also unaffected by MarvelD3 depletion (Figure 6.4B).  
Taken together, these results suggest MarvelD3 is not involved in the hyperosmotic 
activation of p38 or ERK and thus shows preference for the JNK branch of the MAPK 
pathway. 
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Figure 6.4 – MarvelD3 depletion does not affect activation of p38 or ERK, or 
nuclear accumulation of p38, in response to hyperosmotic shock. Hyperosmotic 
shock caused by 600mosM NaCl increases levels of (A) phospho-p38 and (B) 
phospho-ERK.  These increases are not affected by loss of MarvelD3.  (C) Control 
and MarvelD3-depleted cells exposed to hyperosmotic shock were processed for 
immunofluorescence with an anti-phospho-p38 antibody.  Hyperosmotic shock 
caused increased nuclear phospho-p38.  This is not affected by depletion of 
MarvelD3.  All images are representative of three independent experiments. Bar, 
10µm. 
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Regulation of MarvelD3 internalisation in response to hyperosmotic shock 
Immunoblotting lysates of cells exposed to hyperosmotic shock demonstrated that 
levels of MarvelD3 and occludin were not reduced in response to hyperosmotic shock 
(Figure 6.5A).  Thus the loss of junctional MarvelD3 may be due to a redistribution of 
MarvelD3, rather than loss of the total protein.  The EGFR is internalized in response 
to hyperosmotic shock in a mechanism dependent on the Src kinase Yes (Rosette and 
Karin, 1996). Activation of EGFR in response to hyperosmotic shock requires p38 
(Cheng et al., 2002).  Caveolin internalization also occurs in response to hyperosmotic 
shock and requires active p38 and c-Src (Volonte et al., 2001).  To determine the 
mechanism of MarvelD3 internalisation, Caco-2 cells were incubated in the presence 
of various inhibitors prior to addition of hyperosmotic shock.  Cells were then fixed 
after 15 minutes hyperosmotic shock and the localization of MarvelD3 was observed. 
Incubation with inhibitors of the Src family of kinases PP1 and PP2, or the negative 
control inhibitor PP3, did not prevent the internalization of MarvelD3 in response to 
hyperosmotic shock (Figure 6.5B).  Some junctional MarvelD3 could be observed 
following PP2 incubation suggesting this inhibitor may partially reduce MarvelD3 
internalisation but junctional staining was much reduced compared to PP2-treated 
cells prior to hyperosmotic exposure.  The specific p38 inhibitor SB202190 also failed 
to prevent internalization of MarvelD3 (Figure 6.5C).  Following JNK or EGFR 
inhibition, however, MarvelD3 remained at the cell membrane in response to 
hyperosmotic shock (Figure 6.5C).   Inhibition of ERK signalling with the MEK1/2 
inhibitor UO126 appeared to partially reduce MarvelD3 internalisation, but 
significant cytoplasmic staining was still observed (Figure 6.5C). This suggests 
MarvelD3 internalisation may occur via an EGFR- and JNK-dependent mechanism. 
Also, though prior incubation with some inhibitors resulted in a reduction in cell size 
 208 
when compared to control-treated cells (Figure 6.5B and C), further hyperosmotic 
shock-induced reductions failed to occur in cells pre-treated with PP2, SP600125 and 
Gefetinib, which also had the greatest effect on MarvelD3 internalisation. 
 
Figure 6.5 – Regulation of MarvelD3 internalisation in response to hyperosmotic 
shock. (A) Immunoblotting cell lysates confirms MarvelD3 and occludin protein levels are not 
lost in response to hyperosmotic shock.  (B) MarvelD3 immunofluorescence showed inhibition 
of Src family kinases does not prevent redistribution of MarvelD3 following hyperosmotic 
shock.  PP3 used as a negative control for PP1 and PP2 (C) MarvelD3 remained at the cell 
membrane after hyperosmotic shock following inhibition of JNK (SP600125) and EGFR 
(Gefitinib), but not p38 (SB202190) or ERK signalling (UO126). Images are representative of 
at least two independent experiments. Bars, 10µm. 
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MarvelD3 depletion affects cytoskeletal reorganisation in response to 
hyperosmotic shock 
To determine the importance of MarvelD3 in the response to hyperosmotic shock, the 
effect of MarvelD3-depletion on the hyperosmotic response was assessed.  
Reorganisation of the actin cytoskeleton is an important osmoadaptive response, 
generating a rigid actin cortex to physically protect the cell from changes to the 
extracellular environment.  The reinforced cortex is in turn believed to facilitate the 
inclusion of additional transmembrane transporters that function to resume the 
isotonic balance within the cell (Kwon and Handler, 1995).  These cytoskeletal 
rearrangements are therefore considered to be critical to the successful response of a 
cell to hyperosmotic stress.  Since MarvelD3 appears to function in cytoskeletal 
rearrangements during epithelial cell migration, it was wondered whether it may also 
play a role in organizing those involved in the hyperosmotic shock response.  Caco-2 
cells, both control and MarvelD3-depleted, were exposed to hyperosmotic stress 
before being stained with FITC-phalloidin to observe the arrangement of the actin 
cytoskeleton.  Figure 6.6 shows that in control cells, hyperosmotic shock causes a 
dramatic loss of cortical actin within 15 minutes of exposure.  After 1 hour in 
hyperosmotic conditions, F-actin can be seen at the cell periphery as well as 
additional enrichment in the underlying cytoplasm.  Further F-actin enrichment at the 
cell cortex after 2 hours is accompanied by a change in cell shape, with cells having 
much more linear edges and appearing less round than at earlier time points.  After 8 
hours of hyperosmotic exposure, control cells demonstrate a highly organized F-actin 
network fortified along the cell periphery. MarvelD3 depletion perturbs these 
hyperosmotic shock-induced F-actin rearrangements.  First, F-actin does not collapse 
from the cortex in response to hyperosmotic shock, with junctional F-actin still clearly 
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visible in MarvelD3-depleted cells at the 15 minutes time point.  After 30 minutes 
exposure, junctional F-actin and the underlying enrichment resembles the control cells 
after 1 hour, suggesting MarvelD3-depleted cells are attempting to rearrange their 
cytoskeleton in response to hyperosmotic shock.  These rearrangements are not able 
to be completed, however, as at later time points the cells begin to come away from 
each other and the actin cytoskeleton appears highly disorganized (Figure 6.6). 
 
 
Figure 6.6 – Effect of MarvelD3 on rearrangements of the actin cytoskeleton in 
response to hyperosmotic shock. Control and MarvelD3-depleted Caco-2 cells 
were fixed in PFA after exposure to hyperosmotic shock for the durations shown.  
FITC-Phalloidin staining showed failure of MarvelD3-depleted cells to reorganize 
their actin cytoskeleton in response to hyperosmotic shock.  Images are 
representative of three independent experiments. Bars, 10µm. 
 
The cells appeared to retract away from each other more following MarvelD3 
depletion than in control cells, prompting the analysis of the effect of hyperosmotic 
shock on the morphology of the tight junctions.  MarvelD3-depleted and control cells 
were fixed after 2 hours of hyperosmotic shock as this was the time point at which the 
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retraction phenotype first became apparent by F-actin staining.  Occludin and ZO-1 
staining were more disrupted in MarvelD3-depleted cells than control cells (Figure 
6.7).  The disruption to ZO-1 staining was more severe than for occludin, which 
perhaps reflects the fact that it is a cytoplasmic protein and not integral to the 
membrane as occludin is.  Impedance measurements were initially reduced in 
response to hyperosmotic shock in both control and MarvelD3-depleted cells.  While 
control cells recovered their integrity, however, MarvelD3-depleted cells failed to do 
so (Figure 6.7B).  In the absence of MarvelD3, therefore, it appears junctional 
integrity is more severely compromised following hyperosmotic insult.  This could be 
due to the disruption of the actin cytoskeleton, which is known to be necessary for 
tight junction barrier function. 
 
Figure 6.7 – MarvelD3-depletion results greater disruption to the tight 
junctions in response to hyperosmotic shock. (A) occludin and ZO-1 staining 
patterns appeared more disrupted in MarvelD3-depleted Caco-2 cells than control 
cells following exposure to hyperosmotic shock for 2 hours. Images are 
representative of at least three independent experiments. (B) Impedance analysis 
shows hyperosmotic shock-induced reduction in impedance values are recovered by 
control Caco-2 cells, but not in those depleted of MarvelD3.  This experiment was 
performed in quadruplicate, but so far has just been performed once. Bar, 10µm. 
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 Staining for F-actin and the tight junction proteins occludin and ZO-1 demonstrated a 
dramatic reduction in cell area, at the level of the tight junction, in control cells in 
response to hyperosmotic shock.  This reduction, however, did not occur in the 
absence of MarvelD3.  Quantification confirmed that MarvelD3-depleted cells have a 
greater apical cell area at the level of the tight junction in comparison to control cells, 
which rapidly contract in response to hyperosmotic shock (Figure 6.8A).  Cell 
shrinkage is a characteristic response to hyperosmotic shock as water rushes out of the 
cell due to the altered osmotic balance.  Cell shrinkage induces p38 activation in 
response to hyperosmotic shock.  Since p38 activation is unaffected by loss of 
MarvelD3, this cell area phenotype is thought to be due to a failure in apical 
contraction of MarvelD3-depleted cells and not because they do not shrink.  Confocal 
microscopy should be used to confirm the effect of MarvelD3 depletion on cell 
volume in response to hyperosmotic shock.  The lack of apical contraction further 
implicates MarvelD3 in the regulation of the cytoskeletal response to hyperosmotic 
shock.  Interestingly, quantification of cell area from MAPK inhibitor-treated cells 
demonstrated that cell area also failed to reduce following inhibition of JNK (Figure 
6.8B).  Since MarvelD3 internalisation is blocked by JNK inhibition, these data 
suggest signalling processes downstream of MarvelD3 internalisation may be 
responsible for constriction of apical cell area. 
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Figure 6.8 – Effect of MarvelD3 depletion and MAPK inhibition on 
hyperosmotic shock-induced reduction in apical cell area.  Cell area at the level 
of the tight junction was quantified using ImageJ software from immunofluorescence 
images of cells exposed to hyperosmotic shock under the conditions shown and then 
stained with an anti-occludin antibody to enable to junction to be seen. (A) 
Comparison of apical cell area between control and MarvelD3-depleted Caco-2 cells 
before and after 15 minutes (15m) exposure to hyperosmotic shock.  (B) Comparison 
of apical cell area after 15 minutes exposure to hyperosmotic shock in cells 
incubated overnight with DMSO (Control), SB202190 (SB), SP600125 (SP) or 
UO124 (UO). Shown are mean values for relative cell area averaged from three 
independent experiments counting 20-40 cells per experiment, plus the standard 
deviation. Significance was determined using Student"s t-test. ***p<0.001, *p<0.05 
compared to relevant controls, or as depicted. 
 
Since the osmoresponsive cytoskeletal changes seem so perturbed in MarvelD3-
depleted cells, attempts were made to determine the mechanism by which MarvelD3 
may be regulating them.  F-actin assembly in response to hyperosmotic shock has 
been shown to involve cortactin/Arp2/3 relocalisation to the cell membrane, 
phosphorylation of MLC and the dephosphorylation of cofilin (Di Ciano et al., 2002; 
Di Ciano-Oliveira et al., 2003; Miranda et al., 2010).  The effect of hyperosmotic 
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shock on phosphorylation of MLC and cofilin in control and MarvelD3-depleted 
Caco-2 cells was subsequently assessed.  Due to antibody difficulties, the effect of 
MarvelD3 on cortactin has not yet been addressed by immunoblotting or 
immunofluorescence.  Levels of phospho-MLC were moderately increased in 
response to 15 minutes exposure to hyperosmotic shock in both control and 
MarvelD3-depleted cells (Figure 6.9A).  Both phospho- and total cofilin appeared to 
reduce with increasing time spent in hyperosmotic conditions in both control and 
MarvelD3-depleted cells (Figure 6.9B). 
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Figure 6.9 – Effect of MarvelD3 depletion on hyperosmotic shock-induced 
changes in cortactin, cofilin and MLC.  Lysates prepared from control and 
MarvelD3-depleted Caco-2 cells exposed to hyperosmotic shock were 
immunoblotted for levels of (A) phospho- and total MLC and (B) phospho- and total 
cofilin. The increase in phospho-MLC relative to total MLC in response to 
hyperosmotic shock was quantified and values normalised to protein levels prior to 
hyperosmotic exposure are shown.  Similarly, the decreases in phospho-cofilin and 
cofilin levels following hyperosmotic exposure were quantified relative to tubulin, as 
shown.   Immunoblots are representative of 3 independent experiments.   
 
To complement the studies of protein levels, the effect of MarvelD3 depletion on the 
localization of phospho-MLC and phospho-cofilin was also characterized. In 
untreated control cells, phospho-cofilin displays a predominantly nuclear localization, 
with some staining at cell-cell junctions (Figure 6.10, yellow arrows).  It is not known 
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if the nuclear phospho-cofilin signal is specific for phospho-cofilin as phospho-cofilin 
has not been reported in the nucleus before.  Specificity for phospho-cofilin should be 
tested before the importance of nuclear phospho-cofilin is addressed.  Hyperosmotic 
shock induced an increase in cytoplasmic phospho-cofilin.  Interestingly, the 
cytoplasmic phospho-cofilin signal was reduced after 1 hour exposure and increased 
in the cytoplasm again after 2 hours, suggesting there may be some biphasic 
regulation of the activity of phospho-cofilin in response to hyperosmotic shock.  After 
8 hours exposure, cytoplasmic phospho-cofilin was once again low shows a 
predominantly nuclear localization with additional staining at the cell-cell junctions.  
Co-staining for F-actin allows one to see the concomitant changes in the organization 
of the actin cytoskeleton.   
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Figure 6.10 – See legend below 
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Figure 6.10 (above) – Cellular localization of phospho-cofilin in response to 
hyperosmotic shock. Control Caco-2 cells were plated on to glass coverslips and 
grown until confluent.  Cells were then exposed to medium containing 600mosM 
NaCl for the times shown before being fixed and processed for immunofluorescence.  
Anti-phospho-cofilin antibody shows increased cytoplasmic staining after 15 and 30 
minutes hyperosmotic shock exposure.  After 1 hour phospho-cofilin localizes 
primarily in the nucleus, and again in the cytoplasm after 2 hours with hyperosmotic 
shock.  Phospho-cofilin can be seen at the junctions at 0 and 8 hour time points 
(yellow arrows).  Shown are representative images of at least 3 independent 
experiments. Bar, 10µm. 
 
Depletion of MarvelD3 impairs the increase in cytoplasmic phospho-cofilin in 
response to hyperosmotic shock. Figure 6.11 shows a nuclear localization for 
phospho-cofilin at all time points and a clear lack of phospho-cofilin in the cytoplasm 
of MarvelD3-depleted cells.  In kidney tubular cells, F-actin remodeling does not 
occur in the absence of phospho-cofilin (Thirone et al., 2009).  Therefore, perhaps the 
reduced phospho-cofilin in MarvelD3-depleted cells prevents F-actin remodelling 
from occurring as it does in control cells in response to hyperosmotic shock.   
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Figure 6.11 – See legend below 
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Figure 6.11 (above) – Cellular localisation of phospho-cofilin remains in 
MarvelD3-depleted cells in response to hyperosmotic shock. Once confluent, 
MarvelD3-depleted Caco-2 cells were exposed to medium containing 600mosM NaCl 
for the times shown and then fixed and processed for immunofluorescence.  
Phospho-cofilin localizes to the nucleus at all time points.  Cytoplasmic phospho-
cofilin staining does not increase in the absence of MarvelD3.  Shown are 
representative images of at least 3 independent experiments. Bars, 10µm. 
 
Phospho-MLC, like cofilin, is downstream of the GTPase RhoA.  In control cells, 
phospho-MLC localizes to the cytoplasmic domain adjacent to the junctions, but not 
actually at the membrane, after 1 hour of exposure to hyperosmotic conditions (Figure 
6.12).   At this location it colocalises with the F-actin enriched adjacent to the plasma 
membrane.  Phospho-MLC assumes a similar distrubution in MarvelD3-depleted cells 
at the 1 hour time point but, in contrast to the cells, the F-actin is very disorganized 
(Figure 6.13).  Therefore, phospho-MLC appears to be able to localize correctly (as 
seen in controls), but between the 30 minutes and 1 hour time points something is 
missing that prevents F-actin from enriching in the sub-junctional cytoplasm.  
Subsequently, the sub-junctional phospho-MLC staining present in control cells at 2 
hours is lost in the absence of MarvelD3 and the F-actin organization is further 
perturbed. 
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Figure 6.12 – See legend below 
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Figure 6.12 (above) – Effect of hyperosmotic shock on phospho-MLC 
localisation in control Caco-2 cells. Control Caco-2 cells exposed to hyperosmotic 
conditions were fixed and processed for immunofluorescence with an anti-phospho-
MLC antibody and FITC-phalloidin to label F-actin.  Phospho-MLC enriches in the 
cytoplasm adjacent to cell-cell contacts after 30 minutes exposure to hyperosmotic 
shock.  Concentration of this signal towards junctional actin appears to begin at the 2 
hour time point and junctional phospho-MLC staining is intense after 8 hours of 
hyperosmotic exposure.  Shown are representative images of at least 3 independent 
experiments. Bar, 10µm. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 (below) – Effect of hyperosmotic shock on phospho-MLC 
localization in MarvelD3-depleted Caco-2 cells.  MarvelD3-depleted cells exposed 
to hyperosmotic shock for the times shown were fixed and processed for 
immunofluorescence with an anti-phospho-MLC antibody and FITC-phalloidin to label 
F-actin.  Phospho-MLC enriches in the cytoplasm adjacent to cell-cell contacts after 
30 minutes exposure to hyperosmotic shock.  Subsequent concentration of this 
signal towards junctional actin at the 2 and 8 hour time points fails to occur.  The 
concomitant disorganization of F-actin can be seen.  Shown are representative 
images of at least 3 independent experiments. Bar, 10µm. 
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Figure 6.13 – See legend on previous page 
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In addition to altering the arrangement of the cytoskeleton, the hyperosmotic response 
also requires changes in gene transcription.  Transcription of osmoresponsive genes in 
response to high NaCl is regulated by Tonicity-responsive enhancer/osmotic response 
element-binding protein (TonEBP/OREBP).  TonEBP/OREBP target genes 
frequently display one or more AP1 binding sites, binding to which enhances 
TonEBP/OREBP-induced gene activation in response to high NaCl (Irarrazabal et al., 
2008).  In the previous chapter, MarvelD3 expression was seen to inhibit activation of 
the AP1 promoter in a reporter assay.  Thus efforts were made to determine the effect 
of hyperosmotic shock on AP1 promoter activity and the regulation of this by 
MarvelD3.  In preliminary experiments, AP1 promoter activity was increased in 
MarvelD3-depleted cells exposed to hyperosmotic conditions for 2 hours, but there is 
variability in the response of control cells, sometimes AP1 promoter activity appears 
unaffected by hyperosmotic shock, and sometimes it is increased (data not shown).  
This provides an early indication that MarvelD3 may regulate AP1 activity in 
response to hyperosmotic shock, but the extent of this regulation is unknown and will 
require further work. 
 
Prolonged exposure or failure to adapt to hyperosmotic conditions results in 
apoptosis.  Since MarvelD3-depleted cells display a defective cytoskeletal response to 
hyperosmotic shock, the effect of MarvelD3 on cell survival following hyperosmotic 
insult was assessed.  Quantifying fragmented nuclei as a marker of apoptosis 
demonstrated that in the absence of MarvelD3, cells were more sensitive to apoptosis 
in response to hyperosmotic shock (Figure 6.14).  During the time course tested, 
apoptosis was not increased in response to hyperosmotic shock in control cells.  This 
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suggests events mediated by MarvelD3 may be important for survival in response to 
hyperosmotic shock.  
 
 
 
Figure 6.14 – Effect of MarvelD3 depletion on nuclei fragmentation in response 
to hyperosmotic shock.  Caco-2 cells previously transfected with control or 
MarvelD3-specific siRNAs were exposed to hyperosmotic shock for the time points 
shown.  Cells were fixed and stained with Hoechst to visualise the nucleus.  The 
number of fragmented nuclei were then quantified across three coverslips for each 
time point.  Shown is the mean % of cells with fragmented nuclei compared to the 
total number of cells plus the standard deviation across three coverslips.  Image is 
representative of 3 independent experiments. 
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Discussion 
The results shown above suggest a role for MarvelD3 in regulating JNK signalling 
and the actin cytoskeleton in response to hyperosmotic shock.  Exposure of Caco-2 
and HCE cells to hyperosmotic conditions induced by 600mosM NaCl resulted in a 
transient redistribution of MarvelD3, but not occludin, to the cytoplasm.  This 
redistribution appears to be dependent on activity of the EGFR and JNK.  MarvelD3 
also appears to regulate the hyperosmotic shock-induced activation of MEKK1 and 
JNK, and the subsequent inactivation of their signalling.  The most striking phenotype 
observed is the failure of MarvelD3-depleted cells to rearrange the actin cytoskeleton 
following hyperosmotic exposure, which may be due to aberrant regulation of MLC 
and cofilin in MarvelD3-depleted cells.  Finally, loss of MarvelD3 predisposes cells 
to apoptosis by hyperosmotic shock.  Taken together these data allude to a significant 
role for MarvelD3, and the tight junction, in coordinating the activation of MAPK 
signalling pathways and cytoskeletal rearrangements in response to hyperosmotic 
shock. 
 
Localisation of MarvelD3 dramatically changes in response to hyperosmotic shock in 
Caco-2 and HCE cells.  Interestingly, however, occludin remains in the cell 
membrane suggesting this is a MarvelD3-specific event.  In an attempt to confirm the 
internalization of MarvelD3, cells were lysed in the presence of Triton-X to separate 
fractions from the plasma membrane (triton insoluble) and the cytoplasm (triton 
soluble).  Immunoblotting these lysates suggested an increase in the cytoplasmic pool 
of MarvelD3 following hyperosmotic shock, but the signal was weak.  Confocal 
microscopy could also be used to determine whether MarvelD3 is indeed internalised, 
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and not just redistributed over the apical membrane. In addition, immunofluorescence 
analyses of various intracellular trafficking pathways may help to identify the 
structures in which cytoplasmic MarvelD3 is found.  Confirmation of MarvelD3 
internalisation could be achieved by performing further extraction protocols 
appropriate to the mechanism of internalisation, once identified. The increased 
cytoplasmic staining could also be attributable to detection of an N-terminal cleavage 
product.  As no additional bands are detected by immunoblotting lysates from cells 
exposed to MarvelD3 with the anti-MarvelD3 antibody, however, this is not thought 
to be the reason for increased cytoplasmic MarvelD3 signal. In addition to the 
junctional and cytoplasmic staining, a strong nuclear signal was also apparent in HCE 
cells stained with anti-MarvelD3 antibody, independent of hyperosmotic shock.  
Immunofluorescence should be performed on HCE cells depleted of MarvelD3 by 
siRNA to determine whether this nuclear signal is specific for MarvelD3. 
 
Internalisation of cell surface receptors is a recognized mechanism for modulating 
receptor activity. Blocking TNF receptor internalisation, for example, prevents the 
activation of JNK and downstream signalling leading to TNF-induced apoptosis 
(Schutze et al., 1999).  The mechanism behind MarvelD3 internalisation is not 
known, though it appears to require EGFR and JNK activity.  The EGFR is activated 
and internalized in response to hyperosmotic shock in a mechanism that is dependent 
on the Src kinase Yes (Rosette and Karin, 1996).  Inhibition of Src kinase family 
members with PP2 inhibitor however had only a minor effect on hyperosmotic shock-
induced internalization of MarvelD3, and MarvelD3 internalisation occurred as in 
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controls following incubation with PP1 inhibitor, thus suggesting MarvelD3 may be 
internalized via a distinct mechanism to that of the EGFR.  
 
Inhibition of JNK activity with the specific inhibitor SP600125 and of the EGFR with 
Gefitinib also impaired internalisation of MarvelD3 in response to hyperosmotic 
shock.  EGFR has been shown to activate JNK in response to hyperosmotic shock 
(Fischer et al., 2004), alluding to the possibility that these events are upstream and 
necessary for MarvelD3 internalisation.  Surprisingly, inhibition of p38, which is 
required for EGFR activation in response to hyperosmotic shock (Fischer et al., 
2004), did not affect MarvelD3 internalisation, suggesting MarvelD3 internalisation 
in response to hyperosmotic shock may rely on another mode of EGFR activation.  
Despite reports of PP3-mediated EGFR inhibition (Klinger et al., 2002; Kong et al., 
2011), redistribution of MarvelD3 was not affected by PP3 inhibitor but was inhibited 
by incubation with Gefetinib. This difference may be due to the efficiency of each of 
these inhibitors to inhibit the EGFR. PP3 demonstrates a moderate inhibition of 
EGFR (IC50=2.7µM; (Klinger et al., 2002)) while Gefetinib is much more potent 
(IC50=0.033µM; (Wakeling et al., 2002)).  To confirm the effect of EGFR inhibition 
on MarvelD3 internalisation, the experiments described should be repeated with other 
commercially available EGFR inhibitors.  In addition, the effect of hyperosmotic 
shock on MarvelD3 localisation in EGFR-depleted cells could also be examined. 
 
Immunoblotting showed activation of JNK in response to hyperosmotic shock to 
occur after MarvelD3 internalisation.  If MarvelD3 internalisation requires JNK 
activity and JNK activation requires MarvelD3 internalisation, this could provide a 
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positive feedback loop whereby MarvelD3 facilitates its own internalisation and 
further amplification of downstream signalling pathways.  In their study, Schutze et 
al., (1999) utilised K+ depletion to impair endocytosis and demonstrated the effects of 
blocking TNF receptor internalisation on the activation of downstream signalling 
pathways.  It would be interesting to see if K+ depletion prevents MarvelD3 
internalisation and, if so, if this prevents activation of MEKK1 and JNK.  This would 
avoid the use of small molecule inhibitors like SP600125, which may complicate 
interpretations as JNK is implicated in more than one stage of the pathway.  
Collecting cell lysates at earlier time points following addition of hyperosmotic 
conditions may also allow the transient nature of JNK activation to be seen and enable 
more detailed dissection of its role in regulating the localisation of MarvelD3.  
 
To determine whether the loss and subsequent restoration of junctional MarvelD3 in 
response to hyperosmotic shock affected protein levels, cell lysates were 
immunoblotted for MarvelD3 and occludin, the localisation of which appears 
unaffected by hyperosmotic exposure.  Interestingly, there was no loss of MarvelD3 
protein compared to cells in isotonic medium.  Thus, at earlier time points, 
hyperosmotic shock appears to cause a relocalisation of MarvelD3 away from the 
junction and in to the cytoplasm.  At later time points, MarvelD3 returns to the 
junction and cytoplasmic staining is reduced.  Total levels of MarvelD3 protein are 
unaffected in this process, but whether this relies on recycling of internalised 
MarvelD3, or its degradation followed by protein synthesis remains to be determined.  
Clathrin-mediated internalization of the EGFR commits it for degradation, while 
clathrin-independent mechanisms promote EGFR signalling by recycling the receptor 
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back to the cell surface (Sigismund et al., 2008).  Identifying the mechanisms behind 
MarvelD3 internalisation could be a focus of future studies. 
 
Regardless of the mechanism, the return of MarvelD3 to the membrane appears to be 
an important event in the response to hyperosmotic shock, as shown by the loss of 
junctional integrity in MarvelD3-depleted cells.  After being exposed to hyperosmotic 
conditions for 2 hours, MarvelD3 begins to return to the junctions in control cells.  
This time course is coincident with the recovery of impedance readings in response to 
hyperosmotic shock.  Control cells recover the initial loss of impedance values during 
the osmoadaptation process, but this does not occur in MarvelD3-depleted cells.  
Disruption of occludin and ZO-1 staining at the tight junction further suggests 
MarvelD3-depleted monolayers are more severely compromised following 
hyperosmotic insult than control monolayers.   
 
The restoration of junctional MarvelD3 also appears to be significant in the regulation 
of JNK signalling in response to hyperosmotic shock.  Both MEKK1 and JNK 
activation are prolonged in the absence of MarvelD3 suggesting failure of these cells 
to restrict MEKK1-JNK signalling and implicating MarvelD3 in the temporal 
regulation of this intracellular signalling pathway.  Earlier in this thesis an interaction 
between MarvelD3 and MEKK1 was identified and it was hypothesised that this 
interaction inhibited the action of MEKK1.  In response to hyperosmotic shock, 
MEKK1 becomes phosphorylated at Ser1455, which lies within the kinase domain of 
MEKK1, but is otherwise not annotated. Thus the significance of this residue and its 
phosphorylation state in the function of MEKK1 is not yet known. The coincidence of 
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MEKK1 phosphorylation at Ser1455 with MarvelD3 internalisation and JNK 
activation stimulated the hypothesis that internalisation of MarvelD3 functions to 
activate MAPK signalling in response to hyperosmotic shock (Figure 6.15).  That is, 
at the tight junction, MarvelD3 interacts with MEKK1 inhibiting its signalling 
activity.  Internalisation of MarvelD3 in response to hyperosmotic shock serves to 
liberate MEKK1 from this MarvelD3-mediated inhibition.  This could be because the 
internalisation of the MarvelD3-MEKK1 complex brings MEKK1 into close 
proximity of an activator, or maybe because internalised MarvelD3 can no longer 
interact with MEKK1, thus releasing it in to the cytoplasm for activation.  Performing 
co-immunoprecipitation experiments with cells exposed to hyperosmotic shock and 
those left in normal complete medium may help to identify whether phosphorylation 
of MEKK1 affects its interaction with MarvelD3.  In addition, immunofluorescent 
analysis of phospho-MEKK1 and MEKK1 localisation in response to hyperosmotic 
shock may help to show the importance of this relocalisation away from the plasma 
membrane.  By relieving its inhibition by MarvelD3, hyperosmotic shock results in 
the activation of MEKK1 and, subsequently, JNK. Loss of both MEKK1 and JNK 
phosphorylation in control cells concomitant with the return of MarvelD3 to the tight 
junction, suggests MarvelD3 switches off this signalling pathway by interacting again 
with MEKK1 at cell-cell contacts.  Since MarvelD3 depleted cells are unable to 
restore MarvelD3 at the membrane, MEKK1 and JNK activity in response to 
hyperosmotic shock is prolonged.  If MarvelD3 internalisation is necessary for 
MEKK1 phosphorylation, SP600125 and Gefitinib-mediated inhibition of MarvelD3 
redistribution should subsequently prevent phosphorylation of MEKK1. Thus the 
effect of SP600125 and Gefitinib on MEKK1 phosphorylation may help determine 
the importance of MarvelD3 internalisation on activation of this signalling pathway in 
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response to hyperosmotic shock.   This model also suggests a link between the 
findings of Samak and colleagues, that osmotic shock-induced activation of JNK is 
responsible for tight junction disruption (Samak et al., 2010), with the initial 
observation here that MarvelD3-depleted monolayers fail to recover alterations to 
impedance values following hyperosmotic exposure.  In addition to inhibiting the 
effect of JNK on gene expression, restoration of junctional MarvelD3 may also serve 
to inhibit JNK activity towards the tight junction, perhaps attenuating junction 
disruption and allowing integrity of the tight junction to be recovered, which thus 
doesn’t occur in MarvelD3-depleted cells. 
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Figure 6.15 – Hypothetical model for the regulation of the hyperosmotic shock 
response by MarvelD3.  Within the membrane domain of the tight junction, the N-
terminus of MarvelD3 interacts with MEKK1 and inhibits its activity.  Thus MEKK1 
and JNK are inactive.  Exposure to hyperosmotic shock results in redistribution of 
MarvelD3 to the cytoplasm and activation of MEKK1 and JNK.  The consequence of 
JNK and MEKK1 activation are discussed in the text below.  Following prolonged 
exposure to hyperosmotic shock, MarvelD3 returns to the membrane where it can 
interact with MEKK1, and inhibit its activity.  JNK activity is also reduced.  In 
MarvelD3 knockdown cells, therefore, MarvelD3 is not available to be returned to the 
membrane and therefore MEKK1 and JNK activity persist. 
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The most striking phenotype observed is the failure of MarvelD3-depleted cells to 
rearrange their cytoskeleton in response to hyperosmotic shock. Previously, the 
increase in F-actin in response to hyperosmotic shock has been shown to require 
phosphorylation of cofilin at Ser3 and inactivation of its actin severing activity 
(Thirone et al., 2009).  In the current study, loss of MarvelD3 did not affect the level 
of phospho-cofilin in response to hyperosmotic shock when compared to control cells, 
but did affect its localization. Immunofluorescence analyses showed a biphasic 
increase in cytoplasmic phospho-cofilin in response to hyperosmotic shock at the 15 
minute, 30 minute and 2 hour time points in control cells, but there was no such 
increase in cytoplasmic phospho-cofilin in MarvelD3-depleted cells, with phospho-
cofilin only localizing to the nucleus.  This may suggest that there is more active, 
unphosphorylated cofilin in the cytoplasm of MarvelD3-depleted cells which, 
according to the results of Thirone et al., (2009), may explain the failure of these cells 
to increase F-actin.  Assaying the ratio of G- and F-actin in control and MarvelD3-
depleted cells in response to hyperosmotic shock would help to confirm this.  
Immunofluorescence analysis should also be performed with anti-cofilin antibodies to 
determine the localization of the active protein in response to hyperosmotic shock and 
if MarvelD3 regulates this.  In response to sucrose-induced hyperosmolarity, cofilin 
phosphorylation is regulated by the RhoA/ROCK/LIMK pathway (Thirone et al., 
2009).   Thus MarvelD3 may regulate cofilin activity in response to hyperosmotic 
shock via RhoA, which is thought to be elevated in MarvelD3-depleted cells, though 
there could also be differences in the GTPases affected by hyperosmotic shock 
induced by NaCl.  Experiments to confirm the effect of MarvelD3 knockdown on 
RhoA activity levels need to be performed.  
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Interaction between MEKK1 and the actin cross-linker #-actinin affords a mechanism 
by which MEKK1 may impact on the cytoskeleton (Christerson et al., 1999).  
Interestingly, in the presence of a severing protein (like cofilin) and a cross-linker 
(like #-actinin), actin filaments aggregate into filament bundles (Maciver et al., 
1991).  Thus MarvelD3 may regulate actin bundling via MEKK1-#-actinin and by 
regulating the localization/activation of cofilin.  The specific mechanism by which 
this is achieved, however, remains to be confirmed. 
 
MLC phosphorylation is also important for bundling of actin filaments and is also 
activated downstream of RhoA (Etienne-Manneville and Hall, 2002). In response to 
hyperosmotic shock, increased phospho-MLC signal is observed in the cytoplasm 
adjacent to the membrane, but not at the membrane in both control and MarvelD3-
depleted cells.  The difference in pMLC staining between control and MarvelD3-
depleted cells may be due to the prior failure of MarvelD3-depleted cells to generate 
actin filaments upon which pMLC and Myosin II can act.  Thus at later time points, 
pMLC staining appears perturbed when compared to controls.   
 
Cells depleted of MarvelD3 seemed to be more sensitive to apoptosis in response to 
hyperosmotic shock than control cells.  This could be due to the prolonged JNK 
activation seen in MarvelD3-depleted cells.  In response to TNF#, JNK activation 
initially promotes cell survival, but when prolonged enhances the expression of 
proapoptotic pathways (Ventura et al., 2006). Thus in response to hyperosmotic 
shock, JNK activation may initially stimulate the expression of genes promoting 
osmoadaptation and cell survival, like AR and Hsp70.  Prolonged activation of JNK, 
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as observed in the absence of MarvelD3, may then lead to the activation of pro-
apoptotic pathways, like the cytochrome c pathway (Tournier et al., 2000).  
Interestingly, AR and Hsp70, which both contain AP1 sites in their promoters, were 
both downregulated in response to MarvelD3 expression in the microarray performed 
in chapter 4.  It would be interesting to examine the genetic profile of MarvelD3-
regulated JNK signalling in response to hyperosmotic shock by performing the AP1 
reporter assay in control and MarvelD3-depleted cells exposed to hyperosmotic shock 
for varying amounts of time.  These studies would be complemented by 
immunoblotting for candidate target proteins, like Hsp70, AR or markers of apoptosis 
like caspase 3 activation, to elucidate the mechanism through which MarvelD3 
expression may be promoting survival and preventing apoptosis after prolonged 
exposure to hyperosmotic shock. 
 
The N-terminal region of MEKK1 contains a plant homeodomain (PHD), which is 
involved in protein-protein interactions and acts as an E3 ubiquitin ligase.  The 
ubiquitination and degradation of cJun by MEKK1 in response to hyperosmotic shock 
has previously been shown to result in increased apoptosis (Xia et al., 2007).  
Assessing the effect of MarvelD3 depletion on levels of cJun in response to 
hyperosmotic shock may hint at whether MarvelD3 expression regulates the ligase 
activity of MEKK1.  In addition, the kinase domain of MEKK1 has been shown to be 
necessary for the induction of apoptosis in response to cytoskeletal disruption (Tricker 
et al., 2011).  Interestingly, phosphorylation of MEKK1 in response to hyperosmotic 
shock occurs within its kinase domain, but the function of this phosphorylation site 
has never before been addressed.  Furthermore, RhoA binds to the PHD of MEKK1 in 
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a GTP-dependent manner and promotes its kinase activity (Gallagher et al., 2004).  If, 
as hypothesised, RhoA activity levels are elevated in MarvelD3-depleted cells, the 
greater abundance of RhoA-GTP could lead to greater levels of active MEKK1, 
which may in turn promote apoptosis via ubiquitination of cJun or prolonged 
activation of JNK, or both.  Identifying how phosphorylation at Ser1455 affects the 
activity of MEKK1 could be key to understanding this.  These data implicate 
MarvelD3 in protecting cells from hyperosmotic shock-induced apoptosis.  
 
The data presented suggests MarvelD3 may play more than one role in the 
hyperosmotic shock response.  First, by enabling MEKK1 and JNK activation, 
MarvelD3 internalisation may be involved in promoting the expression of 
osmoadaptive genes.  Restoration of junctional MarvelD3 then serves to switch off 
MEKK1 and JNK activity and prevents the induction of pro-apoptotic signalling 
pathways.  Concomitant rearrangement of the cytoskeleton and recovery of junctional 
disruption ensures the integrity of the monolayer is maintained despite the 
hyperosmotic surroundings.   In the absence of MarvelD3, regulation of these 
processes is impaired and monolayer integrity is subsequently compromised.  Thus, 
by regulating JNK MAPK signalling, MarvelD3 plays a vital role in maintaining 
monolayer homeostasis in response hyperosmotic stress. 
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Chapter 7 – Analysis of MarvelD3 function during development in 
Xenopus laevis 
Introduction 
Studies performed so far in cell culture have identified a role for MarvelD3 in the 
regulation of epithelial cell proliferation and migration.  As these processes are also 
fundamental to embryonic development, I asked if MarvelD3 might also regulate 
these processes in vivo.  The African clawed frog Xenopus laevis provided an ideal 
system in which to perform these initial studies.  Although the pseudotetraploid 
genome of X. laevis renders it unsuitable for genetic studies, the large size and 
relative robustness of the eggs (approx. 1.2-1.4mm diameter) and embryos means X. 
laevis is easy to manipulate in vitro.  Simple hormone injections are used to induce 
females to lay large quantities of eggs, which can then be collected and fertilized in 
vitro to generate a synchronised population. The aim of this chapter therefore was to 
utilise this relatively simple, yet in vivo, system to examine the function of MarvelD3 
during embryonic development, with particular attention to proliferation and 
migration. 
The initial cleavage stages of Xenopus laevis development 
Following fertilisation, the Xenopus embryo undergoes are series of synchronous cell 
divisions generating 2 (stage 2), 4 (stage 3), 8 (stage 4), 16 (stage 5) and 32 
blastomeres (stage 6).  At stage 6.5 the early embryo consists of a solid ball of 
approximately 48 cells and is termed the morula, which will go on to develop into the 
blastula.  Interestingly, the first 12 divisions of Xenopus development do not require 
gene transcription and rely instead upon the expression of maternal RNAs, which are 
regulated through post-transcriptional modifications in the early Xenopus embryo.  
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These maternal transcripts are stable in the embryo until the mid-blastula transition 
(Paris et al., 1988), an important developmental transition involving the coordinated 
induction of both gene transcription and cell motility (Newport and Kirschner, 1982a, 
b).  
Migration during Xenopus laevis development 
Cell migration is crucial to embryonic development. During gastrulation, the 
precursors of the three distinct germ layers, the endoderm, mesoderm and ectoderm, 
assume their positions through a series of coordinated cell movements to give rise to 
the internal endoderm, the external ectoderm and the mesoderm in between.  Directed 
cell migration is one mechanism through which this is achieved.  The prechordal 
mesodermal cells migrate inside the embryo towards the animal pole as a group, 
relying on extracellular matrix secreted by the blastocoel roof (Winklbauer, 1990).  
Gastrulation also involves the process of convergent extension, which, in Xenopus 
laevis, is a cell sorting mechanism and does not involve migration.  The combined 
effects of migration and convergent extension, however, result in closure of the 
blastopore lip by the end of gastrulation. 
 
Neurulation is the next developmental stage after gastrulation.  During neurulation, 
dorsal ectoderm cells assume a neural fate and involute at the dorsal midline to form 
the neural tube.  The formation of the neural tube during neurulation relies on 
alterations in cell shape and cell packing causing the epithelium to role up in to a 
tubular structure. The border between the neural plate and non-neuronal ectoderm 
gives rise to the neural crest cells, which are induced at gastrulation and maintained 
through neurulation in response to Wnt and BMP signalling (Steventon et al., 2009).  
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The neural crest cells undergo an epithelial-to-mesenchymal transition and delaminate 
from the dorsal side of the neural tube.  Neural crest cells then migrate through the 
embryo and differentiate in to a great number of cell types upon reaching their 
destinations, including neurons, skin pigment cells and a number of connective tissues 
in the head, including skull and jaw bones.  Myoblasts, which are muscle precursor 
cells, are another migratory cell type.  Myoblasts migrate from the somites positioned 
on either side of the notochord and later differentiate into muscle cells. 
Tight junctions in Xenopus laevis 
In Xenopus laevis, tight junctions are observed during the first cell division as the 
blastocoel forms during the early cleavage stages. Tight junction proteins occludin, 
cingulin and ZO-1 are maternally expressed indicating their importance from the 
earliest stages of development (Fesenko et al., 2000).  By observing the degree of 
biotin penetration between blastomeres during development, tight junctions have been 
shown to initially form deep within the embryo before assuming their characteristic 
apical position, prior to the onset of gastrulation (Merzdorf et al., 1998).  Functional 
tight junctions have been implicated in the establishment of left-right asymmetry, 
which becomes randomized following overexpression of Xenopus claudin (Brizuela et 
al., 2001).  Loss of Xenopus claudin following morpholino injection appears to 
prevent convergent extension movements during gastrulation (Chang et al., 2010), 
further alluding to a role for tight junctions during Xenopus embryonic development.  
Importantly for this study, Xenopus laevis expresses a homologue of MarvelD3 
(Chapter 3, Table3.1/Figure 3.3), buts its significance and role in development has not 
been addressed.  Figure 7.1 shows the stages of X. laevis development and the events 
of relevance to the present study. 
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Figure 7.1 – Representation of Xenopus laevis development.  The main stages 
of X. laevis development are shown.  The experiments in this chapter utilize embryos 
from fertilization to stage 37/38, after the appearance of eyes and gills.  Tight 
junctions are established and stabilized during the cleavage stages to enable the 
formation of the blastocoel.  Cell migration is initiated during gastrulation.  Migration 
of neural crest cells and myoblasts through the embryo is also an important 
developmental process requiring cell migration. 
 
Using Xenopus laevis embryos as a tool in which to study migration in vivo, the 
results presented below provide evidence to suggest a role for MarvelD3 during 
Xenopus laevis development and, possibly, in the regulation of neural crest cell 
migration.  Future work looking at the regulation of neural crest cells in the absence 
of MarvelD3 combined with work already conducted in cell culture systems may help 
to consolidate a function for MarvelD3 in the regulation of cell migration. 
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Results 
Expression of MarvelD3 during Xenopus laevis development 
To first confirm the expression of MarvelD3 in the Xenopus embryo (xMD3) and to 
determine its expression pattern during early embryogenesis, RT-PCR was performed 
on RNA extracted from embryos at representative stages of development. Transcripts 
of xMD3 were detected in the unfertilized egg suggesting xMD3, like occludin and 
cingulin (Fesenko et al., 2000), is supplied maternally to the X. laevis embryo (Figure 
7.2).  Expression of xMD3 mRNA persisted through the cleavage stages, in the 
blastula (stage 8) and at the onset of gastrulation (stage 10).  At later stages xMD3 
transcript could still be detected though levels were relatively low.  A doublet also 
appeared in samples taken from stage 10 to stage 35 embryos, the identity of which is 
not yet known.  To confirm the band(s) correspond to xMarvelD3, PCR products 
should be cloned into a TA-cloning vector and sequenced.  This may also enable the 
identity of the second band to be identified, which may represent MarvelD3 variant B.  
 
Figure 7.2 – Expression of xMD3 during X. laevis embryonic development.  
RNA extracted from Xenopus embryos collected at representative stages of 
development was subjected to RT-PCR to identify the temporal expression pattern of 
xMD3 during development.  xMarvelD3 transcript was present in the maternal RNA in 
embryos and in stage 10 embryos after the mid-blastula transition.  xMarvelD3 
transcript persisted in later stage embryos, though levels were relatively low in 
comparison to earlier stages. Amplification of ornithine decarboxylase (ODC) was 
used as a control, due to its ubiquitous expression during early development. 
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Loss-of-function studies 
In order to gain insight in to the functional relevance of MarvelD3 expression in 
Xenopus development, 30ng morpholino specific for the Xenopus sequence of 
MarvelD3 (xMD3-MO) or a control morpholino (Con-MO) was injected into the 
animal pole of both cells of the 2-cell embryo.  Embryos injected with xMD3-MO 
appeared to develop normally and were indistinguishable from Con-MO-injected and 
uninjected embryos until stage 15 (Figure 7.3A). After stage 15, xMD3-MO-injected 
embryos began to develop more slowly than the Con-MO and uninjected embryos.  
Uninjected and Con-MO-injected embryos developed at the same rate (Figure 7.3A).  
The effect of xMD3-MO injection became even more apparent at later stages of 
development.  The appearance of the eye and gills were delayed in xMD3-MO-
injected embryos, although they did eventually appear.  Eye pigmentation in the 
xMD3-MO embryos, however, did not darken in the same way as the controls.  
Embryos injected with xMD3-MO were incubated until they reached stage 37/38, 
staged by position of the proctoderm, but still the pigmentation of the eye did not 
darken to the level of the controls (Figure 7.3B). In addition, the number of 
melanophores and their degree of pigmentation along the lateral epidermis also 
appeared reduced following injection of xMD3-MO.  Disruption of MarvelD3 
function, therefore, appears to slow down development of X. laevis embryos after 
gastrulation.  
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Figure 7.3 – Effect of bilateral xMD3 morpholino injection during early stages 
of Xenopus development.  (A) Injection of 30ng xMD3-MO in to both cells at the 2-
cell stage had no effect on embryonic development prior to stage 16. After stage 16, 
injection of xMD3-MO resulted in developmental delay. Images show time-matched 
representative development of each treatment group until uninjected embryos 
reached stage 37/38.  (b) xMD3-MO injected embryos were left to develop to stage 
37/38 to see if the eye and melanophore pigmentation reached that of the controls.  
(B) Increased magnification of the head shows reduced eye pigmentation following 
xMD3-MO injection.  Injection of xMD3-MO also appears to reduce the number of 
pigmented cells on the head and sides of the embryo.  Shown are representative 
images of stage 37/38 embryos from three independent experiments. 
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MarvelD3 MO was also injected into one cell of the 2-cell embryo.  Injection of 
xMD3-MO caused curvature of the neural axis towards the site of injection, which 
was not observed in Con-MO embryos (Figure 7.4).  Co-injection of !-galactosidase 
enabled identification of the injected side. 
 
 
 
Figure 7.4 – xMarvelD3 morpholino injection results in curvature of the neural 
fold in stage 20 embryos.  Control or xMarvelD3 morpholino (30ng) was injected in 
to a single cell at the 2-cell stage.  Injected embryos were fixed at stage 20 and !-
galactosidase staining allowed identification of the injection side.  Unilateral injection 
of xMD3-MO resulted in curvature of the neural fold (B and D) when compared to 
control-injected embryos (A and C).  Shown are representative embryos from three 
independent experiments. 
 
Given the curvature observed at stage 20 following injection of xMD3-MO into a 
single cell at the 2-cell stage and the more apparent effect of bilateral xMD3-MO 
injection at later stages of development, the effect of unilateral xMD3-MO injection 
on the later stages of development was assessed.  Unilaterally injected embryos were 
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allowed to develop until stage 35/36.  Embryos injected with 5ng xMD3-MO were 
indistinguishable from Con-MO-injected embryos (Figure 7.5).  Injection of 30ng 
xMD3-MO, however, caused a dramatic curvature of the embryo along the anterior-
posterior axis towards the site of injection, which was not seen following injection of 
30ng Con-MO (Figure 7.5).  In addition, injection of xMD3-MO at this and an 
intermediate dose (20ng) resulted in a shortening of the length of the embryo.  
Quantification showed that both the shortening and curvature of the anterioposterior 
body axis increased in severity with increasing concentration of xMD3-MO.  Bending 
of the body axis towards the xMD3-MO-injected side is consistent with the direction 
of curvature of the neural fold in stage 20 embryos following xMD3-MO injection. 
That these effects were not seen in Con-MO-injected embryos suggests this 
phenotype is a result of the disruption to MarvelD3 function following xMD3-MO 
injection. 
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Figure 7.5 – Injection of xMD3-MO results in shortening and curvature of the 
anterioposterior body axis. (A) Con-MO and xMD3-MO-injected embryos were 
fixed at stage 35/36.  Development of !-galactosidase staining was used to identify 
the side of injection.  Embryos injected with 5ng xMD3-MO appear similar to controls.  
Embryos injected with 30ng xMD3-MO have reduced body length and curve towards 
the site of injection.  Injection of 30ng Con-MO caused no observable defect in 
development. (B) Quantification of “curved”, “short” and “normal” phenotypes 
correlates severity with increasing concentration of xMD3-MO.  Between 25 and 30 
embryos were counted for each treatment group across two independent 
experiments.  Images are representative of two independent experiments. 
 
Furthermore, in keeping with the observations made above, unilateral injection of 
xMD3-MO resulted in perturbed eye development when compared to the uninjected 
side of the embryo (Figure 7.6).  The numbers of melanophores present on the 
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injected side were also reduced following xMD3-MO injection.  These observations 
further suggest MarvelD3 may play a role in the regulation of the later stages of 
development, possibly beginning at neurulation. 
 
 
Figure 7.6 – Unilateral injection of xMD3-MO perturbs eye and melanophore 
development.  Embryos injected with 30ng xMD3-MO into a single cell at the 2 cell 
stage were fixed at stage 35 and images taken of the control (uninjected) side and 
the xMD3-MO-injected side.  Within the same embryo, xMD3-MO injection perturbs 
development of eye pigmentation and the number of melanophores on the lateral 
epidermis.  !-galactosidase staining in blue enables the injected side to be identified. 
Images are representative of two independent experiments. 
 
To confirm the phenotypes observed were due to depletion of xMD3, RNA encoding 
human MarvelD3 isoform 2 (hMD3_2) was generated for injection alongside the 
Con- or xMD3-MO.  To confirm the human MarvelD3_2 was expressed following 
mRNA injection, hMD3_2 or GFP mRNA (control) was injected into both cells at the 
2-cell stage and the embryos were lysed at stage 10 to determine protein expression.  
Immunoblotting with the antibody against human MarvelD3 detected a band of 
approximately 40kDa in the hMD3_2-injected embryos but not those injected with 
GFP or not injected (Figure 7.7), suggesting human MarvelD3 protein is expressed 
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following injection of its mRNA in Xenopus embryos.  GFP protein could also be 
detected following injection of its mRNA, providing a control for subsequent 
experiments.   
 
Figure 7.7 – Expression of human MarvelD3 isoform 2 and GFP following 
mRNA injection in Xenopus laevis embryos.  Embryos were injected with mRNA 
encoding GFP or human MarvelD3 isoform 2 (hMD3_2) into both cells of the 2-cell 
embryo and allowed to develop until stage 10.  Embryos were then lysed and protein 
expression analysed by immunoblotting.  MarvelD3 protein is expressed following 
injection of 1ng and 2ng mRNA.  GFP protein is detected following injection of 0.5ng 
and 1ng GFP.  #-tubulin was used as a loading control.  Immunoblotting is 
representative of two independent experiments. 
 
Rescue experiments were designed in which hMD3_2 or GFP mRNA would be 
injected alongside Con- or xMD3-MO both unilaterally and bilaterally at the 2 cell 
stage, to see if hMD3_2 expression could rescue the phenotypes reported above.  
Unfortunately, however, those experiments performed to date have resulted in large 
amounts of embryo death leaving few embryos from which to base conclusions.  
Since the level of death was also high amongst uninjected embryos it is thought these 
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problems were due to poor quality eggs, rather than an effect of morpholino or mRNA 
injection.  Thus these experiments need to be repeated in the future to confirm the 
phenotypes observed following xMD3-MO injection are specific to loss of xMD3 and 
perform additional gain-of-function experiments, to assess the effect of MarvelD3 
overexpression during Xenopus laevis development. 
 
Neural crest cells are a highly migratory cell population, which migrates out from the 
neural fold.  Melanocytes and iris pigment cells are derived from neural crest cells 
and since disruption of xMD3 function appears to reduce their expression and has 
been shown to regulate migration in studies in vitro, the effect of xMD3-MO injection 
on neural crest cell migration was examined.  To do this, embryos were injected 
unilaterally with xMD3-MO and fixed at stages 20 and 23 before being analysed by 
whole mount in situ hybridisation for the expression of the neural crest cell marker, 
Twist (Hopwood et al., 1989).  !-galactosidase staining was used to identify the 
injected side of the embryo and the expression and positioning of neural crest cell 
markers could then be compared to that on the uninjected side of the embryo. Twist 
was unaffected by xMD3 depletion at stage 20 but the staining as lost on the injected 
side at stage 23 (Figure 7.8).   
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Figure 7.8 – Effect of xMD3-MO injection on Twist expression.  Stage 20 and 
stage 23 embryos unilaterally injected with xMD3-MO were subjected to whole mount 
in situ hybridization to determine the effect of xMD3-MO injection on Twist 
expression, as a marker of the neural crest.  (A) Injection of xMD3-MO does not 
affect Twist expression in stage 20 embryos. (B) Injection of xMD3-MO results in 
reduced Twist expression in stage 23 embryos.  As the curvature of the embryo 
makes it difficult to appreciate the extent of lateral staining loss, (Bi) shows clearer 
orientation of the uninjected side and (Bii) shows the xMD3-MO-injected side of the 
embryo imaged in (B). !-galactosidase staining allows the injection side to be 
identifid.  For clarity, embryos were imaged with the uninjected side on the left and 
the injected side on the right. All images are representative of two independent 
experiments. 
 
Myoblasts are also a migratory cell type, ultimately differentiating in to muscle cells.  
The expression of the differentiated muscle marker myosin heavy chain 
(MHC;(Radice and Malacinski, 1989)) was reduced following xMD3-MO injection 
corresponding to curvature towards the injection side (Figure 7.9A). Staining for the 
differentiated primary neuron marker neural !-tubulin (NBT) was also reduced 
ventrally and dorsally on the side of xMD3-MO injection (Figure 7.9B).  Thus 
morpholino-induced depletion of xMD3 appears to result in reduced expression of 
neural crest cell markers, reduced differentiation of muscle and primary neurons and 
repressed formation of neural crest cell derivatives (pigmented cells).  The effect of 
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xMD3-MO injection on early myoblast markers, like MyoD, should also be assessed 
to further appreciate the temporal effects of loss of xMD3. 
 
 
Figure 7.9 – Effect of xMD3-MO injection on myosin heavy chain and neural b-
tubulin expression. Stage 23 embryos unilaterally injected with xMD3-MO were 
subjected to whole mount in situ hybridisation to determine the effect of xMD3-MO 
injection on expression of myosin heavy chain (MHC) and neural !-tubulin (NBT). !-
galactosidase staining identifies the injected side of the embryo.  Injection of xMD3-
MO results in reduced MHC and NBT expression in stage 23 embryos. (A) is the 
dorsal view of the embryo shown in (Ai).  (B) is the dorsal view of the embryo shown 
in (Bi).  Images are representative of two independent experiments.   
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Discussion 
The preliminary work described here indicates a role for MarvelD3 during 
development of Xenopus laevis embryos.  Bilateral injection of xMD3-MO resulted in 
developmental delay after gastrulation and in reduced numbers of melanophores 
along the lateral epidermis and reduced iris pigmentation.  Unilateral injection of 
xMD3-MO caused curvature of the neural fold and anterior-posterior (A-P) axis 
towards the side of injection.  Reduced staining of neural crest cell marker Twist at 
stage 23 and of differentiated primary neuron marker, neural ! tubulin, suggested 
these morphological phenotypes could be due to perturbed neural crest cell migration 
following loss of MarvelD3.  Differentiated muscle marker myosin heavy chain was 
also reduced following injection of xMD3-MO. While further work is certainly 
required before a precise role for MarvelD3 in development can be fully ascribed, 
these results provide intriguing evidence that development is perturbed in the absence 
of MarvelD3. 
 
Before further experiments are performed it is vital to first confirm the results 
presented above are due to MarvelD3.  Rescue experiments using human MarvelD3 
RNA to rescue the phenotypes of xMD3-MO injection have so far failed due to 
unfortunately high death rate in egg batches.  These experiments should be repeated.  
While immunoblotting whole embryo lysates suggested hMD3 is expressed following 
injection its mRNA into Xenopus laevis, it may not be able to function or it may 
function differently to the Xenopus protein.  Thus it would be beneficial to generate a 
morpholino-resistant RNA encoding the Xenopus sequence of MarvelD3 with which 
to repeat the rescue experiments previously described. Rescuing the phenotypes 
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observed by re-expressing xMD3 would confirm their specifity to MarvelD3.   The 
phenotypes themselves should also be confirmed by designing a second morpholino 
targeting a different region of the xMD3 promoter, thus reducing the possibility of 
off-target effects.  Generation of an antibody specific for Xenopus MarvelD3 would 
also be a useful tool to analyse MarvelD3 expression during development and verify 
depletion of the protein following xMD3-MO injection. 
 
RT-PCR performed at a number of developmental stages demonstrated that MarvelD3 
is expressed in the maternal RNA and following the induction of embryonic 
transcription.  RT-PCR of mRNA extracted from embryos at stage 10 and later 
produced a double-band.  To confirm which band corresponds to xMD3 and identify 
the additional product, these RT-PCR products should be sequenced.   
 
Understanding the spatial expression pattern of MarvelD3 during Xenopus 
development might further enhance our understanding of how MarvelD3 functions by 
concentrating on where it is expresssed.  Attempts were made to synthesise probes 
specific for xMD3 for use in in situ hybridisation studies.  Unfortunately however, 
these probes generated high levels of background staining preventing the spatial 
expression pattern of xMD3 from being observed.  The high level of background 
staining may be due to the large size of the probes.  Future studies should perhaps use 
a mix of probes specific for a number of regions in xMD3, which would hopefully 
maintain specificity and reduce background staining. 
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While keeping in mind their limitations, the results presented here suggest that 
MarvelD3 expression may play an important role in embryonic development after 
gastrulation.  Until gastrulation (Stage 15), both unilaterally and bilaterally xMD3-
MO-injected embryos developed in a manner indistinguishable from con-MO injected 
and uninjected embryos.  The lack of effect of xMD3-MO injection on cleavage 
stages and the earliest stages of development suggests xMD3 is not necessary for tight 
junction formation in Xenopus laevis, which is necessary for formation of the blastula, 
and is consistent with the observations made in cell culture presented in chapter 3.  At 
neurulation (Stage 20), however, unilaterally injected embryos presented a curved 
neural fold and at later stages displayed significant curvature of the anterioposterior 
body axis towards the side of injection.  In bilaterally injected embryos, development 
of xMD3-MO-injected embryos proceeded more slowly than con-MO injected or 
uninjected counterparts.  This developmental delay in response to xMD3-MO 
injection could explain the curvature in the unilaterally injected embryos, which are 
outgrown by their uninjected sides. 
 
It also became apparent that the number of melanophores on the lateral epidermis was 
reduced following xMD3-MO, but not con-MO, injection.  Similarly, iris 
pigmentation was also reduced in xMD3-MO-injected embryos when compared to 
controls.  Interestingly, in situ hybridisation studies showed the neural crest cell 
marker Twist to be reduced by xMD3-MO injection in stage 23 embryos, but not at 
stage 20, suggesting induction of neural crest cells is not affected by loss of 
MarvelD3.  This reduction in Twist-positive neural crest cells at stage 23, however, 
could explain the reduced neural crest cell derivatives at later embryonic stages.   
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The induction of neural crest cells and their subsequent transition to a migratory cell 
type involves regulation by a number of signals.  At the gastrula stage, Wnt signalling 
is active and BMP signalling is inhibited inducing neural crest cells in the gastrula 
(Steventon et al., 2009).  During neurulation, BMP signalling is activated alongside 
the already active Wnt signalling which together maintain the neural crest cell 
population (Steventon et al., 2009).  BMP signalling is also responsible for the 
induction of neural crest cell delamination, which depends on the balance between 
BMP and noggin.  As loss of MarvelD3 only appeared to affect Twist staining at later 
stages of neural crest migration, a simple hypothesis would be to propose that 
MarvelD3 regulates the migration of neural crest cells following their EMT, but does 
not regulate their induction, maintenance or delamination.  This increased migration 
of neural crest cells may result in the reduced Twist staining observed as they have 
migrated more rapidly than the control side of the embryo and perhaps no longer 
express it, or they disperse across the embryo, which dilutes the signal and makes it 
appear reduced.  Furthermore, by over-migrating through or beyond their target zones 
or by arriving too early, these neural crest cells may not receive the inductive signals 
necessary for differentiation.  Thus neural crest cell derivatives, like primary neurons 
and pigmented cells, are reduced in xMD3-MO-injected embryos.  This model is by 
no means complete and should be examined further by looking at more markers of 
neural crest cells and their derivatives, to confirm the effect of xMD3-MO injection to 
neural crest cells, and not just Twist-positive populations.  Overexpression of the 
neural crest cell marker Slug, for example, has been shown to result in increased 
levels of neural crest cells and elevate the levels of melanocytes (LaBonne and 
Bronner-Fraser, 1998).  As slug is a transcription factor implicated in the induction of 
EMT, it would be interesting to see the effect of MarvelD3 depletion on slug 
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expression during Xenopus development.  If, like Twist, Slug is also reduced in 
response to loss of MarvelD3, this could provide a mechanism through which 
MarvelD3 reduces the abundance of melanocytes.  Injection of Con-MO into a single 
cell of the 2 cell embryo should be performed to ensure the in situs performed so far 
are specific to xMD3-MO rather than morpholino injection per se.  Furthermore it 
will be important to determine whether the reduced staining is due to increased 
apoptosis in response to xMD3-MO injection by performing whole-mount TUNEL 
staining.  Finally, it is important to note that loss of Twist staining could simply be 
due to inhibition of Twist transcription in the absence of MarvelD3.  The effect of 
MarvelD3 expression on levels of twist protein should be assessed to examine this.   
 
It has recently been shown that MarvelD3 is down-regulated in EMT induced by Snail 
in response to TGF! (Kojima et al., 2011).  If MarvelD3 were an inhibitor of 
migration, as the results presented in this thesis suggest, down-regulation of 
MarvelD3 would lift this inhibition and enable cells to migrate more rapidly. 
Concomitant down-regulation of adhesion proteins like E-cadherin during EMT may 
result in the more rapid migration of single cells rather than collective cell migration 
in the presence of cell-cell adhesion.  The defects presented here concern loss of 
MarvelD3, and therefore suggest the presence of MarvelD3 must also be important.  
Perhaps, therefore, during neural crest cell migration, MarvelD3 expression initially 
serves to inhibit migration of neural crest cells in response to BMP.  Eventually, 
BMP-induced activation of transcription factors like snail may then lead to 
downregulation of MarvelD3, which promotes migration.  Complete loss of 
MarvelD3 in the morpholino scenario however may result in increased migration in 
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response to BMP at an earlier time and/or an elevated rate of migration.  With this in 
mind, it would be useful to identify the specific cell types in which MarvelD3 is 
expressed, or absent, and how this expression changes during the developmental 
process.  This could be achieved by isolating groups of cells and performing RT-PCR 
for xMD3 to obtain a more detailed expression profile at various developmental 
stages. As an inhibitor of migration, the expression of MarvelD3 may be important to 
ensure some cells remain non-motile during development.  To further examine the 
effect of MarvelD3 depletion on neural crest cell migration, neural crest cells can be 
isolated and their migration observed ex vivo.  The effect of loss of MarvelD3 on 
protrusion formation, directional migration, collective or single-cell migration of the 
neural crest cells could all be assessed to begin to see whether the effects of 
MarvelD3 ex vivo are the same as those observed in cell culture.  
 
Interestingly, TGF! signalling induces the expression of AP1 transcription factor 
components cJun and cFos (Verrecchia et al., 2001a) and, furthermore, AP1 has been 
implicated in regulating the transcriptional response to TGF! (Verrecchia et al., 
2001b).  Signalling by TGF! family members, BMPs and activin, is incredibly 
abundant during development.  MarvelD3 could therefore regulate the cellular 
response to TGF!, or other family members, through its inhibition of AP1 signalling.  
In the absence of MarvelD3, loss of this inhibition would result in increased 
transcription of TGF! target genes and promotion of cell migration.  The effect of 
MarvelD3 expression on TGF!-mediated alterations in gene expression should 
therefore be examined.  For simplicity, this could first be studied in cell culture by 
applying TGF! to control and MarvelD3-depleted Caco-2 cells and assessing the 
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effect on levels of cJun and cFos.  Additional experiments to determine levels of cJun 
and cFos transcripts from Xenopus laevis embryos injected with Con- or xMD3-MO 
by RT-PCR would further confirm the regulation of AP1 signalling by MarvelD3. 
 
To summarise, the results in this chapter suggest a role for MarvelD3 during the 
embryonic development of Xenopus laevis, providing a useful model system in which 
to address the function of MarvelD3 in vivo.  Loss of MarvelD3 affected embryonic 
development after gastrulation stage and resulted in developmental delay, indicated 
by slower development of bilaterally injected embryos and curvature following 
unilateral injection of xMD3-MO.  Reduced expression of Twist following xMD3-
MO injection and reduced neural crest derivatives suggested MarvelD3 might 
regulate neural crest cell migration.  After confirming the specificity of these effects 
to MarvelD3, future work should focus on investigating the role for MarvelD3 in 
regulation of TGF! signalling and whether this is facilitated by the inhibitory action 
of MarvelD3 on AP1-mediated transcription. 
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Chapter 8: 
Final Discussion 
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Final Discussion 
At the beginning of this thesis, MarvelD3 was recognised as an occludin-like Marvel 
domain-containing protein of unknown function (Sanchez-Pulido et al., 2002).  The 
aim of this thesis was to determine if, like occludin and tricellulin, MarvelD3 was a 
component of the tight junction and to examine the functional role of MarvelD3 in the 
cell.  Results presented here identify MarvelD3 as a novel component of the tight 
junction and indicate its importance in the regulation of epithelial cell proliferation 
and migration, by impacting on intracellular signalling pathways that regulate gene 
expression and rearrangement of the actin cytoskeleton. Taken together, this suggests 
MarvelD3 serves more than a structural role at the tight junction and offers support to 
the developing hypothesis that tight junctions are important signalling centres in 
addition to providing a paracellular diffusion barrier.  I will now discuss the relevance 
of these findings to our understanding of tight junction biology, in addition to future 
applications and studies.  I will support the direction proposed for future studies by 
showing some preliminary data. 
Identification of MarvelD3 and regulation of tight junction properties 
MarvelD3 was identified as a novel component of the tight junction and showed a 
broad expression pattern in epithelial and endothelial cell lines and in many tissue 
types.  MarvelD3 colocalised with occludin at the tight junction of epithelial cells and 
apically to E-cadherin at the adherens junction.  Depletion of MarvelD3 by siRNA 
transfection demonstrated that MarvelD3 is not required for junction formation in 
Caco-2 cells, in contrast to studies performed by other groups (Kojima et al., 2011; 
Raleigh et al., 2010).  Initial studies performed here in Xenopus laevis also suggest 
MarvelD3 is not necessary for junction formation during embryonic development.  
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While the experiments performed in Xenopus laevis did not address tight junction 
formation directly, the xMD3-MO-injected embryos developed beyond blastula stage, 
which was reported to fail in the absence of tight junction formation, due to the 
inability to seal off the internal cavity from the medium outside (Regen and 
Steinhardt, 1986).  These considerations suggest that MarvelD3 is not necessary for 
the formation of the tight junction, but instead its expression and integration into the 
tight junction serves to alter their properties and regulate intracellular signalling 
pathways in the cytoplasm beneath.  Detailing the recruitment of MarvelD3 during 
tight junction formation may provide further insight in to how the temporal regulation 
of MarvelD3 helps this to be achieved.   
 
Though loss of MarvelD3 did not appear to affect the paracellular permeability 
properties of tight junctions, ion conductance was increased in the absence of 
MarvelD3.  The ability of tight junctions to regulate these two permeability properties 
independently is intriguing.  It is considered that by regulating the complement of 
claudins expressed tight junctions are able to regulate ion conductance based on 
charge.  Thus MarvelD3, if not regulating charge directly, may affect the complement 
of claudin molecules expressed, subsequently resulting in increased epithelial 
resistance.  The regulation of ion conductance by MarvelD3 could, however, be 
subtler, occurring at the protein level rather than the level of transcription.  Recently 
presented data suggested that phosphorylation of occludin on serine residue 408 
altered the dynamic properties of the tight junction, subsequently elevating 
transepithelial resistance (Raleigh et al., 2011).  Post-translational modifications have 
not yet been identified for MarvelD3, but it would be interesting to investigate their 
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existence and, if so, how they may affect tight junction dynamics, as has been 
demonstrated for occludin.  Such studies provide additional insight into the function 
of proteins that are easily missed in loss-of-function studies.  Indeed, loss of 
MarvelD3 protein from the tight junction may itself affect protein dynamics and be 
responsible for the increased ion conductance observed.  
 
In addition to ion conductance, the ability of tight junctions to regulate permeability 
based on size is currently proposed to proceed via the dynamic and constant 
remodelling of the tight junction strand network (Sasaki et al., 2003; Steed et al., 
2010).  In the present study no effect of MarvelD3 depletion was observed on 
paracellular permeability to large dextran tracers.  The possibility of MarvelD3 and 
the importance of the Marvel domain in regulating strand dynamics, however, should 
not be ruled out.  Analysis of the tight junction strand network in MarvelD3-
expressing and MarvelD3-depleted cells by electron microscopy (EM) may provide a 
more comprehensive insight in to the role of MarvelD3 in strand formation that may 
have been missed at the level of confocal microscopy.  Cryo-immuno EM should also 
be performed to confirm the localisation of MarvelD3 to the tight junction strands. 
 
Regulation of cell proliferation and migration by MarvelD3 
The main finding of this thesis is the regulation of epithelial proliferation and 
migration by MarvelD3.  Reduced MarvelD3 expression in epithelial metastatic 
tumour cell lines prompted the examination of the role of MarvelD3 in tumourogenic-
related processes.  Increased proliferation and migration following MarvelD3 
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depletion from Caco-2 cells alluded to the significance of loss of MarvelD3 in 
metastatic tumour cell lines.  Furthermore, expression of exogenous MarvelD3 in the 
pancreatic tumour cell line MiaPaCa confirmed the ability of MarvelD3 to inhibit 
proliferation and migration in epithelial cells.  In keeping, initial studies performed in 
Xenopus laevis have suggested perturbations in neural crest cell migration following 
injection of morpholinos targeting the Xenopus sequence of MarvelD3. Together, 
these data provide convincing evidence for the ability of MarvelD3 to regulate cell 
proliferation and migration. 
 
Identification of an interaction between MEKK1 and the N-terminus of MarvelD3 
provided insight in to how this regulation may be achieved.  MEKK1 is a MAPKKK 
activated in response to growth factor signalling and stresses that change cell shape or 
arrangement of the cytoskeleton (Yujiri et al., 1998; Zhang et al., 2003).  Disruption 
of junctional MEKK1 staining in MarvelD3-depleted cells suggested the importance 
of the MarvelD3-MEKK1 interaction for the junctional localisation of MEKK1.  
Examination of MarvelD3 in response to hyperosmotic shock further confirmed the 
functional relevance of the interaction between MarvelD3 and MEKK1, with 
hyperosmotic shock-induced phosphorylation of MEKK1 being prolonged in 
MarvelD3-depleted cells, suggesting MarvelD3 regulates MEKK1 phosphorylation in 
response to certain stimuli.  MEKK1 has been shown to activate transcription 
mediated by AP1 transcription factors by associating with and activating MAPKK 
with preference for downstream activation of JNK.  Activation of JNK stimulates the 
expression of components of the AP1 transcription factor and further promotes their 
activity by activating phosphorylation.  Levels of active JNK were reduced following 
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expression of MarvelD3 in MiaPaCa cells and MarvelD3 expression reduced AP1 
promoter activity in both MiaPaCa and Caco-2 cells.  These observations prompted 
the hypothesis that the association between MarvelD3 and MEKK1 may serve to 
inhibit MEKK1 activity, which, in turn, would perturb the downstream signalling 
pathways normally resulting in JNK activation and AP1-responsive promoter activity. 
Reduction of AP1 signalling affords a mechanism through which MarvelD3 
expression may regulate gene expression; by regulating the expression of those genes 
with AP1 recognition sites in their promoters.  One such gene is the EGFR, 
expression of which was shown to decrease following MarvelD3 expression and 
increase in its absence.  In addition, expression of cyclinD1 is also regulated by AP1 
signalling, and was reduced here following expression of MarvelD3.  The detailed 
mechanism behind MarvelD3-mediated regulation of these promoters, however, 
requires further investigation.  While depletion of MarvelD3 potentiated cyclinD1 
promoter activity and protein levels, AP1 promoter activity was not increased by loss 
of MarvelD3 alone.  This suggests MarvelD3 may regulate cyclinD1 promoter 
activity by a mechanism independent of AP1 and, further, that MarvelD3-mediated 
regulation of AP1 activity may require additional input before the effect of MarvelD3 
loss is observed. MarvelD3-depletion in Caco-2 cells significantly increased AP1 
promoter activity in response to EGF.  This suggests expression of MarvelD3 inhibits 
activation of AP1 promoter activity induced by EGF.  This could be mediated by 
reduced EGFR expression, and therefore reduced downstream signalling, caused by 
MarvelD3 expression, or a direct effect of MarvelD3 in inhibiting the EGFR 
signalling pathway.  It is proposed that, by regulating MEKK1, MarvelD3 inhibits 
JNK and AP1 activity leading to reduced EGFR expression.  The activation of 
MEKK1 and AP1 signalling by EGF-induced activation of the EGFR provides a 
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negative feedback loop whereby EGF-induced signalling is further reduced following 
MarvelD3 expression (Figure 8.1). 
 
 
Figure 8.1 – Hypothetical model for the regulation of migration and 
proliferation by MarvelD3 in epithelial cells.  As described in the text, interaction 
between MarvelD3 and MEKK1 at the tight junction inhibits MEKK1 activity and 
prevents activation of the JNK branch of the MAPK pathway.  Subsequent reductions 
in AP1 promoter activity may result in reduced expression of AP1 target genes like 
the EGFR and cyclinD1, and reduced proliferation and migration.  By regulating 
MEKK1 and JNK activity, MarvelD3 expression also perturbs cytoskeletal 
rearrangements necessary for productive migration.  MarvelD3 also regulates the 
rearrangements of the cytoskeleton in response to hyperosmotic shock.   
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An important question to address in the near future is the mechanism behind the 
regulation of MEKK1 by MarvelD3.  Interaction with the N-terminus of MarvelD3 
has been suggested here to inhibit MEKK1 activity thus explaining the reduced JNK 
and AP1 activity in response to MarvelD3 expression.  However, the activation state 
of MEKK1 in interaction with MarvelD3 has not yet been determined.  To examine 
this further, antibodies specific to three phosphorylated forms of MEKK1 (MEKK1-
S67, MEKK1-T1402 and MEKK1-S1455; kindly provided by Ewen Gallagher, 
Imperial College London) could be used to determine the phosphorylation state of 
MEKK1 interacting with MarvelD3. Initial studies in MiaPaCa cell lysates could also 
be performed to assess the effect of MarvelD3 expression on the levels of these 
phosphorylated forms of MEKK1.  Phosphorylation of MEKK1 at serine 67 has been 
shown to inhibit the binding of JNK to MEKK1 and therefore prevents MEKK1-
mediated JNK activation (Gallagher et al., 2002). Promoting phosphorylation of this 
site, therefore, would be a simple mechanism through which MarvelD3 may impact 
upon JNK activity via MEKK1.  Alternatively, phosphorylation of T1402 within the 
kinase domain of MEKK1 is thought to be required for MEKK1 kinase activity 
towards JNK (Siow et al., 1997).  Inhibition of T1402 phosphorylation could thus 
provide an alternative mechanism through which MarvelD3 impacts upon the JNK 
MAPK pathway.  Like T1402, S1455 is also found in the kinase domain of MEKK1, 
but the significance of its phosphorylation has not yet been reported.  In the current 
study, this site was phosphorylated in response to hyperosmotic shock and remained 
phosphorylated for longer when Caco-2 cells were depleted of MarvelD3.  Attempts 
should be made, therefore, to determine the effect of S1455 phosphorylation on 
MEKK1 kinase activity towards JNK, by generating phosphomimetic mutants and 
mutants that cannot be phosphorylated for use in kinase assays.  
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When the identity of the phosphorylation state regulated by MarvelD3 has been 
identified it would be informative to discover the mechanism behind this regulation.  
RhoA can bind to MEKK1 and stimulate its kinase activity (Gallagher et al., 2004).  
Interestingly, levels of active RhoA are reduced following MarvelD3.  Thus 
MarvelD3 may inhibit MEKK1 activity by inhibiting the activity of RhoA. The 
mechanism behind MarvelD3-mediated inhibition of RhoA, however, needs to be 
addressed.  One mechanism by which MarvelD3 may be able to inhibit RhoA could 
be by cross-talk with adherens junction proteins involved in RhoA regulation, like 
p120-catenin.  
 
p120-catenin localises to the adherens junction via interaction with E-cadherin and 
has been shown to locally inhibit RhoA activity, important for the stabilisation of 
adherens junctions (Anastasiadis et al., 2000).  Preliminary immunofluroescent 
studies in MiaPaCa cells showed p120-catenin to be recruited to cell-cell contacts in 
MarvelD3-expressing MiaPaCa cells, but not in control MiaPaCa cells (Figure 8.2A). 
At the adherens junction, transient interaction of p190RhoGAP with p120-cadherin 
complex facilitates the inhibition of RhoA by p190RhoGAP (Wildenberg et al., 
2006).  In the absence of p120-catenin, p190RhoGAP fails to recruit to the plasma 
membrane and RhoA activity is significantly elevated alluding to the importance of 
this mechanism in the localised regulation of RhoA.  Interestingly, p190RhoGAP was 
also recruited to cell-cell contacts in MarvelD3 expressing MiaPaCa cells (Figure 
8.2A).   In addition, pulldown assays identified a potential interaction between the N-
terminus of MarvelD3 and both p120-catenin and p190RhoGAP (Figure 8.2B). 
Furthermore, depletion of MarvelD3 from Caco-2 cells altered p120-catenin 
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localisation (Figure 8.2C).  In control cells, p120-catenin colocalised with MarvelD3 
and some more basal staining could also be seen.  In MarvelD3-depleted cells, p120-
catenin demonstrated staining indicative of the adherens junction only, suggesting 
MarvelD3 may serve to localise the tight junctional pool of p120-catenin.  Thus, in a 
similar manner to the cadherin-p120-catenin complex at the adherens junction, 
MarvelD3 may regulate RhoA activity at the tight junction by interacting with p120-
catenin/p190RhoGAP, which may subsequently reduce the activity of RhoA.  This 
hypothesis becomes more intriguing when considering the idea that Rac activation 
provides the stimulus for p190RhoGAP translocation from the cytoplasm to the 
membrane, preceding its interaction with p120-catenin and subsequent inhibition of 
RhoA (Wildenberg et al., 2006).  Rac is activated in response to hyperosmotic shock.  
Thus, one may speculate that translocation of p190RhoGAP to the membrane in 
response to hyperosmotic shock-induced activation of Rac might enable 
p120/p190RhoGAP-mediated inhibition of RhoA at the level of the tight junction.  In 
the absence of the proposed MarvelD3-p120-catenin complex, p190RhoGAP may fail 
to inhibit RhoA at the level of the tight junction resulting in elevated RhoA activity 
and increased phospho-MLC and increased dephosphorylation of cofilin in the 
cytoplasm, ultimately preventing the reorganisation of the actin cytoskeleton 
necessary for the osmoadaptive response.  To investigate this hypothesis, the effect of 
hyperosmotic shock on p120-catenin and p190RhoGAP localisation should be tested.  
These studies may also help understand the spatial regulation of MarvelD3 in the 
membrane and cytoplasm, and its involvement in coordinating changes to intracellular 
signalling pathways with rearrangement of the cytoskeleton.   
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Figure 8.2 – Preliminary observations suggest the MarvelD3 may exist in a 
complex with p120-catenin and p190RhoGAP at the tight junction.  (A) 
Immunofluorescence analysis of p120-catenin and p190RhoGAP shows their 
recruitment to points of cell-cell contact following expression of MarvelD3 in MiaPaCa 
cells.  (B) p120-catenin colocalises with MarvelD3 in control Caco-2 cells. siRNA-
mediated depletion of MarvelD3 in Caco-2 cells disrupts localisation of p120-catenin, 
which appears to localise more basally following loss of MarvelD3.  (C) 
Immunoblotting cell lysates from pulldown assays suggests an interaction between 
the N-terminus of MarvelD3 and p120-catenin, p190RhoGAP and aPKC (see below).  
These are preliminary observations and require repetition.  Immunofluorescence in 
(A) and (B) was performed by Sandra Hemkemeyer during a Masters project.  I 
performed the pulldown assays in (C) and lysates were immunoblotted by Sandra 
Hemkemeyer.   
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Coexpression of conventional PKC!II with MEKK1 in insect cells demonstrated the 
ability of PKC to activate MEKK1 (Siow et al., 1997).  Though no role for aPKC in 
MEKK1 phosphorylation has been shown, aPKC localises to the tight junction and 
preliminary results also indicate an interaction with MarvelD3 (Figure 8.2C).  Using 
aPKC inhibitors it would be interesting to determine whether MEKK1 
phosphorylation can be regulated by aPKC and, furthermore, whether MarvelD3 
plays a role in bringing aPKC and MEKK1 together at the tight junction.  If aPKC is 
capable of phosphorylating MEKK1 and this is regulated by MarvelD3, it could 
provide a mechanism by which MarvelD3 prevents JNK activation in migrating cells. 
  
Regulation of the actin cytoskeleton by MarvelD3 
MarvelD3 has been shown here to inhibit protrusion formation in migrating cells.  
Furthermore, reorganisation of the actin cytoskeleton in response to hyperosmotic 
shock is perturbed in the absence of MarvelD3 suggesting MarvelD3 also functions in 
coordinating remodelling of the actin cytoskeleton in response to hyperosmotic shock.  
The generation of cell protrusions is thought to require JNK activity (Altan and 
Fenteany, 2004).  Inhibition of JNK, therefore, could also be the mechanism behind 
MarvelD3-mediated inhibition of protrusion formation.  In response to hyperosmotic 
shock, the cytoskeleton fails to reorganise which may be due to elevated levels of 
active cofilin preventing the formation of long actin filaments from which bundles 
can be formed. Combined cofilin and Arp2/3 activity act together to drive 
lamellipodia extension at the leading edge (DesMarais et al., 2004; Pollard and 
Borisy, 2003).  Defective regulation of cofilin, therefore, may also be involved in 
increased migration in MarvelD3-depleted cells.  From the results obtained from 
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hyperosmotic shock and migration experiments, it seems MarvelD3 may function in 
stabilisation of the cytoskeleton.  Cell migration requires dynamic remodelling of the 
actin cytoskeleton.  In the absence of MarvelD3, these dynamic properties appear to 
be increased as cells migrate more rapidly and the generation of protrusive structures 
increases.  MarvelD3 expression during migration, therefore, may serve to restrict 
migration speed by capping the speed with which the cytoskeleton remodels.  Under 
hyperosmotic shock, the actin cytoskeleton reorganises to generate a rigid structure 
that enables the cell to physically resist the changes in the extracellular environment.  
This rigid actin network, however, is not achieved in the absence of MarvelD3, 
suggesting again that the actin cytoskeleton may be more dynamic following loss of 
MarvelD3, which, under conditions of hyperosmotic shock, is detrimental to the cell.  
The precise mechanism behind MarvelD3-mediated regulation of the cytoskeleton is 
not well understood though the data here suggests it may involve loss of MarvelD3-
mediated RhoA inhibition and elevated levels of active cofilin.  Analysis of active 
cofilin localisation in control and MarvelD3-depleted cells in response to 
hyperosmotic shock, however, needs to be determined. 
 
MarvelD3 may also impact on the cytoskeleton via its interaction with MEKK1, 
which is required for stress fibre formation in response to TGF!.  Given the 
abundance of TGF! during development and the potential role for MarvelD3 in 
regulating neural crest cell migration, regulating MEKK1 in response to TGF! could 
be a significant function of MarvelD3.  The effect of MarvelD3 on cytoskeletal 
reorganisation in response to TGF! could easily be tested in control and MarvelD3-
depleted cells.  If MarvelD3 inhibits MEKK1, one would expect more stress fibres in 
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MarvelD3-depleted cells and little or none in MarvelD3 overexpressing cells.  
Regulation of TGF! and EGFR signalling by MarvelD3 could be of significant 
physiological relevance. 
 
EGF and TGF! have been shown to cooperate in the induction of EMT. Experiments 
performed in pig thyrocytes, for example, have demonstrated that while individually 
EGF and TGF! are ineffective at inducing EMT, together they can (Grande et al., 
2002).  Furthermore, this response to EGF and TGF! is lost if EGFR kinase activity is 
inhibited (Grande et al., 2002).  In addition, amplification of the EGFR gene and 
subsequent hyperactivity of Ras in breast cancer has been shown to increase their 
responsiveness to TGF! (Yin et al., 1999).  Therefore, by reducing expression of the 
EGFR, MarvelD3 may also reduce the responsiveness of cells to TGF! signalling.  
Thus MarvelD3 expressing cells fail to increase their migration in response to TGF!.  
This regulation of TGF!-induced migration by MarvelD3 may prove significant 
during development where migration of some cell types is required while surrounding 
cells remain stationary.  In tumours, loss of MarvelD3 may encourage metastasis by 
increasing EGFR expression levels and making cells more responsive to EGF and 
TGF!.  It would be interesting to determine if MarvelD3 affects expression of the 
TGF! receptor.  The TGF! receptor 1 localises at the tight junction via an interaction 
with occludin (Barrios-Rodiles et al., 2005) and is therefore ideally situated for 
regulation by tight junction proteins.  By inhibiting MEKK1, MarvelD3 may prevent 
EGF and TGF!-induced activation of JNK and AP1 activity.  The effect of MarvelD3 
depletion on MEKK1, JNK and AP1 activation in response to TGF!, EGF and TGF! 
+ EGF should be tested to further examine this hypothesis. 
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Relevance of MarvelD3 function at the epithelial cell tight junction 
Results presented here demonstrate a role for MarvelD3 in the regulation of 
intracellular signalling pathways governing cell proliferation and migration.  The 
localisation of MarvelD3 to the tight junction in epithelial cells thus implicates the 
tight junction in the regulation of these processes.  So, why regulate proliferation and 
migration from the tight junction?  The tight junction is a site at which epithelial cells 
contact their neighbours.  In order for integrity across the monolayer to be maintained 
it makes sense that cellular processes potentially compromising this integrity be 
regulated from the sites where physical communication between neighbouring cells 
and with the extracellular space is permitted.   In combination with the adherens 
junctions and desmosomes, tight junctions form part of the epithelial junctional 
complex.  Together these junctions mediate cell-cell adhesion and intracellular 
signalling pathways.  The differences in the properties of these junctions, however, 
must be important to the epithelial cells to necessitate the need for more than one type 
of junctional complex.  Adhesion between neighbouring cells is necessary for 
epithelial cell function.  In contrast to tight junctions, adherens junctions and 
desmosomes provide strong cell-cell adhesion between neighbouring epithelial cells.  
Thus, perhaps one may view tight junctions as an additional layer of junctional 
regulation building upon the adhesion provided by these basolateral junctional 
complexes.  Thus the cell-cell adhesion mediated by tight junction proteins, like 
claudins in the strands, is sufficient to draw two already close plasma membranes 
closer together, generating the kissing points, but requires the adhesion already 
provided by the adherens junctions and desmosomes to do so.  By relying on   
adhesion provided by other junctional complexes, therefore, cells may be able to alter 
the expression of transmembrane proteins in the tight junction without compromising 
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adhesion and, in so doing, exploit the signalling properties of their cytoplasmic 
domains.  To consider MarvelD3, integration of this protein into claudin-based 
strands appears to inhibit proliferation and migration from the tight junction.  When 
cells are at low density, lack of MarvelD3, which localises in a cell contact-dependent 
manner, means this inhibition is lifted and cells can proliferate and migrate in 
response to growth factor signalling, like EGF.  By interacting with and inhibiting 
MEKK1 at the tight junction, MarvelD3 expression inhibits expression of the EGFR 
and subsequently reduces the output of its downstream signalling.  Thus, by 
mediating cross-talk between the JNK MAPK pathway and the EGFR signalling 
pathway, MarvelD3 expression inhibits the proliferation and migration of epithelial 
cells.  Regulating this from the tight junction may enable epithelial cells to regulate 
the expression of tight junction transmembrane proteins as required, without 
compromising cell-cell adhesion mediated by the adherens junctions.    Depletion of 
MarvelD3 here did not appear to affect expression of adherens junction 
transmembrane proteins, thought alterations to the localisation of p120-catenin in the 
cytoplasm were observed.   
 
This suggestion, however, is not to say that the expression of tight junction proteins 
within the membrane is not important for more than signalling purposes.  The 
identification of the Marvel domain in proteins involved in membrane apposition 
events alludes to its importance at the tight junction and prompted the studies 
undertaken in this thesis.  The relevance of the Marvel domain itself to the tight 
junction, however, has not been addressed here and is poorly understood.  Depletion 
of occludin results in spreading of tricellulin along the bicellular contacts suggesting 
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there may be some redundancy between Marvel domain-containing proteins of the 
tight junction and that the Marvel domain itself may be of importance to the tight 
junction structure (Ikenouchi et al., 2008).  To better understand this, studies utilising 
double and triple knockdowns of MarvelD3, occludin and tricellulin and the effect 
this has on junction formation, strand morphology and tight junction properties should 
be examined.  In their study, Raleigh et al., (2010) observed a greater delay in 
junction formation following combined depletion of MarvelD3, occludin and 
tricellulin when compared to depletion of any protein alone.  It would be interesting to 
repeat these studies in the system used here to begin to identify a role for the Marvel 
domain itself at the tight junction, away from the signalling properties contained in 
the cytoplasmic portions of these proteins.  Perhaps the Marvel domain is necessary 
for efficient occlusion of the plasma membranes at the tight junction.  Comparing the 
distance between outer leaflets of the plasma membrane of control cells and those 
depleted of the tight junction Marvel domain complement by EM may help to identify 
this.  Differential expression of a complement of proteins with the same 
transmembrane domain, but different cytoplasmic domains, may enable complexes 
like the tight junction to take advantage of their different signalling properties (for 
example, the opposing roles of MarvelD3 and occludin in migration) while ensuring 
the Marvel domain is always present. 
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Final Conclusion 
Experiments conducted in preparation of this thesis have identified MarvelD3 as a 
novel component of the epithelial cell tight junction.  Presence of MarvelD3 in the 
tight junction serves to regulate the activation of intracellular signalling pathways 
promoting cell proliferation and migration in response to physiological levels of 
growth factors, like EGF.  Thus MarvelD3 expression at the tight junction may 
function in maintaining homeostasis of the epithelial monolayer.  Relief of this 
MarvelD3-mediated inhibition results in activation of the JNK MAPK pathway and 
AP1 signalling, facilitating cytoskeletal reorganisation and changes in gene 
expression promoting cell proliferation and migration.  Identification of MarvelD3 
and its role at the tight junction has furthered our appreciation of tight junction 
composition and developed our understanding of the role of these protein complexes 
as mediators of intracellular signalling pathways. 
 279 
Acknowledgements 
The writing of this thesis would not have been possible without the help and support 
of my two supervisors, Professors Karl Matter and Maria S. Balda.  I am delighted to 
have been able to work in your lab and sincerely thank you for your guidance and 
encouragement throughout the last three years, and for showing faith in me when I 
needed it the most.  I have learnt a great deal from both of you and I’m sure I will 
carry it with me wherever I go next. 
I would like to extend my gratitude to Shin-Ichi Ohnuma and member’s of the 
Ohnuma lab for being so welcoming, and a special thank you to Katerina and 
Wanzhou for giving their time and patience so generously to teach me the Xenopus 
techniques.  Thank you to my thesis committee Drs Franck Pichaud, Tim Levine and 
Yasuyuki Fujita for helpful discussions. Thank you also to Dr Ewen Gallagher at 
Imperial College London for kindly providing phospho-MEKK1 antibodies. 
I have met some wonderful people over the past three years and thank everyone at the 
Institute of Ophthalmology and MRC Laboratory for Molecular Cell Biology for 
making my time here so enjoyable.  I feel privileged to have been able to work 
alongside such great people and meet many friends I hope I will know for a long time 
to come.  I’d like to say an extra thank you to Jay, Jenny and Natalie for their 
friendship and encouragement over the last three years and especially while I’ve been 
writing.   
Thank you to my family and friends for creating a happy life around me and helping 
any little blips quickly fade away.  Especially Ella, Cait, Matt and Sam for your 
constant support throughout the years and giving me the knowledge that it will always 
be all right in the end.  Thank you as well to Ami for sharing your time in London, 
 280 
I’m so pleased we came here together.  And of course, to Mark for your patience, for 
always being there to make things better and for giving me so many things to look 
forward to along the way.   
Finally I would like to say a big thank you to my mum and dad and my brother, 
Edward.  I couldn’t have done any of this without your love and support behind me 
and I’ll always be thankful.  I hope you enjoy having a flick through – there’ll be 
questions afterwards! 
 
This PhD was funded by the Medical Research Council. 
 281 
References 
 
Altan, Z.M., and Fenteany, G. (2004). c-Jun N-terminal kinase regulates lamellipodial 
protrusion and cell sheet migration during epithelial wound closure by a gene 
expression-independent mechanism. Biochem Biophys Res Commun 322, 56-67. 
 
Amasheh, S., Meiri, N., Gitter, A.H., Schoneberg, T., Mankertz, J., Schulzke, J.D., 
and Fromm, M. (2002). Claudin-2 expression induces cation-selective channels in 
tight junctions of epithelial cells. J Cell Sci 115, 4969-4976. 
 
Anastasiadis, P.Z., Moon, S.Y., Thoreson, M.A., Mariner, D.J., Crawford, H.C., 
Zheng, Y., and Reynolds, A.B. (2000). Inhibition of RhoA by p120 catenin. Nat Cell 
Biol 2, 637-644. 
 
Angelow, S., Ahlstrom, R., and Yu, A.S. (2008). Biology of claudins. Am J Physiol 
Renal Physiol 295, F867-876. 
 
Balda, M.S., Garrett, M.D., and Matter, K. (2003). The ZO-1-associated Y-box factor 
ZONAB regulates epithelial cell proliferation and cell density. J Cell Biol 160, 423-
432. 
 
Balda, M.S., and Matter, K. (2000). The tight junction protein ZO-1 and an 
interacting transcription factor regulate ErbB-2 expression. EMBO J 19, 2024-2033. 
 
Balda, M.S., and Matter, K. (2009). Tight junctions and the regulation of gene 
expression. Biochim Biophys Acta 1788, 761-767. 
 
Balda, M.S., Whitney, J.A., Flores, C., Gonzalez, S., Cereijido, M., and Matter, K. 
(1996). Functional dissociation of paracellular permeability and transepithelial 
electrical resistance and disruption of the apical-basolateral intramembrane diffusion 
barrier by expression of a mutant tight junction membrane protein. J Cell Biol 134, 
1031-1049. 
 282 
 
Barrios-Rodiles, M., Brown, K.R., Ozdamar, B., Bose, R., Liu, Z., Donovan, R.S., 
Shinjo, F., Liu, Y., Dembowy, J., Taylor, I.W., et al. (2005). High-throughput 
mapping of a dynamic signalling network in mammalian cells. Science 307, 1621-
1625. 
 
Basbaum, C.B., and Werb, Z. (1996). Focalized proteolysis: spatial and temporal 
regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 
8, 731-738. 
 
Basuroy, S., Seth, A., Elias, B., Naren, A.P., and Rao, R. (2006). MAPK interacts 
with occludin and mediates EGF-induced prevention of tight junction disruption by 
hydrogen peroxide. Biochem J 393, 69-77. 
 
Behrens, J., von Kries, J.P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and 
Birchmeier, W. (1996). Functional interaction of beta-catenin with the transcription 
factor LEF-1. Nature 382, 638-642. 
 
Ben-Yosef, T., Belyantseva, I.A., Saunders, T.L., Hughes, E.D., Kawamoto, K., Van 
Itallie, C.M., Beyer, L.A., Halsey, K., Gardner, D.J., Wilcox, E.R., Rasmussen, J., 
Anderson, J.M., Dolan, D.F., Forge, A., Raphael, Y., Camper, S.A., Friedman, T.B. 
(2003).  Claudin 14 knockout mice, a model for autosomal recessive deafness 
DFNB29, are deaf due to cochlear hair cell degeneration. Hum Mol Genet 12, 2049-
2061.  
 
Benais-Pont, G., Punn, A.., Flores-Maldonado, C., Eckert, J., Raposo, G., Fleming, 
T.P., Cereijido, M., Balda, M.S., and Matter, K. (2003) Identification of a tight 
junction-associated guanine nucleotide exchange factor that activates Rho and 
regulates paracellular permeability. J Cell Biol 160, 729-740 
 
 283 
Bell, L.M., Leong, M.L., Kim, B., Wang, E., Park, J., Hemmings, B.A., and Firestone, 
G.L. (2000). Hyperosmotic stress stimulates promoter activity and regulates cellular 
utilization of the serum- and glucocorticoid-inducible protein kinase (Sgk) by a p38 
MAPK-dependent pathway. J Biol Chem 275, 25262-25272. 
 
Betanzos, A., Huerta, M., Lopez-Bayghen, E., Azuara, E., Amerena, J., and 
Gonzalez-Mariscal, L. (2004). The tight junction protein ZO-2 associates with Jun, 
Fos and C/EBP transcription factors in epithelial cells. Exp Cell Res 292, 51-66. 
 
Bjorklund, M., and Koivunen, E. (2005). Gelatinase-mediated migration and invasion 
of cancer cells. Biochim Biophys Acta 1755, 37-69. 
 
Brizuela, B.J., Wessely, O., and De Robertis, E.M. (2001). Overexpression of the 
Xenopus tight-junction protein claudin causes randomization of the left-right body 
axis. Dev Biol 230, 217-229. 
 
Buchwalter, G., Gross, C., and Wasylyk, B. (2004). Ets ternary complex transcription 
factors. Gene 324, 1-14. 
 
Bustamante, M., Roger, F., Bochaton-Piallat, M.L., Gabbiani, G., Martin, P.Y., and 
Feraille, E. (2003). Regulatory volume increase is associated with p38 kinase-
dependent actin cytoskeleton remodeling in rat kidney MTAL. Am J Physiol Renal 
Physiol 285, F336-347. 
 
Campos, S.B., Ashworth, S.L., Wean, S., Hosford, M., Sandoval, R.M., Hallett, M.A., 
Atkinson, S.J., and Molitoris, B.A. (2009). Cytokine-induced F-actin reorganization 
in endothelial cells involves RhoA activation. Am J Physiol Renal Physiol 296, F487-
495. 
 
Carlton, V.E.H., Harris, B.Z., Puffenberger, E.G., Batta, A.K., Knisely, A.S., 
Robinson, D.L., Strauss, K.A., Schneider, B.L., Lim, W.A., Salen, G., Morton, D.H., 
 284 
Bull, L.N. (2003).  Complex inheritance of familial hypercholanemia with associated 
mutations in TJP2 and BAAT. Nat Genetics 34, 91-96. 
 
Carmona-Fontaine, C., Matthews, H.K., Kuriyama, S., Moreno, M., Dunn, G.A., 
Parsons, M., Stern, C.D., and Mayor, R. (2008). Contact inhibition of locomotion in 
vivo controls neural crest directional migration. Nature 456, 957-961. 
 
Cereijido, M., Contreras, R.G., and Shoshani, L. (2004). Cell adhesion, polarity, and 
epithelia in the dawn of metazoans. Physiol Rev 84, 1229-1262. 
 
Chang, D.J., Hwang, Y.S., Cha, S.W., Chae, J.P., Hwang, S.H., Hahn, J.H., Bae, 
Y.C., Lee, H.S., and Park, M.J. (2010). Xclaudin 1 is required for the proper 
gastrulation in Xenopus laevis. Biochem Biophys Res Commun 397, 75-81. 
 
Chen, X., and Macara, I.G. (2005). Par-3 controls tight junction assembly through the 
Rac exchange factor Tiam1. Nat Cell Biol 7, 262-269. 
 
Cheng, H., Kartenbeck, J., Kabsch, K., Mao, X., Marques, M., and Alonso, A. (2002). 
Stress kinase p38 mediates EGFR transactivation by hyperosmolar concentrations of 
sorbitol. J Cell Physiol 192, 234-243. 
Christerson, L.B., Vanderbilt, C.A., and Cobb, M.H. (1999). MEKK1 interacts with 
alpha-actinin and localizes to stress fibers and focal adhesions. Cell Motil 
Cytoskeleton 43, 186-198. 
 
Colegio, O.R., Van Itallie, C.M., McCrea, H.J., Rahner, C., and Anderson, J.M. 
(2002). Claudins create charge-selective channels in the paracellular pathway between 
epithelial cells. Am J Physiol Cell Physiol 283, C142-147. 
 
Daro, E., van der Sluijs, P., Galli, T., and Mellman, I., (1996) Rab4 and cellubrevin 
define different early endosome populations on the pathway of transferrin receptor 
recycling. Proc. Natl. Acad. Sci. USA 93, 9559-9564 
 
 285 
Daniels, M., Dhokia, V., Richard-Parpaillon, L., and Ohnuma, S. (2004). 
Identification of Xenopus cyclin-dependent kinase inhibitors, p16Xic2 and p17Xic3. 
Gene 342, 41-47. 
 
Deng, M., Chen, W.L., Takatori, A., Peng, Z., Zhang, L., Mongan, M., Parthasarathy, 
R., Sartor, M., Miller, M., Yang, J., et al. (2006). A role for the mitogen-activated 
protein kinase kinase kinase 1 in epithelial wound healing. Mol Biol Cell 17, 3446-
3455. 
 
DesMarais, V., Macaluso, F., Condeelis, J., and Bailly, M. (2004). Synergistic 
interaction between the Arp2/3 complex and cofilin drives stimulated lamellipod 
extension. J Cell Sci 117, 3499-3510. 
 
Di Ciano, C., Nie, Z., Szaszi, K., Lewis, A., Uruno, T., Zhan, X., Rotstein, O.D., 
Mak, A., and Kapus, A. (2002). Osmotic stress-induced remodeling of the cortical 
cytoskeleton. Am J Physiol Cell Physiol 283, C850-865. 
 
Di Ciano-Oliveira, C., Sirokmany, G., Szaszi, K., Arthur, W.T., Masszi, A., Peterson, 
M., Rotstein, O.D., and Kapus, A. (2003). Hyperosmotic stress activates Rho: 
differential involvement in Rho kinase-dependent MLC phosphorylation and NKCC 
activation. Am J Physiol Cell Physiol 285, C555-566. 
 
Drees, F., Pokutta, S., Yamada, S., Nelson, W.J., and Weis, W.I. (2005). Alpha-
catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-
filament assembly. Cell 123, 903-915. 
 
Drubin, D.G., and Nelson, W.J. (1996). Origins of cell polarity. Cell 84, 335-344. 
Du, D., Xu, F., Yu, L., Zhang, C., Lu, X., Yuan, H., Huang, Q., Zhang, F., Bao, H., 
Jia, L., et al. (2010). The tight junction protein, occludin, regulates the directional 
migration of epithelial cells. Dev Cell 18, 52-63. 
 
 286 
Du, D., Xu, F., Yu, L., Zhang, C., Lu, X., Yuan, H., Huang, Q., Zhang, F., Bao, H., 
Jia, L., Wu, X., Zhu, X., Zhang, X., Chen, Z. (2010). The tight junction protein, 
occludin, regulates the directional migration of epithelial cells. Dev Cell 18, 52-63. 
 
Ebnet, K., Suzuki, A., Horikoshi, Y., Hirose, T., Meyer Zu Brickwedde, M.K., Ohno, 
S., and Vestweber, D. (2001). The cell polarity protein ASIP/PAR-3 directly 
associates with junctional adhesion molecule (JAM). EMBO J 20, 3738-3748. 
 
Etienne-Manneville, S., and Hall, A. (2001). Integrin-mediated activation of Cdc42 
controls cell polarity in migrating astrocytes through PKCzeta. Cell 106, 489-498. 
 
Etienne-Manneville, S., and Hall, A. (2002). Rho GTPases in cell biology. Nature 
420, 629-635. 
 
Fackler, O.T., and Grosse, R. (2008). Cell motility through plasma membrane 
blebbing. J Cell Biol 181, 879-884. 
 
Fanning, A.S., Jameson, B.J., Jesaitis, L.A., and Anderson, J.M. (1998). The tight 
junction protein ZO-1 establishes a link between the transmembrane protein occludin 
and the actin cytoskeleton. J Biol Chem 273, 29745-29753. 
 
Farquhar, M.G., and Palade, G.E. (1963). Junctional complexes in various epithelia. J 
Cell Biol 17, 375-412. 
 
Fesenko, I., Kurth, T., Sheth, B., Fleming, T.P., Citi, S., and Hausen, P. (2000). Tight 
junction biogenesis in the early Xenopus embryo. Mech Dev 96, 51-65. 
 
Fischer, O.M., Hart, S., Gschwind, A., Prenzel, N., and Ullrich, A. (2004). Oxidative 
and osmotic stress signalling in tumor cells is mediated by ADAM proteases and 
heparin-binding epidermal growth factor. Mol Cell Biol 24, 5172-5183. 
 
Friedl, P., and Wolf, K. (2010). Plasticity of cell migration: a multiscale tuning 
model. J Cell Biol 188, 11-19. 
 287 
 
Fujimoto, K. (1995). Freeze-fracture replica electron microscopy combined with SDS 
digestion for cytochemical labeling of intergral membrane proteins: aplication to the 
immunogold labeling of intercellular junctional complex. J Cell Sci 108, 3443-3449. 
 
Fujishiro, S.H., Tanimura, S., Mure, S., Kashimoto, Y., Watanabe, K., and Kohno, M. 
(2008). ERK1/2 phosphorylate GEF-H1 to enhance its guanine nucleotide exchange 
activity toward RhoA. Biochem Biophys Res Commun 368, 162-167. 
 
Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K., and Tsukita, S. (1998a). Claudin-1 
and -2: novel integral membrane proteins localizing at tight junctions with no 
sequence similarity to occludin. J Cell Biol 141, 1539-1550. 
 
Furuse, M., Hirase, T., Itoh, M., Nagafuchi, A., Yonemura, S., and Tsukita, S. (1993). 
Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 
123, 1777-1788. 
 
Furuse, M., Itoh, M., Hirase, T., Nagafuchi, A., Yonemura, S., Tsukita, S., and 
Tsukita, S. (1994). Direct association of occludin with ZO-1 and its possible 
involvement in the localization of occludin at tight junctions. J Cell Biol 127, 1617-
1626. 
 
Furuse, M., Sasaki, H., Fujimoto, K., and Tsukita, S. (1998b). A single gene product, 
claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. 
J Cell Biol 143, 391-401. 
 
Furuse, M., Sasaki, H., and Tsukita, S. (1999). Manner of interaction of 
heterogeneous claudin species within and between tight junction strands. J Cell Biol 
147, 891-903. 
 
Galcheva-Gargova, Z., Derijard, B., Wu, I.H., and Davis, R.J. (1994). An 
osmosensing signal transduction pathway in mammalian cells. Science 265, 806-808. 
 
 288 
Gallagher, E.D., Gutowski, S., Sternweis, P.C., and Cobb, M.H. (2004). RhoA binds 
to the amino terminus of MEKK1 and regulates its kinase activity. J Biol Chem 279, 
1872-1877. 
 
Gallagher, E.D., Xu, S., Moomaw, C., Slaughter, C.A., and Cobb, M.H. (2002). 
Binding of JNK/SAPK to MEKK1 is regulated by phosphorylation. J Biol Chem 277, 
45785-45792. 
 
Garrod, D., and Chidgey, M. (2008). Desmosome structure, composition and 
function. Biochim Biophys Acta 1778, 572-587. 
 
Garrod, D.R., Merritt, A.J., and Nie, Z. (2002). Desmosomal cadherins. Curr Opin 
Cell Biol 14, 537-545. 
 
Getsios, S., Huen, A.C., and Green, K.J. (2004). Working out the strength and 
flexibility of desmosomes. Nat Rev Mol Cell Biol 5, 271-281. 
 
Ghassemifar, M.R., Sheth, B., Papenbrock, T., Leese, H.J., Houghton, F.D., and 
Fleming, T.P. (2002). Occludin TM4(-): an isoform of the tight junction protein 
present in primates lacking the fourth transmembrane domain. J Cell Sci 115, 3171-
3180. 
 
Giampieri, S., Manning, C., Hooper, S., Jones, L., Hill, C.S., and Sahai, E. (2009). 
Localized and reversible TGFbeta signalling switches breast cancer cells from 
cohesive to single cell motility. Nat Cell Biol 11, 1287-1296. 
 
Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W.G., and 
Quaranta, V. (1997). Induction of cell migration by matrix metalloprotease-2 cleavage 
of laminin-5. Science 277, 225-228. 
 
Gonzalez-Mariscal, L., Chavez de Ramirez, B., and Cereijido, M. (1985). Tight 
junction formation in cultured epithelial cells (MDCK). J Membr Biol 86, 113-125. 
 
 289 
Gow, A., Southwood, C.M., Li, J.S., Pariali, M., Riordan, G.P., Brodie, S.E., Danias, 
J., Bronstein, J.M., Kachar, B., Lazzarini, R.A., (1999). CNS myelin and sertoli cell 
tight junction strands are absent in Osp/claudin-11 null mice. Cell 99, 649-659. 
Grande, M., Franzen, A., Karlsson, J.O., Ericson, L.E., Heldin, N.E., and Nilsson, M. 
(2002). Transforming growth factor-beta and epidermal growth factor synergistically 
stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent 
mechanism in primary cultured pig thyrocytes. J Cell Sci 115, 4227-4236. 
 
Guillemot, L., Paschoud, S., Pulimeno, P., Foglia, A., and Citi, S. (2008). The 
cytoplasmic plaque of tight junctions: a scaffolding and signalling center. Biochim 
Biophys Acta 1778, 601-613. 
 
Haskins, J., Gu, L., Wittchen, E.S., Hibbard, J., and Stevenson, B.R. (1998). ZO-3, a 
novel member of the MAGUK protein family found at the tight junction, interacts 
with ZO-1 and occludin. J Cell Biol 141, 199-208. 
 
Henson, J.H. (1999). Relationships between the actin cytoskeleton and cell volume 
regulation. Microsc Res Tech 47, 155-162. 
 
Hirokawa, N., and Tilney, L.G. (1982). Interactions between actin filaments and 
between actin filaments and membranes in quick-frozen and deeply etched hair cells 
of the chick ear. J Cell Biol 95, 249-261. 
 
Hofmann, I., Mertens, C., Brettel, M., Nimmrich, V., Schnolzer, M., and Herrmann, 
H. (2000). Interaction of plakophilins with desmoplakin and intermediate filament 
proteins: an in vitro analysis. J Cell Sci 113 ( Pt 13), 2471-2483. 
 
Hoover, K.B., Liao, S.Y., and Bryant, P.J. (1998). Loss of the tight junction MAGUK 
ZO-1 in breast cancer: relationship to glandular differentiation and loss of 
heterozygosity. Am J Pathol 153, 1767-1773. 
 
 290 
Hopwood, N.D., Pluck, A., and Gurdon, J.B. (1989). A Xenopus mRNA related to 
Drosophila twist is expressed in response to induction in the mesoderm and the neural 
crest. Cell 59, 893-903. 
 
Horikoshi, Y., Suzuki, A., Yamanaka, T., Sasaki, K., Mizuno, K., Sawada, H., 
Yonemura, S., and Ohno, S. (2009). Interaction between PAR-3 and the aPKC-PAR-6 
complex is indispensable for apical domain development of epithelial cells. J Cell Sci 
122, 1595-1606. 
 
Huang, C., Rajfur, Z., Borchers, C., Schaller, M.D., and Jacobson, K. (2003). JNK 
phosphorylates paxillin and regulates cell migration. Nature 424, 219-223. 
 
Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-
57. 
 
Huber, O., Korn, R., McLaughlin, J., Ohsugi, M., Herrmann, B.G., and Kemler, R. 
(1996). Nuclear localization of beta-catenin by interaction with transcription factor 
LEF-1. Mech Dev 59, 3-10. 
 
Huerta, M., Munoz, R., Tapia, R., Soto-Reyes, E., Ramirez, L., Recillas-Targa, F., 
Gonzalez-Mariscal, L., and Lopez-Bayghen, E. (2007). Cyclin D1 is transcriptionally 
down-regulated by ZO-2 via an E box and the transcription factor c-Myc. Mol Biol 
Cell 18, 4826-4836. 
 
Hurd, T.W., Gao, L., Roh, M.H., Macara, I.G., and Margolis, B. (2003). Direct 
interaction of two polarity complexes implicated in epithelial tight junction assembly. 
Nat Cell Biol 5, 137-142. 
 
Ikenouchi, J., Furuse, M., Furuse, K., Sasaki, H., and Tsukita, S. (2005). Tricellulin 
constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol 171, 
939-945. 
 
 291 
Ikenouchi, J., Sasaki, H., Tsukita, S., and Furuse, M. (2008). Loss of occludin affects 
tricellular localization of tricellulin. Mol Biol Cell 19, 4687-4693. 
Ilina, O., and Friedl, P. (2009). Mechanisms of collective cell migration at a glance. J 
Cell Sci 122, 3203-3208. 
 
Irarrazabal, C.E., Williams, C.K., Ely, M.A., Birrer, M.J., Garcia-Perez, A., Burg, 
M.B., and Ferraris, J.D. (2008). Activator protein-1 contributes to high NaCl-induced 
increase in tonicity-responsive enhancer/osmotic response element-binding protein 
transactivating activity. J Biol Chem 283, 2554-2563. 
 
Ishiyama, N., Lee, S.H., Liu, S., Li, G.Y., Smith, M.J., Reichardt, L.F., and Ikura, M. 
(2010). Dynamic and static interactions between p120 catenin and E-cadherin regulate 
the stability of cell-cell adhesion. Cell 141, 117-128. 
 
Itoh, M., Furuse, M., Morita, K., Kubota, K., Saitou, M., and Tsukita, S. (1999a). 
Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, 
with the COOH termini of claudins. J Cell Biol 147, 1351-1363. 
 
Itoh, M., Morita, K., and Tsukita, S. (1999b). Characterization of ZO-2 as a MAGUK 
family member associated with tight as well as adherens junctions with a binding 
affinity to occludin and alpha catenin. J Biol Chem 274, 5981-5986. 
 
Itoh, M., Sasaki, H., Furuse, M., Ozaki, H., Kita, T., and Tsukita, S. (2001). 
Junctional adhesion molecule (JAM) binds to PAR-3: a possible mechanism for the 
recruitment of PAR-3 to tight junctions. J Cell Biol 154, 491-497. 
 
Joshi, B., Strugnell, S.S., Goetz, J.G., Kojic, L.D., Cox, M.E., Griffith, O.L., Chan, 
S.K., Jones, S.J., Leung, S.P., Masoudi, H., et al. (2008). Phosphorylated caveolin-1 
regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration 
and invasion. Cancer Res 68, 8210-8220. 
 
Kaihara, T., Kusaka, T., Nishi, M., Kawamata, H., Imura, J., Kitajima, K., Itoh-
Minami, R., Aoyama, N., Kasuga, M., Oda, Y., et al. (2003). Dedifferentiation and 
 292 
decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal 
cancer are closely related to liver metastasis. J Exp Clin Cancer Res 22, 117-123. 
 
Kakiashvili, E., Dan, Q., Vandermeer, M., Zhang, Y., Waheed, F., Pham, M., and 
Szaszi, K. (2011). The epidermal growth factor receptor mediates tumor necrosis 
factor-alpha-induced activation of the ERK/GEF-H1/RhoA pathway in tubular 
epithelium. J Biol Chem 286, 9268-9279. 
 
Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal 
transition. J Clin Invest 119, 1420-1428. 
 
Kamai, T., Tsujii, T., Arai, K., Takagi, K., Asami, H., Ito, Y., and Oshima, H. (2003). 
Significant association of Rho/ROCK pathway with invasion and metastasis of 
bladder cancer. Clin Cancer Res 9, 2632-2641. 
 
Karin, M., Takahashi, T., Kapahi, P., Delhase, M., Chen, Y., Makris, C., Rothwarf, 
D., Baud, V., Natoli, G., Guido, F., et al. (2001). Oxidative stress and gene 
expression: the AP-1 and NF-kappaB connections. Biofactors 15, 87-89. 
 
Kavurma, M.M., and Khachigian, L.M. (2003). ERK, JNK, and p38 MAP kinases 
differentially regulate proliferation and migration of phenotypically distinct smooth 
muscle cell subtypes. J Cell Biochem 89, 289-300. 
 
Keon, B.H., Schafer, S., Kuhn, C., Grund, C., and Franke, W.W. (1996). Symplekin, a 
novel type of tight junction plaque protein. J Cell Biol 134, 1003-1018. 
 
Kevil, C.G., Oshima, T., Alexander, B., Coe, L.L., and Alexander, J.S. (2000). 
H(2)O(2)-mediated permeability: role of MAPK and occludin. Am J Physiol Cell 
Physiol 279, C21-30. 
 
Kikuchi, A. (2000). Regulation of beta-catenin signalling in the Wnt pathway. 
Biochem Biophys Res Commun 268, 243-248. 
 
 293 
Klinger, M., Kudlacek, O., Seidel, M.G., Freissmuth, M., and Sexl, V. (2002). MAP 
kinase stimulation by cAMP does not require RAP1 but SRC family kinases. J Biol 
Chem 277, 32490-32497. 
 
Kojima, T., Takasawa, A., Kyuno, D., Ito, T., Yamaguchi, H., Hirata, K., Tsujiwaki, 
M., Murata, M., Tanaka, S., and Sawada, N. (2011). Downregulation of tight 
junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal 
transition in human pancreatic cancer cells. Exp Cell Res. 
 
Kolligs, F.T., Kolligs, B., Hajra, K.M., Hu, G., Tani, M., Cho, K.R., and Fearon, E.R. 
(2000). gamma-catenin is regulated by the APC tumor suppressor and its oncogenic 
activity is distinct from that of beta-catenin. Genes Dev 14, 1319-1331. 
 
Kong, L., Deng, Z., Shen, H., and Zhang, Y. (2011). Src family kinase inhibitor PP2 
efficiently inhibits cervical cancer cell proliferation through down-regulating 
phospho-Src-Y416 and phospho-EGFR-Y1173. Mol Cell Biochem 348, 11-19. 
 
Koshikawa, N., Giannelli, G., Cirulli, V., Miyazaki, K., and Quaranta, V. (2000). 
Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over 
laminin-5. J Cell Biol 148, 615-624. 
 
Kottke, M.D., Delva, E., and Kowalczyk, A.P. (2006). The desmosome: cell science 
lessons from human diseases. J Cell Sci 119, 797-806. 
 
Kouklis, P.D., Hutton, E., and Fuchs, E. (1994). Making a connection: direct binding 
between keratin intermediate filaments and desmosomal proteins. J Cell Biol 127, 
1049-1060. 
 
Kovacs, E.M., Goodwin, M., Ali, R.G., Paterson, A.D., and Yap, A.S. (2002). 
Cadherin-directed actin assembly: E-cadherin physically associates with the Arp2/3 
complex to direct actin assembly in nascent adhesive contacts. Curr Biol 12, 379-382. 
 
 294 
Koval, M. (2002). Sharing signals: connecting lung epithelial cells with gap junction 
channels. Am J Physiol Lung Cell Mol Physiol 283, L875-893. 
 
Kowalik, T.F., DeGregori, J., Schwarz, J.K., and Nevins, J.R. (1995). E2F1 
overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis 
and apoptosis. J Virol 69, 2491-2500. 
 
Krause, G., Winkler, L., Mueller, S.L., Haseloff, R.F., Piontek, J., and Blasig, I.E. 
(2008). Structure and function of claudins. Biochim Biophys Acta 1778, 631-645. 
Kwon, H.M., and Handler, J.S. (1995). Cell volume regulated transporters of 
compatible osmolytes. Curr Opin Cell Biol 7, 465-471. 
 
Kreis, T.E. (1987) Microtubules containing detyrosinated tubulin are less dynamic. 
EMBO J. 6, 2597-2606 
 
LaBonne, C., and Bronner-Fraser, M. (1998). Neural crest induction in Xenopus: 
evidence for a two-signal model. Development 125, 2403-2414. 
 
Lammermann, T., and Sixt, M. (2009). Mechanical modes of 'amoeboid' cell 
migration. Curr Opin Cell Biol 21, 636-644. 
 
Li, H., Ung, C.Y., Ma, X.H., Li, B.W., Low, B.C., Cao, Z.W., and Chen, Y.Z. (2009). 
Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signalling 
pathway via MEKK1. Bioinformatics 25, 358-364. 
 
Liu, J., and Lin, A. (2005). Role of JNK activation in apoptosis: a double-edged 
sword. Cell Res 15, 36-42. 
 
Maciver, S.K., Wachsstock, D.H., Schwarz, W.H., and Pollard, T.D. (1991). The actin 
filament severing protein actophorin promotes the formation of rigid bundles of actin 
filaments crosslinked with alpha-actinin. J Cell Biol 115, 1621-1628. 
 
 295 
Maeda, O., Usami, N., Kondo, M., Takahashi, M., Goto, H., Shimokata, K., 
Kusugami, K., and Sekido, Y. (2004). Plakoglobin (gamma-catenin) has TCF/LEF 
family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 
23, 964-972. 
 
Mandai, K., Nakanishi, H., Satoh, A., Obaishi, H., Wada, M., Nishioka, H., Itoh, M., 
Mizoguchi, A., Aoki, T., Fujimoto, T., et al. (1997). Afadin: A novel actin filament-
binding protein with one PDZ domain localized at cadherin-based cell-to-cell 
adherens junction. J Cell Biol 139, 517-528. 
 
Matter, K., Aijaz, S., Tsapara, A., and Balda, M.S. (2005). Mammalian tight junctions 
in the regulation of epithelial differentiation and proliferation. Curr Opin Cell Biol 17, 
453-458. 
 
Matter, K., and Balda, M.S. (2003a). Functional analysis of tight junctions. Methods 
30, 228-234. 
 
Matter, K., and Balda, M.S. (2003b). Signalling to and from tight junctions. Nat Rev 
Mol Cell Biol 4, 225-236. 
 
Matter, K., and Balda, M.S. (2007). Epithelial tight junctions, gene expression and 
nucleo-junctional interplay. J Cell Sci 120, 1505-1511. 
 
Merzdorf, C.S., Chen, Y.H., and Goodenough, D.A. (1998). Formation of functional 
tight junctions in Xenopus embryos. Dev Biol 195, 187-203. 
 
Millan, J., Puertollano, R., Fan, L., Rancano, C., and Alonso, M.A. (1997). The MAL 
proteolipid is a component of the detergent-insoluble membrane subdomains of 
human T-lymphocytes. Biochem J 321 ( Pt 1), 247-252. 
 
Minden, A., Lin, A., Smeal, T., Derijard, B., Cobb, M., Davis, R., and Karin, M. 
(1994). c-Jun N-terminal phosphorylation correlates with activation of the JNK 
 296 
subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell 
Biol 14, 6683-6688. 
 
Miralles, F., Posern, G., Zaromytidou, A.I., and Treisman, R. (2003). Actin dynamics 
control SRF activity by regulation of its coactivator MAL. Cell 113, 329-342. 
 
Miranda, L., Carpentier, S., Platek, A., Hussain, N., Gueuning, M.A., Vertommen, D., 
Ozkan, Y., Sid, B., Hue, L., Courtoy, P.J., et al. (2010). AMP-activated protein kinase 
induces actin cytoskeleton reorganization in epithelial cells. Biochem Biophys Res 
Commun 396, 656-661. 
 
Miravet, S., Piedra, J., Miro, F., Itarte, E., Garcia de Herreros, A., and Dunach, M. 
(2002). The transcriptional factor Tcf-4 contains different binding sites for beta-
catenin and plakoglobin. J Biol Chem 277, 1884-1891. 
 
Muresan, Z., Paul, D.L., and Goodenough, D.A. (2000). Occludin 1B, a variant of the 
tight junction protein occludin. Mol Biol Cell 11, 627-634. 
 
Nadkarni, V., Gabbay, K.H., Bohren, K.M., and Sheikh-Hamad, D. (1999). Osmotic 
response element enhancer activity. Regulation through p38 kinase and mitogen-
activated extracellular signal-regulated kinase kinase. J Biol Chem 274, 20185-20190. 
 
Newport, J., and Kirschner, M. (1982a). A major developmental transition in early 
Xenopus embryos: I. characterization and timing of cellular changes at the 
midblastula stage. Cell 30, 675-686. 
 
Newport, J., and Kirschner, M. (1982b). A major developmental transition in early 
Xenopus embryos: II. Control of the onset of transcription. Cell 30, 687-696. 
 
Nie, M., Aijaz, S., Leefa Chong San, I.V., Balda, M.S., and Matter, K. (2009). The Y-
box factor ZONAB/DbpA associates with GEF-H1/Lfc and mediates Rho-stimulated 
transcription. EMBO Rep 10, 1125-1131. 
 
 297 
Nobes, C.D., and Hall, A. (1995). Rho, rac, and cdc42 GTPases regulate the assembly 
of multimolecular focal complexes associated with actin stress fibers, lamellipodia, 
and filopodia. Cell 81, 53-62. 
 
Nusrat, A., Giry, M., Turner, J.R., Colgan, S.P., Parkos, C.A., Carnes, D., Lemichez, 
E., Boquet, P., and Madara, J.L. (1995). Rho protein regulates tight junctions and 
perijunctional actin organization in polarized epithelia. Proc Natl Acad Sci U S A 92, 
10629-10633. 
Nusrat, A., Parkos, C.A., Verkade, P., Foley, C.S., Liang, T.W., Innis-Whitehouse, 
W., Eastburn, K.K., and Madara, J.L. (2000). Tight junctions are membrane 
microdomains. J Cell Sci 113 ( Pt 10), 1771-1781. 
 
Ozawa, M., Baribault, H., and Kemler, R. (1989). The cytoplasmic domain of the cell 
adhesion molecule uvomorulin associates with three independent proteins structurally 
related in different species. EMBO J 8, 1711-1717. 
 
Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H.R., Zhang, Y., and Wrana, J.L. 
(2005). Regulation of the polarity protein Par6 by TGFbeta receptors controls 
epithelial cell plasticity. Science 307, 1603-1609. 
 
Paris, J., Osborne, H.B., Couturier, A., Le Guellec, R., and Philippe, M. (1988). 
Changes in the polyadenylation of specific stable RNA during the early development 
of Xenopus laevis. Gene 72, 169-176. 
 
Pedersen, S.F., Hoffmann, E.K., and Mills, J.W. (2001). The cytoskeleton and cell 
volume regulation. Comp Biochem Physiol A Mol Integr Physiol 130, 385-399. 
 
Pedersen, S.F., Mills, J.W., and Hoffmann, E.K. (1999). Role of the F-actin 
cytoskeleton in the RVD and RVI processes in Ehrlich ascites tumor cells. Exp Cell 
Res 252, 63-74. 
 
Pollard, T.D., and Borisy, G.G. (2003). Cellular motility driven by assembly and 
disassembly of actin filaments. Cell 112, 453-465. 
 298 
 
Radice, G.P., and Malacinski, G.M. (1989). Expression of myosin heavy chain 
transcripts during Xenopus laevis development. Dev Biol 133, 562-568. 
 
Raleigh, D.R., Boe, D.M., Yu, D., Weber, C.R., Marchiando, A.M., Bradford, E.M., 
Wang, Y., Wu, L., Schneeberger, E.E., Shen, L., et al. (2011). Occludin S408 
phosphorylation regulates tight junction protein interactions and barrier function. J 
Cell Biol 193, 565-582. 
 
Raleigh, D.R., Marchiando, A.M., Zhang, Y., Shen, L., Sasaki, H., Wang, Y., Long, 
M., and Turner, J.R. (2010). Tight junction-associated MARVEL proteins marveld3, 
tricellulin, and occludin have distinct but overlapping functions. Mol Biol Cell 21, 
1200-1213. 
 
Razani, B., and Lisanti, M.P. (2001). Caveolin-deficient mice: insights into caveolar 
function human disease. J Clin Invest 108, 1553-1561. 
 
Regen, C.M., and Steinhardt, R.A. (1986) Global properties of the Xenopus blastula 
are mediated by a high-resistance epithelial seal. Dev Biol 113, 147-154 
 
Reyes, J.L., Lamas, M., Martin, D., del Carmen Namorado, M., Islas, S., Luna, J., 
Tauc, M., and Gonzalez-Mariscal, L. (2002). The renal segmental distribution of 
claudins changes with development. Kidney Int 62, 476-487. 
 
Riazuddin, S., Ahmed, Z.M., Fanning, A.S., Lagziel, A., Kitajiri, S., Ramzan, K., 
Khan, S.N., Chattaraj, P., Friedman, P.L., Anderson, J.M., et al. (2006). Tricellulin is 
a tight-junction protein necessary for hearing. Am J Hum Genet 79, 1040-1051. 
 
Ridley, A.J. (2001). Rho family proteins: coordinating cell responses. Trends Cell 
Biol 11, 471-477. 
 
 299 
Roh, M.H., Fan, S., Liu, C.J., and Margolis, B. (2003). The Crumbs3-Pals1 complex 
participates in the establishment of polarity in mammalian epithelial cells. J Cell Sci 
116, 2895-2906. 
 
Rosenblatt, J., Raff, M.C., and Cramer, L.P. (2001). An epithelial cell destined for 
apoptosis signals its neighbors to extrude it by an actin- and myosin-dependent 
mechanism. Curr Biol 11, 1847-1857. 
 
Rosette, C., and Karin, M. (1996). Ultraviolet light and osmotic stress: activation of 
the JNK cascade through multiple growth factor and cytokine receptors. Science 274, 
1194-1197. 
 
Rosse, C., Formstecher, E., Boeckeler, K., Zhao, Y., Kremerskothen, J., White, M.D., 
Camonis, J.H., and Parker, P.J. (2009). An aPKC-exocyst complex controls paxillin 
phosphorylation and migration through localised JNK1 activation. PLoS Biol 7, 
e1000235. 
 
Saitou, M., Fujimoto, K., Doi, Y., Itoh, M., Fujimoto, T., Furuse, M., Takano, H., 
Noda, T., and Tsukita, S. (1998). Occludin-deficient embryonic stem cells can 
differentiate into polarized epithelial cells bearing tight junctions. J Cell Biol 141, 
397-408. 
 
Saitou, M., Furuse, M., Sasaki, H., Schulzke, J.D., Fromm, M., Takano, H., Noda, T., 
and Tsukita, S. (2000). Complex phenotype of mice lacking occludin, a component of 
tight junction strands. Mol Biol Cell 11, 4131-4142. 
 
Samak, G., Suzuki, T., Bhargava, A., and Rao, R.K. (2010). c-Jun NH2-terminal 
kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal 
epithelium. Am J Physiol Gastrointest Liver Physiol 299, G572-584. 
 
Sanchez-Pulido, L., Martin-Belmonte, F., Valencia, A., and Alonso, M.A. (2002). 
MARVEL: a conserved domain involved in membrane apposition events. Trends 
Biochem Sci 27, 599-601. 
 300 
 
Sasaki, H., Matsui, C., Furuse, K., Mimori-Kiyosue, Y., Furuse, M., and Tsukita, S. 
(2003). Dynamic behavior of paired claudin strands within apposing plasma 
membranes. Proc Natl Acad Sci U S A 100, 3971-3976. 
 
Schulzke, J.D., Gitter, A.H., Mankertz, J., Spiegel, S., Seidler, U., Amasheh, S., 
Saitou, M., Tsukita, S., and Fromm, M. (2005). Epithelial transport and barrier 
function in occludin-deficient mice. Biochim Biophys Acta 1669, 34-42. 
 
Schutze, S., Machleidt, T., Adam, D., Schwandner, R., Wiegmann, K., Kruse, M.L., 
Heinrich, M., Wickel, M., and Kronke, M. (1999). Inhibition of receptor 
internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor 
receptor death domain signalling. J Biol Chem 274, 10203-10212. 
 
Shaulian, E., and Karin, M. (2002). AP-1 as a regulator of cell life and death. Nat Cell 
Biol 4, E131-136. 
 
Shin, K., Fogg, V.C., and Margolis, B. (2006). Tight junctions and cell polarity. Annu 
Rev Cell Dev Biol 22, 207-235. 
 
Shin, K., Wang, Q., and Margolis, B. (2007). PATJ regulates directional migration of 
mammalian epithelial cells. EMBO Rep 8, 158-164. 
 
Sigismund, S., Argenzio, E., Tosoni, D., Cavallaro, E., Polo, S., and Di Fiore, P.P. 
(2008). Clathrin-mediated internalization is essential for sustained EGFR signalling 
but dispensable for degradation. Dev Cell 15, 209-219. 
 
Simon, D.B., Lu, Y., Choate, K.A., Velazquez, H., Al-Sabban, E., Praga, M., Casari, 
G., Bettinelli, A., Colussi, G., Rodriguez-Soriano, J., McCredie, D., Milford, D., 
Sanjad, S., Lifton, R.P., (1999). Paracellin-1, a renal tight junction protein required 
for paracellular Mg2+ resorption. Science 285, 103-106. 
 
 301 
Siow, Y.L., Kalmar, G.B., Sanghera, J.S., Tai, G., Oh, S.S., and Pelech, S.L. (1997). 
Identification of two essential phosphorylated threonine residues in the catalytic 
domain of Mekk1. Indirect activation by Pak3 and protein kinase C. J Biol Chem 272, 
7586-7594. 
 
Smart, E.J., Graf, G.A., McNiven, M.A., Sessa, W.C., Engelman, J.A., Scherer, P.E., 
Okamoto, T., and Lisanti, M.P. (1999). Caveolins, liquid-ordered domains, and signal 
transduction. Mol Cell Biol 19, 7289-7304. 
 
Stappenbeck, T.S., and Green, K.J. (1992). The desmoplakin carboxyl terminus 
coaligns with and specifically disrupts intermediate filament networks when 
expressed in cultured cells. J Cell Biol 116, 1197-1209. 
 
Steed, E., Balda, M.S., and Matter, K. (2010). Dynamics and functions of tight 
junctions. Trends Cell Biol 20, 142-149. 
 
Steed, E., Rodrigues, N.T., Balda, M.S., and Matter, K. (2009). Identification of 
MarvelD3 as a tight junction-associated transmembrane protein of the occludin 
family. BMC Cell Biol 10, 95. 
 
Steventon, B., Araya, C., Linker, C., Kuriyama, S., and Mayor, R. (2009). Differential 
requirements of BMP and Wnt signalling during gastrulation and neurulation define 
two steps in neural crest induction. Development 136, 771-779. 
 
Straight, S.W., Shin, K., Fogg, V.C., Fan, S., Liu, C.J., Roh, M., and Margolis, B. 
(2004). Loss of PALS1 expression leads to tight junction and polarity defects. Mol 
Biol Cell 15, 1981-1990. 
 
Takagaki, Y., and Manley, J.L. (2000). Complex protein interactions within the 
human polyadenylation machinery identify a novel component. Mol Cell Biol 20, 
1515-1525. 
 
 302 
Takai, Y., and Nakanishi, H. (2003). Nectin and afadin: novel organizers of 
intercellular junctions. J Cell Sci 116, 17-27. 
 
Tan, I., Yong, J., Dong, J.M., Lim, L., and Leung, T. (2008). A tripartite complex 
containing MRCK modulates lamellar actomyosin retrograde flow. Cell 135, 123-
136. 
 
Tanos, T., Marinissen, M.J., Leskow, F.C., Hochbaum, D., Martinetto, H., Gutkind, 
J.S., and Coso, O.A. (2005). Phosphorylation of c-Fos by members of the p38 MAPK 
family. Role in the AP-1 response to UV light. J Biol Chem 280, 18842-18852. 
 
Thiele, C., Hannah, M.J., Fahrenholz, F., and Huttner, W.B. (2000). Cholesterol binds 
to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol 2, 
42-49. 
 
Thirone, A.C., Speight, P., Zulys, M., Rotstein, O.D., Szaszi, K., Pedersen, S.F., and 
Kapus, A. (2009). Hyperosmotic stress induces Rho/Rho kinase/LIM kinase-mediated 
cofilin phosphorylation in tubular cells: key role in the osmotically triggered F-actin 
response. Am J Physiol Cell Physiol 296, C463-475. 
 
Thomason, H.A., Scothern, A., McHarg, S., and Garrod, D.R. (2010). Desmosomes: 
adhesive strength and signalling in health and disease. Biochem J 429, 419-433. 
 
Tournier, C., Hess, P., Yang, D.D., Xu, J., Turner, T.K., Nimnual, A., Bar-Sagi, D., 
Jones, S.N., Flavell, R.A., and Davis, R.J. (2000). Requirement of JNK for stress-
induced activation of the cytochrome c-mediated death pathway. Science 288, 870-
874. 
 
Traweger, A., Fuchs, R., Krizbai, I.A., Weiger, T.M., Bauer, H.C., and Bauer, H. 
(2003). The tight junction protein ZO-2 localizes to the nucleus and interacts with the 
heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B. J Biol Chem 
278, 2692-2700. 
 
 303 
Tricker, E., Arvand, A., Kwan, R., Chen, G.Y., Gallagher, E., and Cheng, G. (2011). 
Apoptosis induced by cytoskeletal disruption requires distinct domains of MEKK1. 
PLoS One 6, e17310. 
 
Tsukita, S., Furuse, M., and Itoh, M. (2001). Multifunctional strands in tight 
junctions. Nat Rev Mol Cell Biol 2, 285-293. 
 
Tuomi, S., Mai, A., Nevo, J., Laine, J.O., Vilkki, V., Ohman, T.J., Gahmberg, C.G., 
Parker, P.J., and Ivaska, J. (2009). PKCepsilon regulation of an alpha5 integrin-ZO-1 
complex controls lamellae formation in migrating cancer cells. Sci Signal 2, ra32. 
 
Uhlik, M.T., Abell, A.N., Johnson, N.L., Sun, W., Cuevas, B.D., Lobel-Rice, K.E., 
Horne, E.A., Dell'Acqua, M.L., and Johnson, G.L. (2003). Rac-MEKK3-MKK3 
scaffolding for p38 MAPK activation during hyperosmotic shock. Nat Cell Biol 5, 
1104-1110. 
 
Van Itallie, C., Rahner, C., and Anderson, J.M. (2001). Regulated expression of 
claudin-4 decreases paracellular conductance through a selective decrease in sodium 
permeability. J Clin Invest 107, 1319-1327. 
 
Van Itallie, C.M., and Anderson, J.M. (2006). Claudins and epithelial paracellular 
transport. Annu Rev Physiol 68, 403-429. 
 
Van Itallie, C.M., Fanning, A.S., Holmes, J., and Anderson, J.M. (2010). Occludin is 
required for cytokine-induced regulation of tight junction barriers. J Cell Sci 123, 
2844-2852. 
 
Ventura, J.J., Hubner, A., Zhang, C., Flavell, R.A., Shokat, K.M., and Davis, R.J. 
(2006). Chemical genetic analysis of the time course of signal transduction by JNK. 
Mol Cell 21, 701-710. 
 
 304 
Verma, S., Shewan, A.M., Scott, J.A., Helwani, F.M., den Elzen, N.R., Miki, H., 
Takenawa, T., and Yap, A.S. (2004). Arp2/3 activity is necessary for efficient 
formation of E-cadherin adhesive contacts. J Biol Chem 279, 34062-34070. 
 
Verrecchia, F., Tacheau, C., Schorpp-Kistner, M., Angel, P., and Mauviel, A. 
(2001a). Induction of the AP-1 members c-Jun and JunB by TGF-beta/Smad 
suppresses early Smad-driven gene activation. Oncogene 20, 2205-2211. 
 
Verrecchia, F., Vindevoghel, L., Lechleider, R.J., Uitto, J., Roberts, A.B., and 
Mauviel, A. (2001b). Smad3/AP-1 interactions control transcriptional responses to 
TGF-beta in a promoter-specific manner. Oncogene 20, 3332-3340. 
 
Volonte, D., Galbiati, F., Pestell, R.G., and Lisanti, M.P. (2001). Cellular stress 
induces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activation of p38 
mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin 
cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J Biol 
Chem 276, 8094-8103. 
 
Wakeling, A.E., Guy, S.P., Woodburn, J.R., Ashton, S.E., Curry, B.J., Barker, A.J., 
and Gibson, K.H. (2002). ZD1839 (Iressa): an orally active inhibitor of epidermal 
growth factor signalling with potential for cancer therapy. Cancer Res 62, 5749-5754. 
 
Welsh, C.F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M.A., and Assoian, R.K. 
(2001). Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat 
Cell Biol 3, 950-957. 
 
Whitmarsh, A.J., and Davis, R.J. (1996). Transcription factor AP-1 regulation by 
mitogen-activated protein kinase signal transduction pathways. J Mol Med (Berl) 74, 
589-607. 
 
Wilcox, E.R., Burton, Q.L., Naz, S., Riazuddin, S., Smith, T.N., Ploplis, B., 
Belyantseva, I., Ben-Yosef, T., Liburd, N.A., Morell, R.J., et al (2001).Mutations in 
 305 
the gene encoding tight junction claudin-14 cause autosomal recessive deafness 
DFNB29. Cell 104, 165-172. 
 
Wildenberg, G.A., Dohn, M.R., Carnahan, R.H., Davis, M.A., Lobdell, N.A., 
Settleman, J., and Reynolds, A.B. (2006). p120-catenin and p190RhoGAP regulate 
cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell 127, 1027-
1039. 
 
Williamson, L., Raess, N.A., Caldelari, R., Zakher, A., de Bruin, A., Posthaus, H., 
Bolli, R., Hunziker, T., Suter, M.M., and Muller, E.J. (2006). Pemphigus vulgaris 
identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J 25, 3298-
3309. 
 
Winklbauer, R. (1990). Mesodermal cell migration during Xenopus gastrulation. Dev 
Biol 142, 155-168. 
 
Wittchen, E.S., Haskins, J., and Stevenson, B.R. (2003). NZO-3 expression causes 
global changes to actin cytoskeleton in Madin-Darby canine kidney cells: linking a 
tight junction protein to Rho GTPases. Mol Biol Cell 14, 1757-1768. 
 
Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U.H., Deryugina, E.I., 
Strongin, A.Y., Brocker, E.B., and Friedl, P. (2003). Compensation mechanism in 
tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular 
proteolysis. J Cell Biol 160, 267-277. 
 
Xia, Y., Wang, J., Xu, S., Johnson, G.L., Hunter, T., and Lu, Z. (2007). MEKK1 
mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. 
Mol Cell Biol 27, 510-517. 
 
Xu, S., Robbins, D., Frost, J., Dang, A., Lange-Carter, C., and Cobb, M.H. (1995). 
MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-
activated protein kinase. Proc Natl Acad Sci U S A 92, 6808-6812. 
 306 
 
Yamada, S., Pokutta, S., Drees, F., Weis, W.I., and Nelson, W.J. (2005). 
Deconstructing the cadherin-catenin-actin complex. Cell 123, 889-901. 
 
Yang, J., and Weinberg, R.A. (2008). Epithelial-mesenchymal transition: at the 
crossroads of development and tumor metastasis. Dev Cell 14, 818-829. 
 
Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., 
Massague, J., Mundy, G.R., and Guise, T.A. (1999). TGF-beta signalling blockade 
inhibits PTHrP secretion by breast cancer cells and bone metastases development. J 
Clin Invest 103, 197-206. 
 
Yu, A.S., McCarthy, K.M., Francis, S.A., McCormack, J.M., Lai, J., Rogers, R.A., 
Lynch, R.D., and Schneeberger, E.E. (2005). Knockdown of occludin expression 
leads to diverse phenotypic alterations in epithelial cells. Am J Physiol Cell Physiol 
288, C1231-1241. 
 
Yujiri, T., Fanger, G.R., Garrington, T.P., Schlesinger, T.K., Gibson, S., and Johnson, 
G.L. (1999). MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase 
activation in response to changes in the microtubule cytoskeleton. J Biol Chem 274, 
12605-12610. 
 
Yujiri, T., Sather, S., Fanger, G.R., and Johnson, G.L. (1998). Role of MEKK1 in cell 
survival and activation of JNK and ERK pathways defined by targeted gene 
disruption. Science 282, 1911-1914. 
Zhang, J., Betson, M., Erasmus, J., Zeikos, K., Bailly, M., Cramer, L.P., and Braga, 
V.M. (2005a). Actin at cell-cell junctions is composed of two dynamic and functional 
populations. J Cell Sci 118, 5549-5562. 
 
Zhang, L., Deng, M., Parthasarathy, R., Wang, L., Mongan, M., Molkentin, J.D., 
Zheng, Y., and Xia, Y. (2005b). MEKK1 transduces activin signals in keratinocytes 
to induce actin stress fiber formation and migration. Mol Cell Biol 25, 60-65. 
 
 307 
Zhang, L., Wang, W., Hayashi, Y., Jester, J.V., Birk, D.E., Gao, M., Liu, C.Y., Kao, 
W.W., Karin, M., and Xia, Y. (2003). A role for MEK kinase 1 in TGF-beta/activin-
induced epithelium movement and embryonic eyelid closure. EMBO J 22, 4443-4454. 
 
Zhang, W., and Liu, H.T. (2002). MAPK signal pathways in the regulation of cell 
proliferation in mammalian cells. Cell Res 12, 9-18. 
 
Zhang, Y., Feng, X.H., and Derynck, R. (1998). Smad3 and Smad4 cooperate with c-
Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 394, 909-913. 
 
Zhurinsky, J., Shtutman, M., and Ben-Ze'ev, A. (2000). Differential mechanisms of 
LEF/TCF family-dependent transcriptional activation by beta-catenin and 
plakoglobin. Mol Cell Biol 20, 4238-4252. 
 
 
